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Abstract
Thrombosis is an initiating response to vascular injury. Physiologically, this process aids
in the repair and remodeling of the vessel wall. However, if left unchecked, luminal
occlusion may rapidly occur. The coronary vascular bed is a life-sustaining environment
in which pathological thrombosis can lead to devastating outcomes such as acute
coronary syndromes or post-interventional thrombosis. In order to study these coronary
thrombotic reactions, it is essential to consider the physical environment in which they
occur. We have developed an in vitro method for creating pulsatile flows to mimic the
coronary hernodynamic setting on a beat-to-beat basis. Furthermore, he have developed
techniques and protocols to parametrically vary both the biological and physical aspects
of thrombosis and in doing so, have investigated the effects of real-world temporal and
spatial flow perturbations on local site platelet adhesion. Not only do such variations
create quantitative differences in local reactions, but qualitative differences as well as
various receptors must interact to create stable adhesions in a given hemodynamic
environments. These findings have implications on the propensity for certain individuals
to form clot under certain condtitions, as well as the environment-dependent efficacy of
various clinically relevant anti-thrombotic strategies
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CHAPTER 1 Background and Significance
1.1 Coronary Thrombosis
1.1.1 Pathophysiology
The vital coronary arteries transport
freshly oxygenated blood to the heart
(see Fig. 1.1). These vessels branch
off of the aorta, curving over the
epicardial surface while bifurcating
and providing tributaries to the ever-
beating myocardial tissue. Such
complex geometries and the pulsing
intramural pressures create a high
degree of spatial and temporal
diversity in the local hemodynamic
environment, resulting in a unique
vascular setting.
Right
Corona
Arter)
iry
Circumflex
Artery
Left
Anterior
ascending
Artery
Figure 1.1 Schematic diagram of the heart and
major overlying coronary arteries.
In states of health, the coronary vessels, as all parts of the vasculature, are lined with a
protective endothelial barrier that separates the highly reactive vessel wall and contained
blood compartments. Traversing through these conduits, changes in the vascular
environment are accompanied by changes in the phenotypes of these cells [1]. Gene
expression patterns, surface receptor expression, and a slew of other cellular mechanisms
are tightly linked to the environment and work to keep this living surface appropriately
matched with local needs.
Within the first decades of life, nearly ubiquitous environmental and genetic
stresses conspire to create loci of low-grade injury to the protective endothelial surface
allowing the accumulation of subendothelial deposits of lipids and lipid-laden
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macrophages [2-6]. These minor breaches instigate a complex cycle of chronic
inflammation and immune recruitment through endothelial activation, smooth muscle cell
proliferation and migration, extracellular matrix turnover, and the build up of cellular and
. necrotic debris. Over time, such processes transform into full fledged atherosclerotic
disease and luminal stenosis. Figure 1.2 a, b depicts a healthy vessel and one whose
lumen has been diminished by atherosclerotic plaque burden.
8.Healthy b.Diseased
Figure 1.2. a. Healthy coronary artery with patent lumen; b. Atherosclerotic
coronary artery with luminal stenosis
Typically, the plaques are characterized by a lipid-laden, highly thrombogenic, necrotic
core, covered by a fibrous cap region. As the plaques continue to grow, regulatory
mechanisms are often able to compensate and uphold the balance between blood supply
and myocardial demand. While such progressive, chronic, atherosclerotic processes can
eventually lead to significant, uncompensatable disease (> 75% area reduction)
characterize a by ischemic episodes and stable angina (exertional chest pain), a far more
devastating and unpredictable outcome is plaque rupture or endothelial erosion (see Fig
1.3) [2-4, 7, 8].
Under such circumstances, the protective endothelial layer is acutely disrupted,
exposing highly reactive subendothelial, atheromatous components. A rapid, thrombotic
process ensues which can either exacerbate disease progression or lead to acute coronary
syndromes (ACS) such as unstable angina, acute myocardial infarction, or ischemic
sudden death.
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1.1.2 Treatments
Prevention is the preferred treatment option for coronary disease. Epidemiological
studies have generated a great deal of information regarding the different genetic and
environmental risk factors involved in coronary disease progression [9-11]. Accordingly,
appropriate measures can be taken to minimize risk. Currently, our cellular and
molecular based understanding of the etiology of atherosclerosis and thrombosis has also
allowed the use of relatively safe, long-term drug strategies. Perhaps the most notable
example is the widespread use of aspirin in treating populations at risk of coronary
disease. By targeting platelet responsiveness (a key component of the arterial thrombotic
response), aspirin has offered a 25% relative risk reduction of severe cardiovascular
incidence (vascular death, MI, stroke) becoming a nearly ubiquitously used background
therapy [12]. A battery of such agents (statins, etc) has shown great risk benefit, with
novel drugs, either targeting new mechanisms for reducing the complications of pre-
existing ones, constantly emerging [13, 14].
Unfortunately, many cases of coronary disease are brought on unexpectedly
(ACS), or are simple too far progressed (severe luminal stenosis), necessitating more
intensive strategies. In cases of thrombosis, highly potent anti-thrombotics and
fibrinolytic agents (which prevent the build up and promote the dissolution of clots
respectively) have proven highly effective if administered within critical windows [15].
Such powerful, systemic agents are not suitable for sustained therapy do to excessive
complications, and while these provide immediate, life-saving benefit, the underlying
problems of' atherosclerosis and plaque instability remain [16, 17]. The supply/demand
mismatch accompanying severe stenosis can also often be managed medically with
agents such as nitroglycerin which, up to a point, can aid innate autoregulatory
mechanisms [18]. While such therapies may provide immediate relief, the chronic need
for medication often indicates a need for more invasive revascularization procedures.
Coronary bypass arterial grafting (CABG) has long been the standard revascularization
procedure [19, 20]. However, the advent of minimally-invasive, ever-improving,
catheter-based therapies has transformed the state of coronary disease management. Two
wide spread approaches include angioplasty, which mechanically disrupts the
atherosclerotic segment through balloon expansion, and stenting, which involves the co-
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expanSIon of a permanent, rigid, foreign structure adding post-procedural, luminal
support. Although the benefits offered by such treatments are indisputable, changes in
the biological and physical environment accompanying mechanical disruption of the
endothelial barrier and insertion of a foreign structure, even as minor as a intravascular
wire, can lead to deleterious complications by iatrogenically creating an ACS-like state.
Endothelial
Iniury
Embolization
SILENT CLINICAL
Figure 1.3. Clinical and silent (subclinical) thrombotic outcomes of vascular
InJury.
Much effort has been placed in understanding and controlling the complex,
pathophysiological mechanisms of atherosclerotic disease and its devastating outcome,
coronary thrombosis. Still, in westernized societies, such endovascular disease processes
account for close to 50% of all deaths [6]. For continued improvement of safe,
efficacious management of coronary events (pathological and iatrogenic), it is important
to gain further understanding into the mechanisms and events leading up to acute
thrombosis within the vital coronary arterial setting.
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1.2 The Platelet
While a multitude of biological
effectors are involved in vascular
thrombosis, we will focus on the
platelet as an essential mediator of the
biological response to vascular injury.
Platelets are circulating cells (1.5-4.5
X 108/ml) which bud off from
megakaryocytes resident in the bone
marrow [21]. Although anucleate,
platelets are highly responsive to their
environment. A multitude of surface
receptor interactions, second messenger
Figure 1.4 Tunneling electron microscope
image of anucleate platelet depicting
numerous internal storage granules and
canalicular system (image reproduced from
Feng D, et aI. Blood. 99( 11), 2(02).
pathways, pre-packaged granule release
substances (Fig 1.4), and translatable proteins allow these cells to provide constant
monitor of the vascular environment and playa key role in initiating biological responses.
The importance of platelets in arterial thrombosis cannot be overstated as attested
to by the clinical effectiveness of anti-platelet therapies in minimizing arterial thrombotic
risk [22]. Upon binding to an injured wall, they alter their expression of surface
molecules and release substances which both attract and adhere to flowing cells, as well
as promote the enzymatically driven coagulative response. Accordingly, platelet wall
reactions and subsequent component interactions are essential to understand when
considering the thrombotic response to vascular injury.
1.2.1 Platelet Reactions
Platelet/wall reactions classically take place in a series of steps, beginning with initial
contact, followed by a sequence of activation, firm adhesion, cell spreading, and
aggregation (Fig. 1.5).
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Figure 1.5. Sequence of platelet/vessel wall reactions.
Tethering/A ctivation
The platelet glycoprotein Ib (GPIb; in complex with GPIX, GPV) and von Willebrand's
Factor (vWF) are important components in enabling initial platelet/surface contact in
arterial, high flow environments [23, 24]. Upon endothelial breach, platelets tether to
sub-endothelial matrix vWF (either directly present or adsorbed to matrix collagen from
the blood) via fast on-off rate GPIb bonds [25]. The speed of these bonds is an essential
quality of this interaction in allowing the platelets to grab onto the surface under high
shear conditions [26-28]. Several studies have shown that these tethering interactions
become increasingly important at shear rates above 300 s-1, becoming essential at shears
above 1500 s' in reducing the platelet relative wall velocity in a start-stop type dynamic
[26, 29]. As the platelet slows and translocates, a multitude of other activating responses
take place. The GPIB-vWF bond itself is known to be one of these activating pathways
by interacting with internal, second messenger machinery [28, 30-32]. Concurrently,
autocrine and paracrine substances, such as ADP, thrombin, thromboxane, and
epinephrine, bind to specific receptors, further potentiating platelet activation [21, 33].
Phrst a 'r .. L , IlrJl nl ClIMnIInn 18we alesl I.. LJaLn'yILuJu allu sJy cIuiiuICIal F
2. Platelets
tether and
translocate
on surface
(GPIb, vWF)
3a. Activation of
platelets (GPVI,
GPIb, ADP, etc.)
3b. Integrin
/Activation/Adhesion
(GPIIbIIIa, a2pl...)
Recently, the importance of the collagen activating receptor GPVI has also been shown to
provide a physiologically essential activating interaction with exposed collagen and vWF
surfaces [341. It is an integration of these coalescing, outside-in, activating pathways that
dictate the final activation decision.
Firm adhesion/Spreading
An essential outcome of platelet activation in supporting shear dependent thrombosis is
the modulation of platelet integrin receptors from their low to high affinity state.
Integrins are cell surface molecules, composed of an a and subunit, and support
adhesion to particular substrates [35]. The major platelet integrins are aIbffII, a2131, and
aV33 [35, 36]. Upon activation, these receptors support the firm adhesion of platelets
onto fibrinogen, collagen, and fibronectin surfaces respectively. However, the existence
of other, less prevalent integrins and substrate cross reactivity create redundancy in the
adhesion pathways and while providing a safety net given the importance of adequate
platelet adhesion, dramatically complicating the mechanistic picture.
After firm adhesion, internal processes that are not fully characterized lead to
filipodial extensions and cell spreading [37]. Such cytoskeletal rearrangement allows
more complete surface contact, enhanced integrin binding, and increased binding strength
of the adherent platelets.
Aggregation
Platelet shape change is accompanied by granular exocytosis which helps to transform
the local biological milieu by the release of substances such as ADP and thromboxane
[21]. Free-stream platelets are potentiated and activated in this pro-thrombotic
environment. As induced during surface interactions, such activation enables high
affinity integrin conformations. Platelet-derived fibrinogen and vWF add to pre-
existing, local plasma concentrations of these proteins, enhancing binding to activated
aIIb3JII integrin receptors [21, 38]. These protein/receptor interactions mediate inter-
platelet cross-linking and aggregation, forming what is commonly referred to as the
primary hemostatic plug.
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1.2.2 Platelet Interactions
Though platelets play an essential, initiating role in arterial thrombosis, they are far from
the only participants. Numerous interactions with other blood-borne cellular and protein
components have long been recognized as mediators of thrombotic disease.
Coagulation
When platelets are activated, negatively charged phospholipids, such as
phosphotidylcholine and phosphotidylserine, are externally presented, localizing various
enzymatic reaction complexes of the coagulation cascade to the platelet surface [21, 33,
39]. This sequestration keeps the reactants in close proximity to one another, while
protecting them from other free-stream anti-coagulative mechanisms. Upon association
with the platelet membrane, conformational changes in enzyme/substrate complexes also
dramatically accelerate the reactions [21, 39]. Such localization and catalysis are
essential for the successful progression of coagulation under flow conditions where
convective mass transport would otherwise wash away the formed products [21].
I INTRINSIC 
ACTIVATION Tissue Factor X - -Charged Surface ACTIVATION
VII -VIIa XIIa + XII
1 |XIa + XI
X
X+Xa a
FINAL
COMMON
PATHWAY
Prothrombin 4 THROMBIN
Fibrinogen - I FIBRIN
Fig 1.6. Classical reactions of the coagulation cascade commensing with the exposure of
tissue factor (Extrinsic activation) and/or an appropriate surface (Intrinsic activation),
leading to the explosive, proteolytic production of thrombin and fibrin
- _, I , I. __ l _ _ x- _ __ _ 20
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While platelets are necessary in supporting coagulative propagation, the products of the
coagulation cascade in turn play a critical role in potentiating and stabilizing primary,
platelet-driven hemostasis. The key reactions of this proteolytic pathway are shown in
Figure 1.6 [21, 39]. Classically, coagulation is initiated via the extrinsic or intrinsic
pathways, merging into the common pathway with the eventual production of thrombin
which catalyzes the conversion of monomeric fibrinogen to fibrin. While numerous
interactions exist, thrombin and fibrin are two of the most important and well
characterized links between platelet function and coagulation.
Thrombin is known to be a potent activator of platelets through a variety of
mechanisms. Protease activated receptors (PAR-I, 4) have been characterized on the
surface of platelets [40-42]. Using a unique cleavage mechanism, thrombin causes
receptor self-association and activation. Interestingly, the various PARs are functionally
activated at different threshold concentrations of thrombin, while additional interactions
with the GPIb"receptor have been recently recognized to affect platelet activation [42-45].
Such connections allude to the delicate control structures poised between the coagulative
network and platelet function.
While the physiological relevance of thrombin-
activation has been shown, its catalYtic conversion
of fibrinogen to fibrin also plays a critical role in
platelet-driven thrombosis. Once formed,
monomeric fibrin quickly polymerizes into a
mesh-like network of filaments. Platelets can
adhere to this fibrin mesh via allbpm receptor
linkage, greatly strengthening the cohesiveness of
r:r-, I
the aggregating, hemostatic plug (Fig. 1.7) [46] .
.Though these classical platelet/coagulation
interactions are key mediators of physiological
thrombus formation, they are only representative
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Figure 1.7 .Platelets 'entangled' in
fibrin mesh (surface electron
microsopy; image by Alisa Morss)
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of a long list of interactions, many of which are characterized, and a great many of which
undoubtedly remain to be found.
Leukocytes
Leukocytes are the cellular mediators of the inflammatory and immune responses. In
blunt categorizations, these responses have often been considered as separate to the
thrombotic reactions. However, upon closer examination, the great deal of interactions
between these biological processes has grayed the distinction. As with coagulation, a
variety of platelet processes are involved in initiating inflammatory responses and vice-
versa. Upon vessel wall injury and platelet recruitment, P-selectin is rapidly presented
on the surface of the activated platelet layer. Surface expression of this selectin is able to
recruit various leukocytic cells. Neutrophils and monocytes initially adhere via P-selectin
glycoprotein ligand-1 (PSGL-1), tethering in a manner analogous to the GPIb-vWF
interactions of platelets [25, 47]. Again, outside-in signaling causes leukocytic activation
and integrin modulation enabling firm adhesion. The importance of platelets in
heralding such inflammatory processes is witnessed in the effectiveness of P-selectin
blockade or powerful platelet inhibition on limiting the development of chronic vascular
inflammatory processes such as atherosclerosis or the neointimal formation after
interventional treatments [48].
Just as platelets play a critical role in inflammation, the importance of
inflammatory mediators in thrombosis is now being recognized. Cytokines produced
during inflammatory processes such as tumor necrosis factor (TNF), interlukin-1 (IL-1),
monocytic chemoattractant protein-1 (MCP-1), and IL-6, have all been found to
upregulate the expression of tissue factor (TF) on endothelial and monocytic surfaces.
TF is the key initiating factor in extrinsic activation (see Fig. 1.6), and it is becoming
recognized that such cytokine-mediated expression of TF acts as a primary initiator of
thrombosis by shifting the vascular environment into a prothrombotic state [49].
Erythrocytes
Erythrocytes (red blood cells; RBCs) are also important in modulating arterial thrombotic
events. Being the most numerous blood cell, RBCs dramatically alter the fluidic
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properties of blood. Flow-dependent gradients in erythrocyte distribution marginalize the
platelets to the flow periphery, dramatically increasing local platelet wall concentrations
[50, 51]. Further, by increasing the viscous forces of blood, erythrocytes dramatically
affect the shear force at a given shear rate which can have significant impact on
biophysical processes such as thrombosis.
RBC's are also one of the primary, physiological sources of ADP, a potent
activator of platelets. Under conditions of shear, ADP pathways have been shown to
greatly enhance platelet activation and adhesion [52, 53]. The relevance of this
mechanism in arterial thrombus formation is attested to by the efficacy of ADP receptor
blockade via thienopyridine derivatives (i.e. clopidogrel, ticlopidine) in minimizing post-
interventional thrombotic risk [53, 54].
In this section, we have described the fundamental processes underlying platelet/wall
adhesion, which serves an essential, initiating role in arterial thrombus formation. We
have also introduced some of the classic interactions that platelets undergo with other
blood-borne, vascular components. While these interactions only breach the surface of
the thrombotic response, they point to the complexity of the biological issue and the need
to develop controllable systems where parameters can be sufficiently isolated, allowing
tractable, mechanistic studies to be performed.
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1.3 The Local Hemodynamic Setting
It is important to recognize that biological interactions both occur in and react to their
physical surroundings. In vascular environments, flow is one of the critical physical
parameters that helps to maintain vascular diversity and dictate vascular responses. The
coronary environment provides a distinctive setting where curving vessels, numerous
branch points, geometric pathologies and the time-dependent nature of the driving
pressure create highly unique, complex flow patterns (see Fig. 1.8) [1, 55-58].
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Figure 1.8. Typical phasic coronary flow profile in the left anterior descending
coronary branch (LAD). In supplying blood to the beating myocardial wall, coronary
flow principally occurs during diastolic relaxation, being driven to a halt with rising,
systolic, intramural pressures.
These spatially and temporally diverse conditions must be appreciated when considering
highly flow-sensitive events such as thrombosis. Here, we introduce some of the
mechanisms whereby physical flow parameters may interact with biological factors and
the manner by which the local hemodynamic environment can be altered in states of
disease.
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1.3.1 Local Flow Interactions
Flow can affect biological interactions on variety of levels, from molecular to
microscopic to macroscopic scales. Often times these dependencies stem from basic
physical concepts such as mass transport and physical forces. However, given the long
time scales that these biological mechanisms have been interacting within relatively
stable physical environments, selective pressures have also enabled biological systems to
evolve sophisticated machinery, allowing them to respond and adapt to their surroundings
in a more complex manner.
Molecular Interactions
The mass transport of molecular substances to and from an activating locus plays an
important role in thrombus formation. In flowing environments, fleeting conditions are
setup as diffusive and convective forces transport substances to and from the reactive site.
The mass flux, J, of a substance reacting at a surface has been shown to be:
J(x,t) C01 1
kw k (xt) (1)
for arteries of diameter > 0. Imm [59]. This relation shows that the flux is dependent on
the mean bulk concentration Co, the wall reactivity of the substance, k, as well as the
mass transport coefficient, kl. In cases where the wall reactivity is very low compared to
the mass transport coefficient, the flux is said to be reaction limited. Alternatively, with
low mass transport coefficients, transport dictates the surface flux.
Flow affects this relation implicitly through kl, which, in the case of the entrance
region in large cylindrical arteries, is given by:
k =.5K 2j
x (2)
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where D is the diffusion constant, K is a proportionality constant dependent on geometry
and boundary conditions, x is the axial distance from the start of the region, and y is the
wall shear rate [59]. Thus, when substances are transport limited (J-Cokl), flow
modulates the surface flux. This becomes highly relevant in cases of static or recirculant
flows such as those which are often established in the complex coronary vasculature
(particularly given the autocatalytic nature of many blood-borne reactions). That the
physiological reactions of thrombosis globally function in this flow dependent regime is
revealed by the morphological differences in thrombus formation under venous (low) and
arterial (high) flow systems and by observations such as the increased likelihood of post-
interventional acute thrombotic events in poorly perfused vessels [21, 60-62].
Microscopic Interactions
Cellular Transport (km)
Just as reactive molecules are transported to and from the reactive surfaces, so are
cellular components. However, due to special non-Newtonian properties of blood, the
effective diffusion coefficient, D, of cells is itself a function of erythrocyte concentration
and flow parameters. As blood flows through the vasculature, RBCs migrate towards the
flow axis creating a flow-dependent, radial concentration gradient. As a result, platelets
are marginalized to the flow periphery, increasing the shear dependence of platelet mass
flux. [50]. Various studies of platelet wall interactions have shown surface accumulation
to be largely dependent on flow parameters, implicating the importance of transport
phenomena and the underlying diffusion limitations involved in this process [50].
Wall Reactivity (kw)
While cells and molecules must be transported to the wall, they must also be able to react
when appropriate, and the wall reactivity, kw, can also be considered a complex function
of fluid flow. Local shear stresses and pressure forces have been shown to greatly affect
vessel wall morphology. Endothelial cells and wall smooth muscle cells are able to sense
these physical forces and respond with directed genotypic and phenotypic changes.
When activated, these cells alter their expression of surface adhesion molecules [1, 63].
These, along with numerous other changes (i.e. TF, vWF, tissue plasminogen activator,
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platelet activating factor-1, thrombospondin, RANTES, monocytic chemoattractant
protein-i), alter the local environment creating a generalized, prothrombotic,
proinflammatory state [1, 58, 64-66].
The paradigm of vascular cell adhesion to this reactive wall in flowing
environments parallels the scheme outlined for platelet adhesion (recall Fig. 1.5),
beginning with the presentation of a particular class of surface adhesion molecules called
selectins (or vWF in the case of platelets). Various cell types express various types of
selectins. These molecules interact with respective ligands on free-stream cells, thereby
:recruiting them to the vessel wall. Selectin/ligand interactions are characterized by fast
binding constants, and are thus able to catch flowing cells under high shear conditions
[25]. While necessary in supporting the initial cell/wall contact under flow, they do not
bind tightly, and instead produce a rolling motion as bonds are sequentially broken and
formed. During this slowed, translocation, several other pathways cause vascular cell
activation, resulting in integrin receptor activation and firm, shear-resistant adhesion to
surface ligands [67]. These prototypical flow mediated interactions are representative of
vascular cell/wall interactions, with the exact receptor/ligand interactions dependent on
the particular cell type and substrate under consideration.
Macroscopic Interactions
On macroscopic scales, shear stresses can integrate to create high local forces which can
have a significant impact on the pathogenic progression of vascular disease.
Atherosclerotic plaques are characterized by atheromatous core regions, covered by a
fibrous cap. Acute thrombotic events often occur when such plaques rupture by sudden
fracture of the cap region and currently there is much interest in studying the strength of
the cap as varied biological properties can affect plaque stability [68-71]. However, the
final rupture event is predicated on the fact the cap strength is too weak in relation to
local fluidic forces.
As cells and molecules aggregate on the reactive wall via the flow-dependent
processes outlined above, larger mural thrombus develops and is increasingly subject to
macroscopic embolizing forces. As in the case of plaque rupture, embolization is known
to be highly dependent on shear rates, with embolic stresses varying linearly with wall
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Figure 1.9. Angiogram of coronary arteries
depicting highly branching, curving geometries
overlying and penetrating the heart tissue (image
reproduced from Dhond, MK, et. al. Clinical
shear at thrombus heights less than 0.1 mm and quadratically at larger heights as a result
of flow separation [72, 73]. In either situation, the rheological situation dictates the
removal forces that help to determine detachment probability.
1.3.2 Local Geometric Environment
Local fluid flow plays an important role in directing the thrombotic response. By
prescribing the flow boundary conditions, the local physical geometry is critical to
determining the contained flow field, and thus also plays a crucial role. These geometries
can be dramatically altered in states of disease or intervention, having great impact on the
local,hemodynamic environment and the tightly dependent biological outcomes.
Physiological Geometries
Physiological vascular properties such as curvature, branching, and tapering are all highly
relevant in establishing the local flow environment, particularly in the coronary bed
where the arteries coarse over the curved epicardial surface, supplying numerous braches
to the demanding myocardial wall (Fig. 1.9) [74].
In purely axial flows, radial and
circumferential sYmmetry ensure
purely axial pressure gradients and
relatively simple flow profiles.
However, in more complex, curved
flow streams, adverse axial and
orthogonal pressure gradients are
established, creating secondary flow
fields and zones of recirculation (Fig.
1.10a, b) [56, 75, 76]. These can
have ,significant impacts on local
wall shear stresses and through the
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biophysical connections outlined above, orchestrate local biological responses.
a. Vessel Branching
Flow recirculation 
//~~~~1
b. Vessel Curvature
Secondary flow
effects
Figure 1.10. Examples of vessel architecture leading to complex flow patterns. a. Vessel branching
and axial flow, reversal and recirculation; b. Vessel curvature and transverse, secondary flows.
Such responses are essential in vascular remodeling and maintaining healthy vessels.
However, when inappropriately harnessed, they can also lead to vascular disease
progression. The effect of local, physiological geometries and the resultant flow fields in
vascular pathology is well recognized, as indicated by the frequent initiation of
atherosclerosis at sites of vessel branching or the increased atherosclerotic burden
observed on the inner curvature of coronary vessels [77, 78].
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Pathological Geometries
While physiological geometries correlate well with disease initiation, local geometries
can be significantly altered with disease progression, often compounding the detrimental
effects. As cellular and necrotic debris accumulate within the wall, volume constraints
result in either inward (stenotic) or outward (aneurismal) remodeling of the vessel wall.
In cases of compensatable stenosis, mass conservation implies increased flow velocities
for a given total flow rate, with wall shear rates at times exceeding 10,000 s-' (typically <
600 s-1 in the coronary arteries) [51, 52, 79]. Under such pathological conditions, free-
stream vascular cell activation and erythrocyte hemolysis can significantly alter
volumetric blood status leading to both local and far-reaching systemic effects [79, 80].
When the total flow rate can no longer be maintained due to excessive stenotic flow
resistance, severe decompensation can conversely result in dramatically reduced flows.
Indeed, when plaques rupture and mural thrombus occludes the lumen, increased
resistance can totally eliminate blood flow, quickly potentiating further thrombus growth.
Alternatively, under aneurismal conditions, flow rheology can also be significantly
affected. As a result of reduced transport and embolic forces in recirculant zones,
significant, venous-like mural thrombus formation is often observed, creating a nidus for
thromboembolic disease [21, 59].
Interventional Geometries
Significant geometry-altering vascular disease is often treated with interventional
revascularization techniques which can in themselves affect the local geometry and
hemodynamic environment. Stenting involves the placement of an intravascular structure
that props open the vessel lumen. The post-interventional luminal shape is determined
by the overall profile of the implanted stent device, and has been shown to have an
impact on long-term biological outcomes, likely due in part to alterations in fluid flow
[81]. Furthermore, in order to provide sufficient radial support, stents are typically made
of a mesh work of steel struts on the order of 100 igm thick. While this thickness is
relatively small compared to the entire flow diameter (> 2 mm), their juxtaposition next
to the vessel wall can significantly alter local wall shear stresses, with complex flow
patterns developing in the inter-strut regions [82-85]. Berry et. al. have shown that
Chapter 1:: Background and Significance 30
changes in stent geometry, can dramatically affect these flow fields and resultant mass
transport parameters [82].
The effects of stent placement can also be more pronounced depending on
implantation technique. Significant over-expansion can lead to aneurismal-like
conditions, while insufficient expansion can results in significant flow abnormalities.
Indeed, such improper expansions have been associated with the high acute thrombotic
rates observed in the early clinical stenting experience [61, 86].
While the placement of intravascular objects can create altered local flow, a more
subtle point is that revascularization itself alters the geometry and 'expected' flow field
of the vessel due to the significant biological adaptations that occur during disease
progression. Recently, Richter and Edelman (unpublished observations, 2003) have
shown that such acute interventional revascularization can lead to adverse, unexpected
outcomes.
We have briefly described some of the key mechanisms by which flow can interact with
the thrombotic processes. Furthermore, we have discussed how the physical, geometric
environment can have a significant impact on flow parameters under physiological,
pathological and interventional conditions. Considering these significant interactions, an
attempt to study thrombotic reactions in the coronary setting would hopefully take these
physical parameters into account, allowing them to be manipulated and studied in a
controlled fashion, along with the pertinent biological components.
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1.4 Methods of studying flow dependent thrombosis
A variety of methods have been utilized to investigate thrombotic reactions under
appropriate hemodynamic conditions. These methods include both in vivo and ex vivo
models, as well as bench-top in vitro setups. Each of these methodologies has offered
unique insights by virtue of inherent advantages, though often these same advantages
limit the types of information that can be gleaned from their use. It has been a combined
use of these techniques, along with an appreciation of their limitations that has
contributed greatly to our current understanding of vascular biology. Here, we present
various methodologies that have been and are currently being used to study flow-
dependent thrombotic reactions and the types of advances they have provided.
1.4.1 In Vivo Models (Realistic)
In vivo models offer a degree of realism and physiological relevance unattainable in
bench-top models, and when chosen appropriately, allow thrombotic outcomes to be
assessed in relevant hemodynamic conditions. The two most basic types of in vivo study
include clinical trials and animal studies.
Human Studies/Clinical Trials
Human studies and clinical trials generate immediately applicable, clinical information,
inherently taking into account the complex biological interactions at work in the human
body. Such studies allow integrated, relevant, systemic and long-term processes to be
observed, offering clear cut advantages over other systems when considering actual
disease characterization, patient risk stratification, and the efficacy of therapeutic options.
Historically, mechanistic insights have been obtained from observing the human
condition, often times becoming evident when systems overtly fail. Indeed, many
important processes of the thrombotic response have been initially discovered through
clinical presentation (GPVI deficiency, Glanzmann's thrombasthenia, Bernard-Soulier,
GJPIb deficiency, vWF disease, etc.) [21]. While such accidental observations are
predicated on patients and patience to search the space of biological processes, they are
implicitly of great relevance.
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Human studies and clinical trials are by definition the most relevant to the human
condition. However, as the primary goal is to benefit the immediate patient, making clear
scientific progress is difficult at best. The lack of ideal controls and patient variability
(particularly given the optimizing nature of medical advance) causes such trials to be
expensive and long, oftentimes yielding unclear conclusions. Further complicating the
issue is that as trials are performed, the evolving ground of clinical experience often races
by, altering the clinical relevance, therapeutic dogmas and potentially, for patient benefit,
the clinical trials themselves.
Animal Studies
One step removed, animal models of physiology and pathology allow detailed
observation of complex biological situations while offering a more controlled setting than
human studies. Though ethical considerations and respect must always accompany the
experimental use of living organisms, an accepted goal in animal use is the progress of
scientific understanding for human benefit, thus allowing intensive, well-controlled,
prospective studies to be carried out to completion.
Animal models of thrombosis span the evolutionary ladder, from the use of non-
human primates to mice. Architectural similarity and flow conditions in large animals
allow highly relevant studies of thrombotic processes under appropriate hemodynamic
settings. Alternatively, the ease of manipulation and relatively low cost of small animal
studies enable more fundamental questions to be epistatically probed, dramatically
accelerating the pace of scientific discovery and understanding. However, the relevance
to the human condition varies tremendously as a result of species-specific biological and
physical differences and the often crude models used to approximate human vascular
disease. Furthermore, while offering greater experimental possibilities than human trials,
there are still limitations in the parameters that can be reasonably manipulated in living
animals, particularly when considering complex traits such as the hemodynamic
environment [79, 87-89].
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1.4.2 In Vitro Models (Perturbable)
To gain detailed mechanistic insight into the heological dependence of thrombosis, it is
important to have parametric control over the hemodynamic and complex biological
environments. In vitro models allow powerful manipulations to be performed on isolated
biological components under highly consistent, prescribed physical conditions, thus
offering a degree of versatility not attainable with in vivo settings. Such models can
broadly be categorized into systems that maintain physical geometric properties and those
that maintain flow conditions.
Maintaining Geometry
Geometrically relevant in vitro systems maintain realistic vascular dimensions and have
been applied towards various issues, from endovascular device thrombogenicity to
cellular adhesion in vascular deformities. One limitation in these models has been in
developing suitable bench-top mechanisms of flow actuation and control. While some
setups have employed gravity to provide a pressure head for generating blood flow, the
need for sizable, static holding volumes in these one-pass systems significantly constrains
the allowable flow rates and experimental run times [89]. Alternatively, loops partially
filled with blood and mounted on a tilted turntable have been employed to create relative
wall motion. This method allows the use of small blood volumes, though effects of
blood recirculation and the required air-fluid interface must be considered when
interpreting results [90-92]. Moreover, the constant flow potential of these gravity-driven
systems results in restricted control of the flow environment. To establish more
controllable flows, the most basic approach has been to use pumps to drive blood through
a model flow circuit [93, 94]. However, even external peristaltic drives have generated
excessive background levels of activation, proving too traumatic in setting up arterial-like
flow conditions.
Maintaining Flow
Strategies that attempt to maintain geometry are typically constrained by the need to
create high flow rates to generate arterial-like conditions. In order to study flow effects,
laxness in the physical circuit architecture has enabled alternate schemes to be employed.
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The use of small circuit geometries such as narrow, parallel-plate flow chambers, allows
high shear rates to be developed under relatively low flow conditions [26, 83, 95-97].
Such in vitro systems allow great control of the biological environment while enabling
microscopic visualization of surface-cellular interactions in real time. As a result of their
controllability and observability, these studies have greatly enhanced our fundamental
understanding of shear-dependent, thrombotic surface reactions.
Techniques such as cone-plate or annular ring devices create relative motion
between two fluid-contacting surfaces, thus generating Cuvette-type flow. These models
can establish well-described surface and volumetric shear profiles. Furthermore, while
these Cuvette-systems dramatically change the physical flow shape, suitable scaling and
experimental design have allowed certain geometrically relevant questions to be asked
under appropriate flow settings [58, 98].
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1.4.3 Proposed Flow System
'Table 1.1 compares prior model systems that have been employed to study the
hemodynamics of thrombosis with respect to the human condition.
Table 1.1. Comparison of prior methods showing an incomplete niche for experimental
strategies supporting the simultaneous parametric analysis of biological and physical
systems. (Subjective scale, using clinical trials to reference extremes ratings: +++ ---;
Excellent --> Poor).
Combining the information obtained from these systems has lead to great leaps in our
understanding of acute thrombosis. Ex vivo hybrids, where external sections are placed
in-line with a natural circulation, have helped to bridge the gap where in vivo and in vitro
models do not meet [51]. Still, cracks remain and alternative models addressing new
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issues are needed. One particular niche which we hope to address in this work is the need
for systems that concurrently retain significant control of both the biological and physical
axes, specifically with regards to the human coronary setting. The key selection criterion
we considered when developing the system were:
1.) Generating and controlling physiologically relevant flows
2.) Creating versatile, geometrically relevant circuits
3.) Retaining control of the biological setting
4.) Maximizing the biological signal/circuit background noise ratio
After considering various strategies, we developed a novel, inertial mechanism that could
produce highly controllable flows in relevant arterial geometries while maximizing the
biological signal to background noise ratio by minimizing the circuit length and surface
discontinuities. Briefly, fluid-filled loops are spun about their axis in a prescribed and
controlled fashion to modulate relative fluid/wall motions through transmitted shear
forces. This method further allows us to maintain low test volumes and cost, enabling
reasonable parametric analysis of the biological and physical settings.
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FIGURE 2.1. Fluid-filled torus. Clockwise
motion of the torus causes relative counter-
clockwise inertial motion of the contained
fluid and vice versa.
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2.1 Theory
2.1.1 Description
In order to create the desired flow
profiles, a fluid-filled torus (figure 4)
is rotated about its axis. When
impulsively started, there is inertial
fluid motion relative to the toroid wall:
With time, the fluid is accelerated due Fluid
to momentum transfer into the fluid
bulk via shear forces. Lyne has
previously analogized such fluid
motion to pressure driven flows where,
moving in a reference frame with the
wall (WRF), the acceleration takes on the driving character of a body force [99]. While
the absolute fluid velocity in an inertial reference frame (IRF) may change under pressure
driven or accelerating wall conditions, it is the maintenance of the velocity gradients, or
shear, that is important in the flow-dependent thrombotic reactions [21, 50, 59]. Rather
than fluid being conducted to and from a reactive wall surface, the relevant reaction
control volumes are conducted away from the lagging fluid.
Using such a technique, we hoped to create time-varying flows whose characteristics, as
defined by the dimensionless mean Reynolds (Re; based on an absolute velocity) and
Womersley (a) parameters were typical of coronary flows, as well as estimate the
secondary flow effects of curvature by considering the peak Dean number (K'peak)
associated with our system (see Table 2.1).
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Table 2.1. List of the
dimensionless parameters
considered, along with
customary definitions and
typical values found in the
left anterior descending
coronary branch (LAD)
[13]. Vfluid is the mean
cross-sectional axial
velocity of the fluid, v is
the kinematic viscosity, o
is the flow oscillatory
frequency, a is the vessel
radius, and R is the radius
of curvature of the loop. T
This value for Kpeak was
calculated assuming a peak
Re of twice the Re and a
aspect ratio, R/a, of 10 as
suggested by Chang and
Tarbell [15].
Table 2.1 defines these conventional dimensionless parameters [100]. In each of these
parameters, a Newtonian approximation for the kinematic viscosity, v, is used, as has
been shown to be valid for high shear conditions (> 100 s- 1) and often applied when
considering coronary flow [76, 78, 101, 102].
2.1.2 Analytical, Straight Tube Approximation
Equations
Simplifying to a linearly accelerating, straight tube model (Fig. 2.2), streamline curvature
effects can be neglected and only the axial (z) component of the Navier-Stokes equation
for cylindrical coordinates need be considered:
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where Vz, Vr, and Vo are the velocity components in the axial (z), radial (r) and tangential
(0) directions respectively, t is time, p is the fluid density, 6P/6z is the axial pressure
gradient, and d2Z/dt2 is the axial wall acceleration.
C
Figure 2.2. Theoretical system assuming linear rather than angular motions.
In the special case of flow in a circular pipe of constant cross sectional area,
circumferential and axial symmetry allow several dependencies to be eliminated, leaving
only an axial velocity component, Vz, dependent on r and t, and the driving pressure and
acceleration terms. These considerations yield the equation:
-av 1 aP d 2 Z a(2v ) av 
__ _-+ v _ z + - (4)
at p az dt 2 a r2 r ar
By prescribing periodic functions for the driving terms of the form,
1 aP(t) = , ina
pj az n=1 (5)
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analytical solutions with appropriate wall and centerline boundary conditions (Vz(R, t)=0;
dV/dr (O,t)=0; where R is the tube radius) have been derived elsewhere [101, 103-105],
yielding:
V(r,t) = -(G + A0)(R2_r2)+ (G + An) 1-
4v n=1 mino
(7)
where the axial flow velocity, Vz(r, t) is a function of radius and time, and can be driven
by pressure gradients (Eq. 5) or wall accelerations (Eq. 6). G and An represent the
amplitudes for the Fourier components of the nth harmonic of co for the pressure gradient
and wall acceleration respectively, while Go and Ao are the steady forcing terms. From
this straight; tube model we see that identical relative flow profiles can be obtained
through either pressure gradients or wall accelerations given the interchangeability of G
and A.
Solutions
Using this linearly accelerating straight tube approximation, we can analytically study the
nature of the contained flows under various prototypical forcing conditions. By applying
an acceleration impulse of the form:
d 2 Z(t) (8)
,'2 n.c.,., (8)
dt n=l
Ldldpwer -.;: FUW aslWI uLJI ywI
and solving equation 7 for Vz(r, t) using R=0.16 cm (typical of coronary geometries), and
a Newtonian approximation for the blood viscosity, u=O.04 dynes cm/sec (valid for
arterial type flows), we obtain the solution shown in figure 2.3.
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Figure 2.3. Evolution of the axial velocity profiles relative to the wall in a radial distribution over
time given an impulsive wall acceleration.
We see that there is an initial spike of relative fluid motion which decays as shear forces
propagate through the fluid, quickly establishing radially parabolic, axial velocities
profiles. It is important to note that an impulse of wall acceleration leads to a step in wall
velocity, and while this means that there continues to be fluid motion in the IRF, relative
wall motion is not sustained through constant wall velocities. The impulsive decay is
governed by a time constant dependent on the fluid viscosity and square of the tube
radius (see Eq. 7) which we find to be equal to ....0.1 sec (time to 36.7% of peak value).
While different amplitudes of acceleration can be used to drive the contained flow, this
characteristic time remains unchanged so long as the fluid and tube properties remain
constant.
In order to maintain a relative fluid/wall motion, the tube wall must continue to
accelerate. For the case of constant acceleration,
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Ao = 628cm/ sec 2 (9)
we can plot the radial, relative velocity profiles with time in the WRF (solid surface),
along with the velocity profiles in an IRF (mesh surface; Fig. 2.4).
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Figure 2.4. Parabolic axial velocity profiles in a radial distribution over time due to a constant wall
acceleration in both a relative wall (solid) and inertial reference frame (mesh); R=O.16 em; v=O.04
dynes em/see
As predicted, the induced, relative, constant velocity profiles are parabolic in nature,
paralleling pressure-driven Pousille flows. While such relative flows can be created and
maintained through wall accelerations, the continuous acceleration leads to unbounded
wall and IRF fluid velocities. More generally, net positive flows require net positive
accelerations. Thus any motor used to drive such a system would quickly reach its
operating limit.
While this situation poses a problem, the unique coronary flow which we hope to emulate
is highly pulsatile, as a systolic rise in intramural pressure drives the flow to a halt (recall
Fig. 1.8). This creates a situation where relative wall motions and tube accelerations are
reduced to zero. If the time for flow decay is gradual and greater than approximately
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three system time constants, the flow can be reduced to within 5% of its peak value
without having to decelerate the tube walls, while slower decay profiles can be quasi-
statically accommodated by modulating the wall motions. On the other hand, rapid flow
decelerations would create flow reversal and more complex flow patterns. Although
identical, repeating acceleration profiles could maintain unidirectional flow pulses, this
situation would lead to impractical, compounding wall velocities in the IRF. Rather,
introducing a one-way valve or allowing bi-directional flow offers two potential
solutions.
By incorporating a one-way valve, the walls can be rapidly brought to a halt once
the contained fluid has reached solid body motion. This action essentially creates a
negative impulsive wall acceleration that would normally drive rapid relative retrograde
flow. However, by virtue of the one-way valve, the fluid can be kept motionless in the
WRF and brought to rest in the IRF. Thus, unidirectional flow pulses can be maintained
without a net compounding wall velocity.
There are various drawbacks to this method. Designing a one-way valve of
sufficiently low profile is difficult, and would itself generate unwarranted resistance and
hemodynamic effects. Even though the flow could be stopped in solid body rotation via a
one-way valve, the imposed pressure wave created in the fluid due to the sudden
deceleration could have consequences on the thrombotic process. As a principle goal of
this system is to reduce noise and minimize external sources of thrombotic activation to
allow sensitive, flow dependent studies, such disruptions are undesirable.
Alternatively, bi-directional flow at one half the frequency ()system) of the desired heart
rate (Ocoronary) can be established by following each tube acceleration profile with a
symmetric deceleration. Such an action would create a flow of identical magnitude
though in the opposite direction, at the end of which the tube would have no net change
in momentum. This limits the maximal required speed of the motor to some value
dependent solely of the characteristics of a single pulse, and is minimized by setting the
bounds symnetrically about a zero angular velocity.
To observe the nature of this type of oscillatory flow, we can model wall
velocities assuming a sinusoidal motion
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dZ(t) Al ;WSYSlemt--=---e
dt OJsystem
d 2Z (t ) = A e ;Wsyslem1
dt2 I
(10)
(11)
where we only consider one harmonic, OOsystem,which is equal to the frequency of
oscillation (heart rate/2=1t). Ai/OOsystemis the amplitude of the wall velocity, and Al gives
the corresponding wall acceleration amplitude (200n cm/sec2). Again solving equation 7
for the radial velocity profiles, w(r, t), we obtain the solution shown in figure 2.5 .
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Figure 2.5. Solid surface depicts the relative axial fluid velocity in a radial distribution as a function
of time given a sinusoidal wall motion while the mesh surface depicts the fluid velocity in the inertial
reference frame; R=O.16 em, v=O.04 dynes em/sec.
Here, we see that oscillatory flows can readily be generated, and moreover, that given the
relatively fast system time constants as compared to physiological pulse rates, the
fluid/wall motion can be smoothly transitioned from beat to beat, with negligible flow at
the beginning of each new pulse. While this example considers a simple, sinusoidal
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forcing function, more complex forcing functions (Eq. 6) can be used to generate more
complex flows.
An extreme case is that of square wave wall accelerations where otherwise steady
absolute wall accelerations are interrupted with discontinuous jumps to motions of equal
magnitude but opposite direction. Such a driving wall motion is given by:
i ~e;nax
n=I.3,5 ... n
(12)
driving the axial velocity profiles shown in figure 2.6. Here, we note that the profile
reaches a uniform, parabolic condition after a time delay of .....0 3 sec (3 time constant, as
expected from our impulsive response, Fig. 2.3). However, the presence of the rapid
directional transition creates brief moments of flow reversal, which can be observed in
the radial profiles.
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Figure 2.6. Solid surface depicts the relative axial fluid veloeit), in a radial distribution as a function
of time given a square bulk fluid flow; R=O.16 em, v=O.04 dynes em/sec.
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2.1.3 Curvature Effects
These solutions cover the case of straight tube, axial wall motions. However, both the
coronary arteries and our toroidal loop model (adopted for low blood volumes and
practical use) have inherent curvature which can have effects on the internal flow.
Curving flow streams are affected by centrifugal forces which can establish secondary,
off-axis, flow fields when interacting within viscous boundary layers. The magnitudes
of these secondary flows are governed by the dimensionless Dean #, K, which is a
function of the secondary inertial and viscous damping forces, and the main stream
centrifugal force. However, the customary definition of K (see Table 2.1) is not
applicable in the rotating toroid case, as the relevant velocity term must take into account
the fluid's axial velocity in an inertial reference frame (Vfluid) which gives rise to the
centrifugal forces and a different wall velocity (Vwal). It is the difference in these
components that gives rise to the relative wall velocity (Vrel) and hence, the centrifugal
pressure mismatch leading to secondary flows.
To determine a modified Kpeak number (K'peak) for comparison with the nominal
conditions of table 2, we can consider the definition of K as a ratio of the square root of
the product of the secondary flow inertial and centrifugal forces to the viscous forces
[1100], where
2
P VsecondarInertial forces --
2a (13)
Centrifugal forces -
2R (14)
U VsecondaryViscous forces () 2
(2a2 (15)
which have been determined from an order of magnitude consideration of the relevant
quantities [106]. In these equations, Vsecondary represents a typical secondary fluid
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velocity, p is the density of the fluid, and jt is the dynamic viscosity of the fluid. The use
of tube and loop diameters (2a, 2R) rather than radii have been used to allow reduction
into a quantitatively conventional form. The differential term in the centrifugal relation
accounts for the relative centripetal motions in an inertial frame. When both motions are
present, K'peak becomes
K peak = Max
(16)
When Vwall is zero, as in the case of forced flow through a curved, stationary pipe, K'peak
reduces to the standard form given in table 2.1 The magnitudes and effects of these
secondary flows an the embodied device are discussed further in section 3.1.2.
While a thorough, quantitative description of the time-dependent fluid flow profiles
within the rotating toroidal case would require more extensive numerical techniques, we
satisfied ourselves with the straight tube characterization and the practical goal of
matching the critical dimensionless Reynolds, Womersley, and modified peak Dean
numbers to those observed in typical coronary flow settings on a beat to beat basis.
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2.2 Embodiment
2.2.1 Prototype evolution
In order to create the inertially driven, relative flows, we needed to develop a suitable
system that could maintain the required, toroidal angular motion profiles. Generally,
such a system requires a rotor, a suitable strategy of inducing motion and a technique for
monitoring the contained flow. In sections 2.2.2-2.2.6, we give a thorough description of
the current system embodiment and composite parts. First, we give a brief prototype
evolution of the developmental stages.
b.
Figure 2.7. Single fluid loop, infra-red sensing rotor stage. a. Top view; b. Side view.
To verify the inertial method of relative flow induction, we developed a system that could
spin a single fluid loop. An Electro-Craft@ NEMA42C motor (selected using a similar
design rational as detailed in section 2.2.4) rotated a rotor stage through a prescribed
motion profile utilizing the control system described in section 2.2.5. The initial
prototype utilized a rotor stage with equi-spaced infra-red (IR) sensors and detectors
positioned around its perimeter, with the held fluid loop passing in between the IR beam
(Fig. 2.7). To detect fluid motion, a small particle of equi-fluid density (typically a fibrin
clot) was placed within the fluid loop. With relative fluid motion, the particle would cut
the IR beam and its velocity could be determined by observing sequential deflections of
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IR detector output. Although this method roughly indicated the suitablilty and
practicality of generating relative flows, the inclusion of a tracer particle with in the
actual flow field interacts with both the biological and physical environments. Such
disturbances could dramatically affect both the observation and performance of the test
system.
Figure 2.8. Single fluid loop rotor stage with ultrasound flow probe. a. Top view; b. Side view
A second prototype was developed which utilized a rotor stage incorporating an external
ultrasound flow probe (see section 2.2.6) to measure relative fluid flows, using the same
motor/controller system used for the IR rotor (Fig. 2.8). The external nature of the probe
allowed unperturbed flows to be measured with greater granularity and precision than the
relatively crude IR technique while verifying the ability to pass the probe signals between
rotating and inertial reference frames for this unorthodoxed use.
These systems have utilized a single rotor stage to create motions within a single fluid
loop. In order to perform parametric, mechanistic studies into complex phenomena such
as vascular thrombosis, it is important to be able to perform many experiments and
developed models and strategies must take this into account. Practically speaking, high
throughput systems allow studies to be perform quickly and efficiently. Speed becomes
an even greater issue when investigating blood. Upon removal from its natural vascular
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environment, it rapidly begins to change. On this shifting ground, studies must be
performed soon after withdrawal to maintain study accuracy and temporally close
together for precision. To enhance our ability to probe vascular situations, we developed
a multi-rotor system which supported six rotors on a single axis allowing six fluid flops
to be spun simulataneously (Fig. 2.9). While the motor needed to be reconsidered to
support the increased requirements (section 2.2.4), the single rotor control structures
could be maintained.
Figure 2.9. Multi-rotor system. a. Side view showing six, stacked rotor stages with alternating
ultrasound flow probes; b. Close-up view of on board probe multiplexer
Using the same evolutionary pressure of study speed and efficiency, we modified the
multi-rotor design to enhance modularity and ease of incorporation onto a multi-axis
system, thus allowing multiple simultaneous flow profiles to be considered (Fig. 2.10).
We now discuss the multi-rotor embodiement in greater detail.
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Figure 2.10. Current system embodiment with two axes, each holding upto six rotors stages. Much
of the electronics have been consolidated into the inertial reference frame, increasing the modularity
of system to support future expansions.
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System Overview
A system was developed in order create the inertially driven flow profiles discussed in
section 2.1. Figure 2.11 shows the key components of the system, which include a fluid
loop, rotor-stage, driving motor, motion controller, and a measurement system.
Top view
I
I
I
I
I
FLUID
LOOP:
PC:
Motion Instructions
& Data Storage
- - - - - -7- - I
+
CONTROLLER 1Electronic
Gearing
-----------
FLOW
RECORDING
SYSTEM
I CONTROLLER 21
Figure 2.11. General mutlti-axis, multi-rotor flow system schematic.
platform and is placed in axial alignment with other loops to be tested under the same
flow conditions. Although any number of loops is allowed, the embodied system allows
six simultaneous runs via six modular rotor platforms per axis. The entire rotor system is
then driven through a desired angular motion profile via the motor and controller system.
This motion creates internal flows, which are measured via onboard flow transducers
built into the rotor stages. Each transducer sends the flow measurements of a particular
fluid loop to the measuring/recording system, which can be used to instantaneously
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monitor the flow profiles and fluidity of the blood. A detailed description of these
components and a rational for there selection follows.
2.2.2 Fluid Loops
Design
A schematic of the basic fluid torus is show in figure 2.12. The loops are made of a 24
cm length of 1/8 " ID::5/32" OD 3350 Tygon silicon tubing. The connecting ends of the
tube are squarely cut, orthogonal to the axial dimension to ensure a matching end-to-end
fit. This connection is held via a 1.5 cm overlapping segment of S-50-HL Tygon tubing
(3/16" ID; 5/16" OD.) The close OD/ID match provides a compression fit and axial
alignment of the juxtaposed ends. Further support is provided by a 1 cm elastic band of
silicon tubing (Silastic; /4" ID; 3/8" OD) placed coaxially over the 1.5 cm joiner segment,
thus radially compressing the junction.
a. b. 0.27
\\ ~ ii1 0.94"\,,\?~ ~~~~I
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Figure 2.12.. Fluid loop design. a. Loop format with three coaxial sleeves, one for maintaing loop
format and two as inlet and outlet ports; b. Coaxial sleeve cross-sectional profile.
Two similar structures are slid onto the 1/8" loop at equally spaced 120 degree intervals
serving as outlet and inlet ports for the replacement of the loop's contained air by the
dtesired fluid. Briefly, a needle is slid under the outer most elastic sleeve and then driven
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into the lumen through the middle sleeve and inner loop layers. To minimize possible
disturbances to the loop's inner, fluid-contact surface, small gauge needles are used.
While a 26+ gauge needle is suitable for air evacuation, 19 or 20 gauge needles are used
for the untraumatic injection of blood components (Fig. 2.13).
Figure 2.13. a. Filling of fluid loop; b. Filled loop. Note the absence of fluid/air interface.
Rational
.In settling on these embodied loop dimensions, a primary concern was to match the
physiological diameters, typical of a coronary setting (3-3.5 mm; LAD). The 1/8" ill
tube was chosen as it fell neatly within this range (3.175 mm), with the 5/32" OD
imposed by specifications of the flow probes (discussed below in section 2.2.6).
The overall 24 cm length was determined by balancing the desire to minimize
blood contact surface and blood volume (both to maximize the biological signal to circuit
noise ratio, while enabling practical biological manipulation) with the need to keep loop
curvature at reasonable levels to dimensionally consider secondary flow effects.
The final consideration in tubing selection was the 3350 Tygon silicon tubing
chosen for its low bioreactivity and suitable gas permeability. However, given the
inertial mechanisms driving the flow, any desirable tube could be used (i.e. rigid vs.
compliant). Furthermore, the tubing can readily be replaced (i.e. vascular graft material,
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ex vivo arterial sections, etc.) or simply coated with a test substance (i.e. proteins, cells,
polymers, etc.) whose thrombotic properties are to be specifically studied.
2.2.3 Rotors
Rotor stage design
The rotors are the platforms upon which the fluid loops are held. In the current embodied
system, each axis holds 6 rotors. Figure 2.14 depicts the design of an individual rotor (3
orientation A; 3 orientation B per flow axis). Each rotor was manufactured out of a stock
of 3" diameter delrin plastic chosen for its machinability and ease of handling. The key
features of the rotor are a resting stage for the fluid loop, an axial hole for alignment of
the rotors, a notch for the placement of the flow transducer, and a shaft through which the
transducer connections may be passed.
a.
Keyed
Axial Hole
Connector /I/J~
Shaft, I
, Probe
Notch
b.
Figure 2.14. Schematic drawing of a single rotor-stage. a. Orientation A; b. Orientation B. Note the
chirality of the probe notch.
The stage was designed to fit the embodied fluid loops. As such, they snuggly fit the
inner most diameter (5.75 mm) of the loop which is outlined by the outer most Silastic
tubing layer of the fluid loop's inlet, outlet, and junction structures. Only this Silastic
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band is in contact with the stage, thus suspending the fluid loop. The notch for the flow
probe accommodates a Transonic 3CA flow probe (described in further detail in section
2.2.6), and its dimensions were defined by the need to allow the suspended 1/8" ID, 5/32"
OD fluid loop to pass through the flow probe's sensor (Fig. 2.15). As shown in figure
2.13, two chiral rotor conformations exist, based upon notch orientation. This chirality
allows the probes to face opposite directions as the rotors are sequentially stacked, thus
minimizing asymmetrical, processional loading.
3. b.
Figure 2.15. Fluid loop positioned on rotor stage. a. Top view showing coaxial positioning; b. Fluid
loop passing through the probe's sensor.
The shaft for the transducer connections was designed to accommodate a specialized
connector (described in section 2.2.6) which relays real-time flow information. A 1/8"
hole connects this shaft to the probe's notch serving as a conduit for essential wires.
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Rotor shaft design
The rotor axis is shown in figure 2.16, a. b.
along with a diagram depicting six
I I I 1 -
stacKed, alternating rotor stages. ne
shaft was machined from a 1" diameter
stock of delrin and consists of two
sections. The top section has been
lathed down to a diameter of 3/4", with
a milled /4" groove running its entire
length to accommodate a strip of
nylon. This strip protrudes from the
shaft and serves as a key to hold the
rotor stages in axial alignment via a
matching perimeter center-hole in each Figure 2.16. a. Rotor shaft; b. Shaft w/ six stacked
rotor stages
rotor stage as shown in figure 2.8. The
square key design holds each stage in tight tolerance while undergoing angular
accelerations. The bottom section remained at the initial stock diameter of 1". Into it, a
centered 1/2" hole allows communication with the driving axis (see Section 2.2.4 for
motor selection). To ensure a non-slip junction, a screw key was also placed to grip the
motor shaft.
A final caveat that can be observed in figure 2.16 is that the shaft extends past the
length of six combined rotor heights. This is critical in allowing for the fit of a cap
structure that houses on-board instrumentation for the flow transducers (see Section
2.2.6).
2.2.4 Motor Selection
The driving motor is an Electro-Craft® E643 DC servo-brush motor. The critical design
parameters that were considered were the peak torque and maximum operating speed
which were estimated from the straight tube, Newtonian fluid approximation outlined in
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the previous section, augmented by an impedance factor to account for curvature effects
as suggested by Chang and Tarbell [76].
The peak torque was determined from the maximum angular acceleration required
to drive the fluid, which in turn was constrained by the desired flow rates. Peak
physiological flow rates are around 100 ml/min in the coronary arteries. While the actual
profiles are highly pulsatile, the extreme steady flow case (see Fig. 2.4) can be obtained
using a constant wall acceleration of 6.28 m/sec 2. For the embodied loop diameter of
0.0762 m (3"), this axial wall motion transforms into an angular acceleration (a; A/2xr),
of 26.2 sec-2. This value can further be augmented by an impedance factor as suggested
by Chang and Tarbell [76] to account for curvature effects [100, 104], as well as
compounded to allow more extreme flow rates and varying blood conditions (i.e.
increased hematocrit), yielding a critical design a of 40 sec 2 .
The torque, T, needed to drive the system at this angular acceleration is given by:
T= Ia (17)
where I is the moment of inertia of the rotor system. I was estimated to be 7.26X10 -4 kg
n2 assuming the rotor was a solid delrin cylinder 0.0762 m in diameter (m-l kg;
1= 1/2mR2), resulting in a peak torque of 0.029 Nm.
The maximal operating speed was estimated from the rotor speed required to
accommodate one acceleration pulse. With a physiological rate of 60 bpm, we again
over-designed our criteria by considering a 2 second pulse duration (30 bpm). This
yields a maximum angular velocity of 500 rad/sec (4775 RPM).
The Electro-Craft® E643 model satisfies these criteria, supplying a peak torque of 0.16
Nm and a maximum operating speed of 4800 RPM. A chassis was built to house the
motor in a vertical configuration, allowing the rotor system to mount directly on top. It
was decided to allow the rotor to communicate directly with the drive shaft, given both
the heavy duty nature of the E643 motor and the care taken in axial alignment and
minimizing asymmetrical loading. Still, a bearing system to accommodate off-axis
loading could be used in future designs.
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2.2.5 Control System
Single Axis
In order to control the Electro-Craft@ E643 DC servo-brush motor, the control structure
shown in figure 2.17 was developed. The components of the motor control system
integrate readily and allow specific flow profiles to be generated. These components
include a Renco RM15 Encoder, an Electro-Craft@ IQ-550 Position Control Module, an
Electro-Craft@ Max-100 PWM Servo Drive, and a Windows compatible PC terminal
running IQ Master software.
TO ROTORS
E643
MOTOR
MAX-lOO
DRIVER
IQ550
CONTROLLER
Figure 2.17. Control schematic for single axis
The RM 15 Encoder is a 1000 line encoder that is placed in axial alignment with the
drive, transducing rotor position. This position signal is then sent to the IQ-550 which
sends a +/-10 volt analog velocity command signal to control the motion of the motor.
The analog signal is dictated by a program written in the IQ Master programming
language and stored on the IQ-550's EPROM. This velocity command is relayed to the
MAX-100 drive which serves as a power amplifier, supplying up to +/-3 amps of
continuous current to drive the motor.
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The rational for choosing these components was their integratability and the ease
with which the motor's motion profile could be adjusted via software rather than
hardware means, allowing various flow profiles to be readily generated and modified
according to the desired experiment. Specific IQ Master programs used to create the
various flow profiles used in the current work are given in the Appendix.
Multiple Axes
While this control structure allows the control of a single rotor axis and hence one flow
profile, we wanted the ability to drive multiple flow profiles simultaneously to increase
the precision and accuracy of our model in studying flow
To AXIS 3
•••
AXIS 1
MAX-tOO
t
IQ550
CONTROLLER
Figure 2.18. Control schematic for multiple-slaved axes.
dependent processes. The most versatile option would be to have multiple IQ-550
controllers, each driving an individual axis via a specific, implanted IQ program.
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However, a simple, cost-effective method to control multiple flow rates at once is to
'slave' additional motor axes to the controlled, master motor's velocity profile which can
be obtained directly from the line-encoder output on the master motor (Fig. 2.18). By
using a slaved velocity command signal that is a variable ratio of the master motor's
profile, proportional velocities, accelerations, and hence flow rates can be easily
generated. For each additional axis, a motor and feedback tachometer is required, along
with a driving MAX-loo whose on-board control structures can accept velocity feedback
to maintain the slaved velocity command signal.
2.2.6 Measurement/Recording System
In order to measure and record the flow profiles, the outlay shown in figure 2.19
developed. The components of the system are the Transonic 3CA
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Figure 2.19. MeasurementlRecording system schematic and information flow.
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flow probes, probe multiplexer, rotary junctions, 10 volt Tecma power supply, Transonic
T106 Flowmeter, and a Windows compatible PC equipped with a National Instruments®
LAB-PC A/D interface and LABTECH Version 8.1 software package (Laboratory
Technologies Corporation ©)
Probes
The Transonic flow probes measure bi-directional flow via an ultrasound transit time
method. Typically, four piezoelectric transducers are positioned around the tube. These
elements pass ultrasound beams in alternating up- and downstream directions through the
fluid, each serving as a transmitter and receiver in turn. The differential, directional
transit time can then be used to measure the bulk flow in the tube. The probes were
specifically calibrated for use with the 1/8"ID/5/32" OD 3350 Tygon tubing used for the
fluid loops, and further modified so that only 2 of the transducers were required (1
upstream, 1 downstream) allowing 4 connections per transducer rather than 8.
Accordingly, the total number of connections on a six rotor/six probe axis was reduced
from 48 to 24. This reduction, though not necessary, greatly simplified the construction
and wiring of the embodied system.
On each rotor stage, the four transducer leads were passed to the connector shaft and
soldered onto a given pin on a specially constructed 24 pin connector (Fig. 2.20). Once
the proper connections were made, these pieces were press fit into the connector shaft on
the corresponding rotor stage. Upon stacking, the male junctions on a given rotor stage
communicates with the female junctions on stage immediately below it. Thus, each
stacked rotor stage is hardwired to all of the probes via the 24 pin connections. This
design allows the stages to be modular for loading and possible future expansion
purposes, with the top most stage relaying all probe signals to the probe multiplexer.
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Figure 2.21. Multiplexing schematic; Six probe signals are merged into one continuous waveform
and subsequently decoded using concurrently recorded probe label information.
A rotary electrical coupling interfaces the rotating loop reference frame with the inertial
frame. To limit the number of rotary junctions, the probe multiplexing stage is located on
the rotor frame itself (Fig 2.18), thus reducing the required number of rotary junctions
from 24 to 8 (or 7 in the multi-axes scenario as some functions could be consolidated
onto inertial frame circuitry). The onboard multiplexer probe output is wired to four of
the rotary couplings. Three additional couplings provide power (+10V, GND) to the
multiplexer as well as information on the probe label. A final connection is required to
pass the probe switch trigger in cases when multiplexing logic is distributed to indIvidual
axes in the rotating reference frames.
Although this measurement system can monitor and record the full flow profiles in the
fluid loops, often times only the peak flow values are stored to disk. This data
compression is performed in real-time using the LABVIEW software capabilities. To do
this, the IQ550 was programmed to send a brief 5V pulse to the PC during peak
acceleration, signaling an appropriate, consistent point in each flow pulse to be sampled.
Thus, even if the flow is significantly reduced (as in thrombotic loop occlusion),
consistent portions of the cycle can still be recorded.
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2.2.7 Design Summary
The system described allows an oscillating type flow of a prescribed flow pattern to be
produced in fluid loops. The manner in which the flow is produced is atraumatic, thus
allowing delicate processes such as thrombosis to be studied in a low noise setting, even
under high flow rates. Furthermore, this strategy allows the entire fluid contact surface to
be prescribed and minimized, without the use of valves, connectors, or other potential
disturbances, further reducing potential sources of background noise. By readily
allowing changes in flow profiles, the system also allows the thorough, parametric
investigation of how flow may interact with biological processes such as thrombosis.
While the current embodiment allows multiple, 1/8" ID loops to be run under two
simultaneous, bidirectional flow rates, various modifications can be readily made to
extend the system's applicability. More axes can easily be added (Fig. 2.17), allowing
multiple, simultaneous comparisons at several flow rates. By incorporating additional
IQ550 Controllers, these flow variations can be extended to include not only flow rates,
but profiles as well. Altering rotor and loop characteristics, can also offer a wide degree
of variation in the geometric properties. Furthermore, incorporating a one-way valve
could be used to allow unidirectional flows, though the impact of such a structure on the
hemodynamic loop environment would have to be considered as discussed in section
2.1.2. It is important to recognize that each of these adjustments would also require
reconsidering the embodied motor specifications and other aspects of the system design.
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CHAPTER 3 Flow System Testing
3.1 Mechanical validation
To demonstrate the range of system capabilities, a single fluid loop was filled with a 6:4
water/glycerol mix to match the Newtonian approximation blood viscosity under arterial
flow conditions (0.04 cm2s- ) [78] and placed on a rotor stage. The rotor was driven
through a variety of motion profiles to generate impulse, square, triangle, sinusoidal, and
coronary-type flows. The full flow profiles, rather than just peak data, were recorded via
the LABTECH software.
3.1.1 Flow profiles
The impulsive response of the system was examined after a brief burst of torque was
supplied to the rotor. Some points to note in this profile (Fig. 3.1) are the 0-135 ml/min
rise time of 0.1 sec and a decay time constant of 0. 1 sec, which matches fairly well with
the value obtained from our theoretical, linear approximation (Fig. 2.3). The finite rise
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Figure 3.1. Relative fluid flow to impulsive wall accelerations.
time was a result of the limitations of rotor inertia, friction, and peak obtainable torque.
If a quicker response is required, these parameters can be adjusted through design
modifications. The decay time constant on the other hand, being constrained by the
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vessel radius and kinematic fluid viscosity, is not readily subject to change. Therefore,
relative flows decaying to nearly zero (<5% peak) in times less than 3 time constants are
not possible without some flow reversal or the incorporation of a directional valve.
These parameters help to characterize the realistic impulse response achievable with the
current setup, which serves as the limiting building block from which other functions can
be composed.
Some examples (square, triangular, sine waves) of other possible flows are
shown in figure 3.2 a-c. Here, the periodic, bi-directional nature of the flow is evident.
Again, this type of oscillation is necessary in the methodology used to create flow, as no
valves were present in the circuit.
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Figure 3.2. Various flow profiles depicting the easily alterable flows. a. Square; b. Triangular; c.
Sinusoidal profiles. **It should be noted that the square profile depicted in panel a is blunted at the
corners. This is a result of the inherent time decay in the system, as shown computationally in Fig.
2.6. More accurate square profiles can be discussed through the use of more complex driving
functions as discussed in later in section 6.1.1.
IfPlfarJr 1. FlrA. IIL-V m TIr!ytIIn 68
~rrcrr ci .. I wvv J7YOLU111 I Crourry
3.1.2 Coronary-Flow
Since we hope to investigate coronary arterial events, a coronary flow pattern [19] (scaled
to a 60 bpm frequency) was approximated with our bi-directional model (Fig. 3.3a).
Figure 3.3b gives the driving wall velocities, Vwall, required to achieve this coronary-type
flow, Vrel, and the derived absolute fluid velocity in the inertial frame, Vfluid.
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Figure 3.3 Generating coronary type flows. a. Bidirectional bulk flow rate relative to the
rotating wall (solid line), superimposed on idealized coronary pulse (dashed line); b. The
wall and fluid velocities in the inertial reference frame (blue, magenta lines respectively)
in phase with the target, relative, peak fluid velocity (red line; derived from bulk flows
assuming parabolic motion, justified for low Wormesley # flows). Prior to a new pulse,
there is no fluid motion relative to the wall.
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2
This simulated coronary-type flow is characterized by a Re of 150 (based on IVrelI), an ot
of 2 (based on a (coronary), and a K'peak of 135 (as defined by equation 1). Re and , when
compared with table 2.1, indicate the ability to achieve coronary-type principle flows
while keeping secondary flow effects (as estimated by K'peak) to within physiological
levels. The relatively low a (which compares the magnitude of the driving frequency to
the system frequency response) indicates that the flows are, for the most part, driven in a
relatively quasi-steady manner. This is further indicated experimentally in Figure 5b,
which shows that the relative flow velocity is approximately zero by the time the wall
velocity begins to initiate a new pulse.
While Vrei essentially resets to zero initial conditions after each unidirectional pulse, we
must again point out that the created flows are bi-directional in nature. Though many of
the thrombotic protein and cellular surface reactions have been shown to be dependent on
shear (Section 1.3.1) which we attempt to approximate by matching beat-to-beat
dimensionless parameters, the potential influences of such oscillation on factors such as
mass transport [59] and cellular function (adhesion, activation, response) [23] may
eventually need to be considered.
Another aspect of the flow that is altered is the secondary flow. Physiologically,
such flows in curved vessel geometries have been shown to be up to 5% of the axial flow
velocity, shifting the peak of the velocity contour towards the outer wall via half-tube,
single vortex flows (recall Fig. 1.7c). Peak wall shear rates due to these flows can be up
to 40% of the peak axial wall shear rates [76]. While precise determination of these
secondary flow fields through numerical simulation would be interesting and of value in
finding the exact time-dependent wall shear rates, we have found that the magnitude of
the secondary flows in our system (as determined by comparing KCpeak values observed in
the coronary setting with K'peak values in our system using equation 16) are comparable to
those found in a coronary setting of similar axial flows. Qualitatively, a deviation in the
secondary flow pattern results from a disconnect between the centrifugal force and the
relative wall velocity (which are normally linked in stationary wall flows). During part
of the cycle, the bulk fluid velocity is greater than the wall-boundary layer velocity as is
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typically the case [76]. However, in our rotational system, there are also times when the
wall-boundary layer velocity in the IRF is greater than the bulk fluid's, resulting in a
counter-rotating secondary flow drive. Considering these effects, we see that we can
minimize the secondary flows as well as maintain beat-to-beat symmetry by using a zero
DIC component of Vwall. If needed, redesigning the fluid loop characteristics to have a
larger curvature to tube radius ratio (R/a) can further reduce the magnitudes of these
flows.
The versatility of the system allows fundamental wave characteristics such as amplitude
and frequency to be readily varied as desired. Figures 3.4 a and b depict such profile
manipulations as the amplitude is varied by a factor of 2. Furthermore, the system allows
for tailoring of more detailed parameters such as the systolic:diastolic ratio if desired
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Figure 3.4. Changing amplitude of coronary type flow (100, 200, 400 mi/min peak flow rates in a
triangular (Tri) profile).
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3.2 Biological validation
We performed an initial assessment of the model's suitability to study issues of vascular
thrombosis by observing the impact of endoluminal stenting on thrombotic outcomes. In
this preliminary study, we evaluated loop occlusion times as a straightforward, integrated,
measure of thrombosis. This evaluation allowed us to address the system's repeatability,
as well as background levels of circuit thrombotic activation. Together, these qualities
play a major role in determining the system's signal to noise ratio. As a concrete
example of this, we compared the loop occlusion times of stents of dissimilar surfaces.
3.2.1 Materials
Blood Source
In this preliminary study, surplus American Red Cross blood products were used to
obtain quantities sufficient to allow several experiments to be performed on the same
batch of blood for precision testing. Fresh frozen plasma and fresh platelet concentrates
(both anticoagulated with 10mmol acid citrate dextrose; ACD) were utilized as these
contained the key ingredients of classical thrombosis, neglecting the erythrocytic and
leukocytic components in this first level of study. Type AB+ fresh frozen plasma (FFP)
with a prescribed storage life of 6 months post-collection was stored at -20 C. The
plasma was thawed in a 37 C water bath for 45 minutes and then spun down at 10000 G
to eliminate debris such as preformed platelet micro-particles. The supernatant was
filtered 4 times through a 0.2 pm low protein binding filter to further ensure clean FFP.
The platelets (type AB+ PRP) were obtained within one day of collection and stored on a
70 RPM rocker at room temperature. These were used within the first two days post-
collection as was justified from adequate functional comparisons with freshly drawn
volunteer platelets.
One hour before a planned experiment, the platelets were added to the FFP at a
constant ratio of 1:4 PRP to FFP and returned to the rocker for equilibration. Each loop
required 2.5 ml of the FFP/platelet mix to ensure proper filling. To reduce experimental
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error from mixing and handling variation, the total volume of the suspension for a given
run (15 ml; 2.5 X 6) was pooled and prepared in a single tube.
Stented Loops
7-9 stainless steel NIR@ endovascular stents were obtained from Medinol Ltd.
(Jerusalem, ISRAEL). While the platelets were equilibrating in the filtered FFP, the
stents were expanded within the 1/8" tubing midway between two coaxial sleeves via a
36mm MaxxumTM 3.5 SCIMED@ balloon catheter under a pressure of 12 atm (see Fig.
3.5). The tubes were closed into their loop format ensuring a gapless fit. When the
Figure 3.5. Picturte of stent placement within fluid loop.
plasma/platelet mix was ready, 5M Ca2+ was added to bring the sample to an additional
IOmmol Ca2+ concentration, negating the citrate's anticoagulant, calcium chelating
effect. The stented loops were then filled with the plasma/platelet mix as described
above and placed onto the rotors. This process was sequentially performed as rapidly as
possible (~I5 sec/loop) while ensuring safe handling of the blood components and proper
filling of the tubes (no air bubbles). Once complete, the rotors were placed onto the rotor
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shaft and spun under a coronary-like motion profile (150 ml/min peak flow) within the 37
°C incubator.
3.2.2 Systemic Noise Characterization
PrecisionIV ariance
As a preliminary test of systemic noise, six stents were positioned in their respective fluid
loops and run through the described coronary flow protocol. The results obtained after
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Figure 3.6. System precision. Single run of 6 identical stainless steel stents, showing recorded
peak flow profiles and loop occlusion times.
parsing the data into individual loop, peak flow profiles (as discussed in Section 2.2.6)
show a constant flow rate followed by a fairly rapid drop to zero flow (Fig. 3.6). The
actual initial flows in each loop are identical as they have the same dimensions, fluid
properties, and driving motion profiles. Variation in the measured start-up flow rates
arises from the hard-wire calibration of the meter for a specific flow probe's signal while
our system employs six different probe signals. To account for this, each signal can be
re-calibrated according to these initial deviations where identical fluid conditions are
known to exist. The drop-off point indicates when the thrombus is occluding the stent. If
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a zero-flow condition is taken as the end point, the average occlusion time for this run is
43.1 :!::6.8 min (mean:!:: standard error).
Circuit Background Noise
As another initial test of the system, we compared a trial of three stented tubes to three
empty control tubes. The transformed peak flow data for such a run is given in figure
3.7. As above, the initial flow period followed by a drop-off is witnessed in the stented
samples, with an average clotting time of 39.1 +/- 1.7min. The stentless controls
remained patent for the +2 hour duration of the test, indicating low levels of circuit
thrombotic noise.
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Figure 3.7. Background thrombotic noise levels. Peak flow tracings for stented and control, non-
stented loops.
3.2.3 Signal to Noise
These results give insight into the important characteristics of the system's precision and
background noise levels. Maximizing precision and minimizing background noise
potentiates high signal to noise ratios which enable effective, powerful, parametric
studies. We investigated the preliminary effectiveness of our in vitro method in creating
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sufficient signal to noise ratios by exploring the loop occlusion times of 7-9 NIR® stents
of dissimilar surfaces properties. Four kinds of stent surface treatments were selected as
motivated by clinical and industrial perspectives: untreated stainless steel, standard
electropolished stainless steel, gold-coated (7 + 2 jim), and gold-coated + heat treatment.
Effects of polishing on loop occlusion times
We first tested the occlusion times between untreated stainless steel stents with those put
through a standard, electropolishing procedure which has been shown to significantly
reduce surface roughness. To minimize possible bias due to placement order, 3 polished
and 3 untreated stents were loaded in an alternating pattern (#1,3,5 polished; #2,4,6
untreated or vice versa) and run under the prescribed coronary-type flows. Three runs
were performed in total, yielding a sample size of 9 untreated and 9 polished stents. To
correct for variability in blood samples, all occlusion time values were normalized to the
average, polished stent clotting time for each run. Figure 3.8 shows that the non-polished
stents took significantly less time to clot than polished stents (unpolished, 0.73 +/- .06
normalized mean run steel occlusion time; two-tailed t-test, p <.05). Therefore, when
looking at end point, loop occlusion time as a measure of thrombogenicity, the positive
effects of polishing on stent thrombotic potential can be seen.
Effects of gold-coating on loop occlusion times
Gold-coating is a desirable surface property due to increased radio-opacity and easier
stent placement. However, such processing has been shown to alter other surface
parameters (i.e. roughness, surface energy, etc.) which can have detrimental side effects
[107]. By subsequently heat-treating the coated stents, roughness is significantly reduced
to precoating levels. Thus, we tested the loop occlusion times between standard, polished
stainless steel with and without gold coating, along with the post-coating, heat processed
devices.
Comparisons were performed on the stent types, using the average run, polished
steel surface as a normalization control to account for inter-run variability. Stents were
loaded (standard vs. gold-coated; standard vs. processed gold) and run in an alternating 1,
:3, 5 / 2, 4, 6 pattern as in the preceding trial. From figure 3.8, we see that basic gold-
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coating significantly reduced the normalized loop occlusion times (gold, 0.68 +/- 0.03
normalized mean run steel occlusion time; two tailed t-test p-value < .01), while the heat-
processing treatment was able negate this pro-thrombotic effect (heat+ gold, 1.0. +/- .05
normalized mean run steel occlusion time; two tailed t-test p value --). Comparing the
normalized, gold-coated pre- and post- treatment results, we see that the treatment effect
is significant (two-tailed t-test, p <.02).
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Figure 3.8. Inter-stent studies. a. Polished vs. Untreated; b. Polished vs. Gold vs. Gold + Heat
Treatment. Note that the Polished steel values are by definition 1.
When designing tests, it is important to consider a studies power, which is a function of
the differences that are trying to be measured (signal), the inherent variance in the
measurement (noise), and the number of trials that must be performed to be relatively
certain that observed differences are real rather than merely a consequence of
measurement error. At one extreme, clinical trials are plagued with high variance. As a
result, they typically require massive trials of hundreds to thousands of human subjects to
sift through this noise for relevant signals. The expense and time needed for such trials
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creates very real, practical limitations on the types of studies that can be performed. In
vitro methods are often able to significantly reduce such population variance by offering
greater experimental control. In our studies, we see that significant results (as indicated
by the p values) could be obtained with relatively small sample sizes (-10).
Having powerful methods is essential to explore complex biological situations
where isolation and directed manipulation of variables with observable outcomes enable
epistatic pathway dissection. While sufficient power is only definable in reference to a
particular signal of interest, our preliminary case studies of endovascular stent loop
occlusion times add confidence that similar techniques will allow for other mechanistic
investigations of coronary thrombotic events and processes.
In this section, we have tested our model flow system and found it to be suitable for
reproducing coronary-type flow patterns on a beat to beat basis as judged by dimensional
consideration. We have further applied this system towards an investigation of
endovascular device thrombosis by considering acute loop occlusion times as a measure
of the thrombotic response. The approximate 40-minute stent occlusion times that we
observed are phenomenological findings that occur in our model system. In vivo
thrombotic occlusion occurs at a much lower rate and generally takes place subacutely
over the course of several days. There are various potential explanations for such
observational discrepancies. The clinical situation has both innate and external counter
measures, such as a reactive endothelial layer and drug therapies that help to regulate
thrombosis. Indeed, with the advent of suitable drug regimes and implantation
techniques, the thrombosis rate has dropped from nearly 25% in initial studies to its
current low levels (<5%) [86, 108, 109]. Furthermore, our system is a closed, in vitro
model where produced substances are not cleared. This could not only help to explain
the regularity of clotting seen within our system, but also the fairly rapid drop to zero
flow as confined, explosive reactions could augment rapidly due to positive feedback
processes.
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Due to such differences between our model and the physiological situation, we
hope not to study the physical occurrence of end-state occlusion (though this is an
important preliminary observation), but the cellular and protein factors leading up to
thrombosis. Such dependencies are not only key mediators of occlusive events, but
essential in vascular remodeling and sub-clinical responses to injury.
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CHAPTER 4 Parameterizing the Thrombotic Response
There are many components and interactions involved in the thrombotic response to
injury (section 1.2). In the previous chapter (section 3.2), we have used our flow model
to investigate an integrated, loop occlusion response to endovascular stenting. Such
overt occlusion occurs as platelets and enzymatic mediators interact with both the device
surface and with each other to mediate thrombosis. When observing such complex, high
level outcomes, these interactions may be significantly misrepresented in model systems.
Rather than observing phenomenological loop occlusion times, we hope to develop a
deeper level of understanding of the thrombotic response, initially focusing on the
platelet as essential component of vascular thrombosis (section 1.2). Upon binding to an
injured wall, platelets alter their expression of surface molecules and release substances
which both attract and adhere to flowing cells while promoting the enzymatically driven
coagulative response. The richness and importance of this platelet level demands the
pursuit of understanding how this component interacts within its hemodynamic
environment to promote vascular thrombosis.
observation and control are required.
To accomplish this, methods of
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Figure 4.1. Platelet responses and coagulation interact within a black box to potentiate loop
occlusion. We hope to focus on the platelet response as an important biological mediator of the
thrombotic response to injury. To tease out this response, we need methods of observation and
biological parameter control\
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In this chapter, we first review common techniques that have been used to parameterize
the platelet axis in terms of methods of isolation, observation, and manipulation. We
then apply such methodologies to perform a directed study on the effects of endovascular
stent surface, specifically looking at the clinically relevant example of gold vs. stainless
steel surfaces and how they interact in flow to mediate the reactions of thrombosis. In
doing so, we show that the body's response to implanted devices such as vascular stents
is a multifaceted phenomenon where complex dynamics take place and that several
distinct reactions may occur which may be coupled through various biological and
physical mechanisms, the balance of which determines the integrated biological response.
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4.1 Platelet Function
4.1.1 Observing Platelet Function
Phenomenological loop occlusion is readily observed in our model. To focus on the
platelet, we need more directed methods of observation and assessment. Platelets adhere,
activate, and aggregate on reactive surfaces during which time they undergo
morphological and functional changes. Each step in this process offers a handle by
which to assess platelet function. Broadly speaking, we can divide observational
techniques into two categories: volume measures and surface measures of platelet
function.
Volume Observation
Clinically, circulating markers of platelet activation are valuable given their accessibility.
Accordingly, many volumetric techniques have been developed and correlated with
clinical disease and platelet function. The two principle methods of detecting platelet
function through volumetric screening include assaying soluble plasma factors or
assessing free stream platelets themselves.
Upon activation, a variety of soluble products (granule products, cleaved
membrane glycoproteins, and metabolic factors) are released from platelets. The
generation of these factors and innate clearance mechanisms create a dynamic plasma
pool which can be tapped for insight into the activating source. To be effective, platelet-
specific factors with low clearance rates are required due to the integrated nature of the
pool. Plasma products such as platelet factor 4, thromboglobulin, P-selectin, and
thromboxane A2 can be readily monitored by isolating and assessing platelet poor plasma
samples through various immunoassays (enzyme-linked, ELISA, radio-labeled, RIA).
While these techniques are relatively straightforward and inexpensive, isolating the
plasma samples tends to generate high levels of background activation making it difficult
to observe small signals.
Flow cytometry is powerful method of analyzing platelet function by observing
individual particles as they pass through a laser. Through the use of fluorescence labeled
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antibodies, populations of cell suspensions (whole blood, platelet rich plasma, etc.) can
be assessed for particular cell types and activation status (Fig. 4.2). This technique
results in minimal artefactual activation and background noise (particularly if samples are
fixed soon after collection) with added ability to distinguish subpopulations and
distributions of activation status on individual cells. By selecting and observing discrete
cells of interest, flow cytometry thus offers a highly sensitive, highly specific method of
detecting volumetric cell parameters.
To assess a population, constitutively expressed and activation dependent markers
are required. GPIb or components of the aIIbPIII integrin (GPIIb, GPIIIa) are commonly
used constitutive platelet markers. Depending on the motivation, a slew of activation
targets can be used to monitor different pathways of the activation process (P-selectin,
activated caIIb3III, annexin V, CD40L, etc.). Flow cytometry also allows cells to be
distinguished on physical measures of forward or side scatter (representing light
refraction and reflection respectively). These additional axes make it easy to detect
platelet aggregates and microparticle formation, which have been associated with platelet
activation and correlated with thrombotic disease [80, 110]. The versatility of flow
cytometry in distinguishing multiple parameters on a single particle has also been used to
observe platelet-leukocyte microaggregates, which has been recently shown to be a good
marker of platelet activation in vivo [11].
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Figure 4.2. Flow cytometry where the x-axis, FLI-H, indicates presence of CD61 marker (GPIIIa
constitutively present on platelets) and the y-axis, FL2-H indicates presence of CD62 marker (P-
selectin present on activated platelets); a. Sample of resting platelets, and b. ADP activated platelets
Surface Observation
While volumetric measures of platelet function are readily obtainable and have proven
valuable in both clinical and research settings, a fundamental concern is that volume
measurements only provide an indirect indication of the platelet/surface reaction. Being
a function of activation, embolization, and clearance rates from Inultiple potential
sources, no volumetric standard has been accepted as the holy grail of surface activation.
To obtain a more direct handle on the surface reactions, various strategies have been
employed that directly assess the surface itself.
There are many methods of detecting platelets that have adhered and aggregated
on a surface. One technique is to strip surface adherent cells from the surface and count
them directly through a cell counter. While this technique has been widely used, the use
of an extra surface removal step increases the possibility of introducing noise and bias
into the measured signal.
One common technique that doesn't require surface removal is with the use of
radio labeled platelets which requires the isolation and incorporation of a radio labeled
marker such as IIIIn (indium-Ill) or 51Cr (cromium-51) into a subset of platelets [21,
112-114]. Subsequently, this set is recombined with the total pool and circulated over a
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test surface. Upon reacting with the surface, a proportionate amount of the surface bound
platelets will have a radioactive signal. While the surface count can easily be obtained
and quantified in either in vivo or in vitro systems, the subset isolation/marking process
can significantly affect the labeled platelets, thus creating atypical surface reactions and
the accumulation of unexpected population proportions [114].
Another technique that doesn't require subset isolation is via the employment of
specific cellular enzymes such as lactase dehydrogenase or acid phosphatase [115, 116].
These hardy enzymes are constitutively expressed in platelets and their activity can be
detected through simple, inexpensive, colorimetric assays providing a robust, quantitative
measure of cell number. However, the enzymes are generally not platelet-specific and
the signal is more a marker of total thrombus rather than platelet mass. Accordingly, care
must be taken when interpreting results, particularly at long time points when significant
leukocytes may be incorporated into a growing thrombus. Specificity can be improved
by labeling the surface adherent cellular layer with platelet specific antibodies and
detecting their presence through a variety of quantitative assays (enzyme, radio labeled).
Perhaps the most direct technique comes with visualizing platelet/surface
interactions. Visualization not only gives information on basic platelet adhesion, but on
other important cellular and global aspects such as cytoskeletal rearrangements and
thrombus height/stability. Techniques range from the use of basic histological
preparations and staining with standard light field microscopy which offers a broad tissue
level perspective, to more involved surface and tunneling electron microscopy where
significantly greater information can be obtained at the cellular level [21, 47, 117]. In the
past, many of these visualization techniques have required time-consuming fixation and
sample preparation procedures. Recently, the use of unintrusive, fluorescent labeling
(mepacrine, platelet-specific antibodies, calcium dies, etc.) has enabled the real time
observation of platelet interactions with a variety of surfaces (curved, rough, opaque),
providing much needed insight into the dynamics of thrombus growth [97, 117].
Chapter 4:: Parameterizing the Thrombotic Response

85
a.
c.
b.
Figure 4.3. Visual examples of surface platelet responsiveness a. Light field microscope of
thromboses coronary artery (@ Cornell University Medical College); b. Scanning electron
micrograph of platelet adherent to stent surface. c. Fluorescence actin stained image of platelet
adhesion to stented and non stented collagenized surfaces.
4.1.2 Parameterizing Platelet Function
Observational tools allow us to assess biological responses. However, understanding
these results within a web of multiple interactions is not straightforward. While in vitro
systems diverge from physiological settings making complex outcomes increasingly
difficult to interpret, the huge advantage of these models is that tangled situations can be
unwound, parameterized and investigated in a thorough fashion using techniques which
isolate and manipulate specific subsets of components.
Chapter 4:: Parameterizing the Thrombotic Response 86
Isolating Platelet Function
Isolating the platelet axis allows it to be studied independently of other components. So
long as the relevant processes are left intact, such separation can make observations more
lucid by focusing and enhancing the pertinent biological signal. There are several levels
of platelet isolation that can be performed in vitro. A most basic isolation is the
extraction of whole blood along with its innate platelet component from its typical
vascular surround. Blood-borne effects can thus be studied without the added complexity
of an active vessel wall. To further isolate the effects of platelets, platelet rich plasma
can be readily separated from whole blood (as in our initial biological analysis of section
3.2), removing the effects of erythrocytes and leukocytes. Fully isolated platelets can be
generated from PRP through a series of pelleting and washing steps or via a platelet
filtration column, leaving only the intact cell sons its reactive protein environment [21].
Oftentimes, these physical isolation processes cause significant background levels of
activation and thus, are typically performed in the presence of anti-platelet agents (i.e.
prostaglalandins. PGE1) which themselves can have a significant impact on the observed
platelet response [23].
Another method of component isolation that doesn't require physical separation
comes with the use of powerful inhibitory agents. However, it is imperative to consider
the effectiveness and specificity of potential agents. When isolating platelets from the
effects of coagulation, citrate or EDTA work by chelating divalent cations which are
required in several coagulation reaction [39]. However, these cations are also an
important mediator of platelet function and their sequestration can have unwanted effects
on platelet surface reactions [33]. Other agents, such as the commonly used clinical
drugs heparin and coumadin, are also not ideal for in vitro studies as heparin's actions are
far reaching, while the mechanism of coumadin's action requires an in vivo system [21,
39]. A good strategy for in vitro platelet isolation is through the use of specific serine
protease blocking agents such as corn trypsin inhibitor (CTI) and PPACK or hirudin
which target activated Factor XII and thrombin respectively [23, 118, 119]. The isolated
or combined synergistic use of such agents can be used to strongly suppress coagulation,
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thereby functionally isolating platelets without traumatic, physical component removal
(Fig 4.4).
a. wI out Anticoagulant b. wI Anticoagulant
Figure 4.4. a. Surface platelet reaction with coagulation; b. Platelet Reaction with coagulation
suppressed (80 ug/mi CTI + 3 U/mi Hirudin)
Manipulating Platelet Function
Once trimmed, isolated subsystems can be mechanistically studied through causative
manipulation and observation. This can be accomplished by either adding back
(knocking in) and/or removing (knocking out) specific components.
To observe the importance of platelet function, a fundamental manipulation is to
remove platelets altogether through the use of serial centrifugations, filters and
component recombination to obtain the desired, platelet poor medium. To observe which
platelet functions were pivotal, individual platelet components can be added back to this
depleted scheme. For example, as detailed in section 1.2, activated membrane serves as
an essential catalyst for coagulation reactions. Thus, 'activated' membrane analogs (such
as cephalin) can be added as a functional substitute [119, 120]. Alternatively, platelets
are known to play a role in supporting leukocyte surface reactions through P-selectin.
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The importance of this interaction can be observed by removing platelets and using P-
selectin coated surfaces to mechanistically observe this platelet function [121].
Rather than complete removal (which, but for a matter of perspective, creates a
new subsystem of observation), more pointed methods can be used to study particular
platelet reactions. Genetic variants with enhanced or diminished functions (polymorphic
surface receptor expression levels, point mutations, etc.) are sometimes accessible [97,
122, 123]. In the modem era of genetics, directed gene over expression or knockouts
have greatly expanded the library of such genetic anomalies.
It is oftentimes easier to create manipulations through the addition of external
agents rather than searching for or developing specific genetic alterations. For instance,
cyclooxygenase inhibitors or thienopyridine derivatives are known to knockdown the
thromboxane axis or block ADP receptors respectively, greatly reducing platelet
activatability in flow environments. Alternatively, function blocking antibodies have
offered a highly versatile strategy of inhibiting specific platelet events from adhesion
(anti-GPIb, GPVI, aIIb3III, a2B1, avB3) to activation (anti-a2B1, PY2, GPVI, GPIb) to
aggregation mechanisms (anti- aIIbIII). While potential side effects must always be
considered when using external agents, their use allows a degree of versatility not readily
possible with genetic mutation. Dose-dependent effects can be readily studied, helping to
distinguish causative relations while adding great insight into the underlying system
kinetics and function (binary vs. graded interactions, etc.). Additionally, the combined
use of multiple agents facilitates the directed investigation of complex interactions, not
readily possible with genetic mutation [(concurrent blockade of aIIbPIII and GPIb].
In this section, we have reviewed methods of platelet isolation, observation, and
manipulation. Together, these techniques allow us to parameterize the platelet axis to
gain access and insight into this key factor in the thrombotic process. As we have already
begun to explore (section 3.2.3) material surface can have a significant impact on the
device dependent thrombotic response. These initial results considered the loop
occlusion time of endovascular stents as a marker of device thrombotic potential.
However, these coarse measures are the result of a complex interplay of surface mediated
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interactions. Parameterization is an essential strategy with which to begin to unravel
findings that are otherwise limited to phenomenological, model occurrences. We now
apply these methods towards a more in depth study of stent surface interactions.
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4.2 Dynamic Bio-lmplant Platelet Reactions
When a foreign structure comes into contact with tissue and blood, a variety of biological
consequences occur which can result in acute or long-term device failure. Vascular
patency relies on a careful balance of chemical mediators and local fluid dynamics. The
thrombotic reactions of the foreign surface are initiated by surface protein absorption
followed by cellular and enzymatic interactions with this modified surface. Different
surfaces have different absorption rates for various plasma proteins which eventually
reach a surface dependent steady state distribution [124, 125]. The deposited proteins
subsequently interact with other components of thrombosis (platelets, coagulant
proteins), generating the potential for varied surface dependent responses. For instance,
surfaces which preferentially bind fibrinogen have been shown to be pro-thrombotic
while relatively inert albumin deposition confers a reduced potential [126-131].
Overtime, trace proteins such as coagulative or compliment proteins can accumulate on
the surface, promoting their respective biological reactions and can greatly influence the
overall foreign surface response.
Flow can further dynamically affect the components of thrombosis either through
physical shear dependent mechanisms, such as von Willebrand's Factor (vWF) dependent
platelet adhesion, or through the mass transport of cellular and molecular substances into
and out of a given region (section 1.3). Such physical involvement is complicated by the
fact that several interactions exist between platelets and coagulation. Activated platelet
membrane is essential for sequestering and localizing coagulation reactions from the
flowing blood to the site of injury, which in turn can potentiate further platelet activation
and stabilization the aggregating platelet mass through the production of thrombin and
fibrin (section 1.2).
The biological and physical interactions taking place at a prosthetic surface must be
considered when assessing device biocompatibility as implantation can occur in a variety
of biophysical settings [127, 132]. We currently address such surface interactions by
developing in vitro techniques to parameterize the thrombotic response. We then apply
strategies these to study platelet reactivity between stainless steel endovascular stents of
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identical geometry, coated with dissimilar surface materials as a function of fluid flow
conditions and coagulative interactions.
4.2.1 Methods
Hemodynamic Environment
For the current work, a high flow, typical coronary pattern, was approximated with a
peak flow of 200 mlImin and a mean pulse flow rate of 100 ml/min along with a low flow
pattern with a peak of 40 ml/min and a mean of 20 ml/min (Fig. 4.5).
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Figure 4.5. Generated coronary-like triangular flow profiles (200 mllmin High; 40 ml/min Low Peak
Flow); ** It should be explicitly noted that these figures only represent one cycle of a bidirectional
flow as previously shown in Fig. 3.3.
Stainless steel stents left intact or coated with a 7 + 2 urn layer of gold were examined as
a relevant clinical comparison (section 3.2.3) [107, 133-136]. Surface roughness of the
two surfaces was determined using atomic force microscopy, showing a significant
increase in surface roughness with coating (coated average roughness, Ra=154.6:t5.4 nm
vs. uncoated Ra=48.4:t2.2 nm).
These geometrically identical stents [107] were all 9 mm in length and were
expanded directly within a flood loop to a 3.5 mm post-inflation diameter under 12 atm
of pressure via a balloon catheter (Fig. 3.6). Subsequently, the 24.0 cm long tubes (3.2
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mm ID / 4.8 mm OD silicone tubing ) were closed into their loop format, filled with the
appropriate blood components (see below; Parameterizing Thrombotic Subsystems) and
run at 37C under the desired flow conditions. The flow was monitored and motion of
the loops could be stopped at any time to assess specific biological markers.
Parameterizing Thrombotic Subsystems
Along with these physical factors of flow and stent surface, we hoped to study the
synergistic effects of coagulation as a potential influencer in determining endovascular
stent platelet reactivity. To accomplish this, we needed mechanisms of isolating and
observing the platelet and coagulative systems as well as methods of recombining them
in a controlled fashion to observe their interactions. Blood components were derived
from whole blood obtained from healthy volunteers drawn via a 20-gauge needle into a
1/10 dilution of ACD anticoagulant. To decrease the complexity of the situation, platelet
rich plasma (PRP) was used as a source of platelets by centrifuging the blood at 200g for
15 min and colleting the top, platelet rich layer.
Decoupling the Platelet Subsystem
The decoupled platelet response was measured using PRP anticoagulated with 5 U/ml
hirudin and 80mg/ml Corn Trypsin Inhibitor (CTI; specific thrombin and activated Factor
XII inhibitors respectively). Significantly prolonged activated partial thromboplastin
times and electron microscopy studies of post-run stent surfaces indicated the
effectiveness of this method in eliminating coagulative function (Fig 4.4 depicts surface
visualization).
Decoupling the Coagulative Subsystem
To consider the decoupled coagulative response, the platelets were removed by further
centrifugation of the PRP at 1500g for 15 minutes. The platelet-free supernatant was
recentrifuged at 2500g for 20 minutes to ensure platelet free plasma. To test the discrete
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coagulation response, 100 !al/tube of 8mg/ml phosphadidylethanolamine was added to the
platelet-depleted plasma to function as a decoupled phospholipid source [120].
Coupling Platelet and Coagulative Subsystems
To probe the coupled effects of coagulation on platelet reactivity, graded amounts of the
specific activated Factor XII inhibitor, CTI (0-40 mg/ml), were added to PRP with higher
levels of anticoagulant corresponding to diminished levels of coagulation presence.
Platelet Assessment
To measure volumetric platelet activation, 100 ld of each post-run PRP sample was
suspended in 1 ml of 1% paraformaldehyde/PBS fixing solution and stored at 4 °C for 24
hours. 50 jl of the fixed sample was incubated for 20 minutes with 20 ul of CD61-FITC
(anti-gpIIIa) and CD62p-PE2 (anti-p-Selectin) as constitutive and activation dependent
platelet markers respectively. The reaction mix was quenched with 1 ml 1%
paraformaldehyde and assessed via flow cytometery3 (FAC) by determining percentage
of CD62p+ counts in the total CD61+ population (% activation).
For an index of surface activation, a platelet extraction protocol was developed.
Briefly, the flushed tubes were filled with 1% paraformaldehyde fixative and stored at 4
°C for 24 hours. After fixing, the tubes were again flushed with HBSS and closed. Each
loop was filled with 0.05% trypsin w/ 0.02% EDTA and spun in the flow setup under
high shear conditions (500 ml/min peak flow rate) for 2.5 hours (25 °C) to extract
adherent platelets. The loops were emptied into 200 jtl trypsin inhibitor (60mg/ml;
Sigma). The platelets were pelleted (2500g for 15 minute; 4 C) and concentrated in 100
pl PBS (pH 7.2). Following the antibody staining protocol, total CD61+ counts and
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counts expressing both CD61 and CD62p were determined through FACs analysis as
measures of surface adherent and activated platelets respectively. Fixation and
trypsinization procedures were found not to alter CD61 or CD62p labeling.
Coagulative Assessment
While platelets are required for the catalytic progression of coagulation, the enzymatic
cascade can be initiated directly by a surface through classical intrinsic and extrinsic
mechanisms. These two pathways of activation then join in a common pathway that
leads to the production of thrombin and subsequent fibrin clot.
This cascading enzymatic process generates activated proteases and cleavage
byproducts which can be assessed by specific enzymatic assays or through antibody
detection (ELISA, RIA). We currently assessed decoupled coagulative function by
detecting the prothrombin fragment, PT1+2 (formed upon enzymatic cleavage of
prothrombin by activated Factor X), using a prothrombin fragment ELISA kit (Behring-
Dade).
4.2.2 Decoupled Platelet/Coagulation Responses
Anticoagulated, PRP was recalcified (13mM) and injected into the fluid loops to assess
decoupled platelet reactivity to stent surface. Twelve stents of either plain or gold coated
stainless steel and 4 non-stented controls were run at high flow conditions to assess
platelet responsiveness. The anticoagulated runs were stopped at 1 hour and both the
tube and bulk fluid were assessed for platelet reactivity.
To test the discrete coagulation response, platelet-depleted plasma enriched with
phosphadidylethanolamine was recalcified (13mM) and injected into the respective fluid
loops. Six stents of each type and 4 stentless controls were run in total under the high
flow conditions. The tubes were all stopped after 1 hour and the circulant fluid was
assessed for PT1+2 fragment levels. All values were normalized to the mean, stainless
steel values of the specific run.
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In these decoupled trials, plasma exposed to the bare stainless steel stents contained
higher normalized PTI +2 levels (Fig. 4.6, 1.00:tO.13) than plasma with gold-coated stents
(0.50:tO.07, p<O.OOl). Conversely, using highly anticoagulated PRP, we found
significantly more normalized surface bound, activated platelets in the gold stented loops
as compared to the stainless steel stented loops (1.45:tO.l 0 vs. 1.00:tO.08, p<0.05). This
increase in platelet response was not well represented in the normalized bulk percentage
activation (gold 1.21:tO.16, steel1.00:tO.14, control1.19:tO.24).
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Figure 4.6. Decoupled coagulation (PTI +2) and Platelet (Surface adhesion, Bulk activation)
responses. All results presented after normalization to the average stainless steel values for a given
run to account for inter-run variability.
The effect of surface in differentially mediating isolated limbs of the thrombotic response
is intriguing and alludes to the richness that underlies bio-implant reactions. We found
that stainless steel stents had a higher independent coagulation response, while exhibiting
reduced independent platelet reactivity as compared to gold stents. While stainless steel
is known to form a protective oxide layer on its surface, gold does not, enabling strong,
chemical surface protein interactions to highly abundant plasma proteins such as
fibrinogen [107, 126, 129]. On less reactive, oxidiziable surfaces such as stainless steel,
the Vroman effect may occur allowing less abundant proteins such as high molecular
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weight kininogen (HMWK) and FXII to accumulate on the surface [124, 126, 129, 131].
Such effects could account for the enhanced coagulative action of stainless steel devices,
while the enhanced platelet reactivity of gold-plated stents could be in part due to tightly
binding fibrinogen mechanisms. In addition, surface roughness (whose importance is
indicated by the decreased thrombotic response upon stent polishing; Section 3.2.3), was
found to be greater on the gold-coated stents, and may also play a role.
4.2.3 Coupled Platelet Response
Effect of Coagulation Strength on Stent Platelet Reactivity
To evaluate the effects of coagulation on platelet reactivity, varying levels of CTI
anticoagulant (40, 20, 4, 0 jig/ml) were added to recalcified PRP. Stainless steel stents
were run under the high flow conditions until a reduction in the flow recordings could be
detected under any of the CTI conditions. All loops were subsequently stopped and
analyzed for surface and volumetric platelet response as described above (section 4.2.1).
This procedure was repeated for a total of four runs.
When we combined PRP with reducing amounts of CTI, the normalized surface bound
platelet number rose (Fig. 4.7). This is likely due to synergistic interactions between the
two thrombotic limbs. Although surface measures of platelet response were observable
in each of these platelet reactivity trials, changes in bulk platelet activation that have been
used as a marker in various other studies [94, 137, 138] were not appreciable. This
discrepancy may reflect the generalized low degree of platelet activation within our flow
system and the adherence of the activated platelet population to the circuit wall. One
exception is in the most highly coupled condition (0 mg CTI), where observable
thrombus formation occurred. Here, we see a dramatic increase in the number of surface
bound platelets, accompanied by an increase in bulk activation levels. For such a
progressed thrombotic stage, there is likely an explosive accumulation of coagulative
products within our closed, in vitro system. Such uncontained coagulation could lead to
volumetric platelet activation, creating a situation that may no longer be representative of
surface thrombotic phenomenon. That levels of bulk activation were relatively constant
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in our trials indicates that we were indeed studying the proposed, "pre-explosive", surface
thrombotic phenomenon.
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Figure 4.7. Surface and Bulk platelet response with increasing CTI anticoagulant (0-40 mg/ml CTI;
decreasing coagulation). Results have been normalized to the 40 mg/ml CTI condition to account for
inter run variablility.
Interactions of Flow and Coagulation on Stent Platelet Reactivity
The interactive influence of coagulation and flow on determining the relative platelet
reactivity of the biomaterial surfaces was considered by performing 4 1-hour runs of 4
steel and 4 gold stents using recalcified PRP supplemented with 20 g/ml CTI
anticoagulant. In each run, 2 of each stent type were run under the high flow and 2 under
the low flow conditions. Platelet response was measured as described above. Four
similar runs were performed at a lower, 4 g/ml CTI condition. In each of these trials,
an additional 20 jig/ml CTI, high flow, stainless steel case was tested to allow relative
scaling between the 4 and 20 g/ml anticoagulant conditions (section 4.2.1).
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Two-way ANOVA analysis revealed significant dependence on both flow and CTI levels,
with significant interaction effects in the gold group. At low flow there was an increase
in normalized platelet activation with increased coagulation strength for both gold
(0.89_0.09 vs. 2.38+0.27; p<0.001) and steel (0.59+0.08 vs. 1.77+0.20; p<0.001) stents
(Fig. 4.8). Similarly, at low coagulation levels (20mg/ml CTI), a generalized increase in
platelet reactivity was observed with the higher flow rate for both gold (0.89+0.09 vs.
1.28+0.14; p<0.05) and steel (0.59±0.08 vs. 1.00±0.07; p<0.01). At high flow, there is an
increased trend in platelet reactivity with decreased anticoagulation reaching significance
for the steel group (1.00±0.07 vs. 2.13+0.30; p<0.01). At 4mg/ml CTI, we do not witness
a common trend with gold showing a significant decrease in platelet reactivity with
increased flow (2.38+0.27 vs. 1.44+0.12; p<0.05), while the steel group showed a non-
significant increase.
In three of the four test conditions (Low Flow, 20mg/ml CTI; Low Flow, 4mg/ml
CTI; High Flow, 20mg/ml CTI), gold reacted more strongly with platelets (first condition
significant: 0.89+0.09 vs. 0.59_0.08; p<0.05), while at low levels of CTI and high flow,
the steel stent reacted more strongly (2.13_0.03 vs. 1.44+0.12; p<0.05 using a one-tailed
Student t test to assess this directional change). In all of these conditions, CD62+ bulk
platelet activation levels (data not shown) did not significantly vary between the different
groups.
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Figure 4.8. Effects of flow and coagulation strength on platelet reactivity to bare stainless steel and
coated gold surfaces.
With decreased coagulative function, stent platelet reactivity increased with flow. It is
known that platelets adhere and activate more effectively at higher shear rates [50, 62,
139]. In our studies, average estimated wall shears were 500 s- 1 and 100 s-1 for the high
and low flow cases respectively (with peak shears reaching significantly higher values),
well within the dynamic range of shear-dependent platelet activity. However, it must be
pointed out that the shear rates at the stent surface may vary considerably as suggested by
finite element studies [82, 84].
Under conditions of low flow consistent with those found within the venous
vasculature or impeded arterial flow, we witnessed an increase in platelet function when
coagulative function was added. Such a coupled increase is expected as the coagulative
process leads to the production of substances that can promote platelet activation,
adhesion, and aggregation [39, 40]. However, with the role of coagulation increased, the
flow-dependent increase of platelet reactivity was no longer evident. This may reflect the
complex mutual interactions between the various components of thrombosis, flow, and
the instigating surface. Increased flow could alter the balance of coagulation products
within the stent vicinity, as evidenced in the case of platelet rich arterial versus fibrin rich
venous thrombi [60]. Whereas the higher independent coagulative potential of stainless
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steel may compensate for such clearance causing a non-significant increase in platelet
reactivity, the lower potential of the gold may not.
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4.2.4 Richness in the Thrombotic Response
Implanted devices are increasingly used to combat complex diseases in a range of
pathophysiological settings. Issues of biocompatibility must now encompass far more
than the inert nature of the reaction to local implantation. Among the most commonly
used devices are intravascular implants which are subject to a multitude of biological
responses taking place within a dynamic flow field. As implanted devices are made of
multiple and composite materials, it must be recognized that devices of dissimilar
compositions may stimulate different aspects of thrombosis to a variable degree [126,
127, 131]. Here we provide an example of the complexity underlying body/device
interactions. By parameterizing aspects of the biological and physical setting, we
demonstrate that various independent device responses may exist in vitro. It is a dynamic
balance of these normally interactive components in the context of a local biological and
physical environment that determines measures of biocompatibility such as stent-
mediated platelet-reactivity.
Based on a reduced theoretical coagulative network model, Basmadgian et. al.
have shown that the effects of flow and surface are intertwined. [60, 140]. Their
calculations revealed the possibility of multiple steady states and regions of high and low
parameter sensitivity in coagulative function, but they were limited to a single surface
interaction. In physiological systems, several, distinct prosthetic reactions occur
(platelets, coagulation, etc.) creating the possibility for more complex, divergent
outcomes. Such dynamic interactions can have a significant impact on integrated
biocompatibility measures of devices.
A surface plot presenting the parametric flow and coagulation data (Fig. 4.9) depicts the
continuity of' platelet reactivity, with each plane representing the biological activity of a
particular device. That these formed planes are not parallel infers the existence of
various biocompatibility regimes. Although more platelets adhered to the gold-coated
stents under most conditions tested, the stainless steel adhered more platelets under our
conditions of high flow and low anticoagulant. Practical device rankings can be made
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only if the depicted reactivity surfaces are close to parallel or far enough apart over some
range.
E"Z 2.5
~~6 .....=~ Q
Q s: .-
~ r/} 2
... "C ~~ ~ ..cQ N "C.- <fi:'i~
..c e ~ 1.5
bIJ-~.- Q=Z== ...00=1-04~~
~U
Flow (ml/min) 50 o 5 10 15
CTI (mg/ml)
20
Figure 4.9. Potential platelet reactivity surfaces as a function of flow and coaglation depiciting
dynamic biocompatibility.
Recognizing the dynamic nature of biocompatibility is valuable as there are several ways
(both in vitro and in vivo) that parameters may be varied over considerable scales. For
instance, the use of anti-thrombotic agents or considering patients or blood deficient in
certain thrombotic components could dramatically affect biological variables leading to
different biocompatibility regimes. When performing studies, it is important to keep such
parameters in mind as these biases could help to explain discrepancies found both within
and between various in vivo and in vitro systems [107, 127, 134-136]. Alternatively,
human physiology encompasses a wide range of physical conditions. For vascular
devices, materials suited for high flows may not be best suited for low flow conditions
[132]. Dynamic biocompatibility knowledge could not only lead to such a situation-
optimized use of implants and materials, but the optimization of concurrently
administered drug regimes. These issues become especially relevant when considering
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the present day push to locally deliver drugs from implant surfaces, where the local
dynamic environment can be directly and specifically modulated.
While addressing dynamic issues is important, as they undoubtedly play a key
role in determining biological outcomes (which have evolved under dynamic conditions),
we must also acknowledge the difficulty in doing so. As more axes are parameterized the
number of tests grows exponentially and to fully characterize these dynamic regimes
would negate the cost-effectiveness of bench-top methodologies. These studies must be
performed selectively and restrictively. One bound which we can impose is to aim for
predictive relevance. While the use of simplistic in vitro models precludes any certainty,
it is a reasonable direction in which to head (at least as good as any other).
Prediction, Parameterization and Placement
In this chapter, parameterization of the biological and physical environments has allowed
us to extend the use of our model from coarse observations of loop occlusion time to a
more mechanistic appreciation for the interplay of thrombotic surface reactions. Whereas
non-treated gold initially seemed a less suitable candidate in terms of thrombotic
response (Fig. 3.8), we show that this ranking is not necessarily the case (Fig. 4.8, 4.9).
Predictive statements based on in vitro model outcomes must be made with caution as
responses are highly dependent on condition. While model-based prediction is an
important goal given the increased societal cost (money, time, risk, and ethics) of
studying real-world situations, the same reductive simplicity that enables comprehensible
studies acts as a double edged sword, inherently detracting from predictive relevance.
Models may be adjusted to compensate for unrealistic, skewed parameters. In
engineering systems, this established process is formally referred to as dimensional
analysis. When considering situations such as the lift of a model airplane wing or the
fiel efficiency of a model car, dimensional analysis ensures that relevant, dimensionless
parameters are equivalently scaled, bringing real-world relevance to model outcomes. In
chapter 3, we go through a similar procedure to create real-world, coronary-like flow
conditions by maintaining key dimensionless flow parameters (Re, Wo, De; see section)
within our hemodynamic model.
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While dimensional analysis is applicable to well characterized engIneenng
systems, biological models are formed through empirical evidence and deal with
incompletely characterized, qualitative concepts rather than quantitative parameters. As a
result, these systems are adrift somewhere between predictive and reductionist goals.
Progress generally occurs through gradual movements from in vitro to in vivo to clinical
environments as predictive statements are projected over safe, stable experimental
distances (Fig. 4.10). In the rapidly advancing medical arena, it is important to attempt to
optimize this process by establishing firm in vitro foundations in appropriate settings and
making well-directed vertical projections towards increasingly complex, increasingly
relevant systems. Although thorough dimensional analysis is not possible, model
parameterization and placement help in this optimization via a kind of dimensional
consideration.
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Figure 4.10. Pyramidal representation of the path to clinically pertinent developments. Given
the increased societal expense at higher levels, more trials are performed at base levels, though
at the expense of potential relevance. To maintain the efficiency of this scheme, well directed
vertical projections from stable foundations must be attempted.
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Already, we have seen that parameterization allows reductive, mechanistic studies. From
another vantage point, model parameterization also adds predictive insight into biological
models. While a rigorous understanding of the involved processes and parameters is not
established, the underlying principles of dimensional analysis and model scalability are
still valid and may be considered by varying parameters (handles; i.e. coagulation
strength, flow rate; section 4.2) over a range of possibilities and observing outcomes.
Such scaling offers a handle on hidden, dimensionless functions (much the same way
varying fluid velocity may vary the Re). As in more rigorous engineering examples, if the
necessary hidden dimensionless functions are preserved, predictive relevance can be
maintained. However, since the hidden functions are not known or quantifiable, handles
must be parametrically searched, in essence scanning a space of experimental
possibilities.. If similar findings are obtained over large parameter scale changes then
predictive robustness is increased allowing safer projections to increasingly complex,
relevant scenarios (i.e. in vivo / clinical situations). On the other hand, findings that
change with handle manipulation indicate potential directions for further reductionist
understanding and model stabilization, which indirectly benefits future predictive efforts
by establishing firm foundations. To search such experimental spaces many tests must be
performed and strategies that accommodate quick, efficient testing are important in order
to maintain the effectiveness of these in vitro trials. The small loop volumes and multi-
rotor, multi-axis design which we developed allows the consideration of multiple loops
run under multiple conditions at once, greatly enhancing the efficiency of the described
strategy making parametric studies feasible.
Along with efficient tests which potentiate model parameterization, model
placement is essential to consider to maintain the efficacy of in vitro studies. While
parameterization allows indirect manipulation on hidden functions, some of these
functions may be only weakly dependent on (or completely independent of) the available
handles. The potential experimental space may altogether exclude pertinent regions.
While inclusion of relevant regions cannot be guaranteed in complex, incompletely
characterized biological models, it is important to carefully consider the qualitative
dynamics of the situation as the benefits of reductive simplicity are balanced with
promoting predictive relevance.
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By developing and applying techniques of parameterizing the biological and physical
axes of our in vitro system, the current example of endovascular stenting shows the
richness underlying vascular responses. While this is of great relevance in studying
foreign surface thrombotic reactions, it is limited in making statements about complex
thrombotic situations where devices are placed within a complex vascular environment.
Not only do blood components interact with the stent surface and with each other, but
with the vessel wall itself. Not considering the wall component could significantly affect
the local response, potentially placing our findings outside the regimes of viable
responses. Given the amount of energy that must be spent in parametrically studying
dynamic environments, it is important to attempt to place models well to maximize the
chance of predictive relevance. We now turn to the development of a model of wall
reactivity with the goal of increasing the real-world applicability of our in vitro system.
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CHAPTER 5 The Coronary Lesion Environment
5.1 Reactive Site Development
While such reduction reveals the
Model parameterization promotes the
effective use of in vitro systems by
enabling mechanistic reduction and
testing predictive robustness. In
chapters 2-4, we have begun to
parameterize both physical and
biological axes of our system, uSIng
handles on coagulation, platelets, flow,
and foreign surface to study aspects of
endovascular device thrombosis.
Figure 5.1. Angiogram (@ Cornell University
Medical College) despicting a coronary lesion (near
total occlusion). Note the lengh of the lesion
(LReactive Site) in relation to both the vessel
diameter (D) and the vessel length (LArtery);
D<LReactive Site<LArtery.
complexity underlying more blunt,
loop occlusion time measures (section 3.2.3), these parameterized experiments do not
consider vessel wall interactions. Not including this important wall component in our
model could result in a significant, qualitative misrepresentation of the vascular situation.
The geometry and surface of the vessel wall serves as a boundary to both the physical and
biological environments and thus plays a critical role in determining local reactions (see
sections 1.2, 1.3). Before the true power of parameterization can be realized, careful
consideration must be given to proper model placement. To gain a parametric handle on
critical aspects of the vessel wall, we incorporated discrete reactive sites into our
previously homogenous fluid loop model as a more complete biophysical model of
localized vascular lesions.
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Figure 5.2. Schematic, idealized representation of a localized reactive site within an extending vessel.
Typically, individual coronary lesions are on length scales of several arterial diameters
with this aspect ratio imposing a basic geometric constraint on lesion architecture.
Current AHA/ACC classification stratifies Type A, Band C lesions as <10 mm, 10-20
mnl, and> 20 mm respectively [141, 142]. Stents have accordingly been designed to
treat these lesions, with typical lengths ranging from -10-30 mm [143]. Although with
diffuse disease these lesions may overlap and extend over considerable distances, isolated
cases of disease or instances presenting upon plaque rupture or post intervention are
characterized by a localized, spatial change in wall surface and/or geometry (Figs. 5.1,
5.2). To accommodate such situations, we used both glass and silicone reactive sites
coated with various physiologically relevant substrates allowing both wall geometry and
surface features to be individually isolated and controlled. In doing so, we positioned our
model to study not only foreign surface reactions, but more generalized vascular
situations.
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5.1.1 Geometry
Geometry plays an important role in determining the local hemodynamic environment.
In states of pathology and intervention, geometries can be significantly altered (section
1.3). To accommodate such local changes in wall geometry, we developed a discrete 3
cm reactive segment as a prototypical embodiment of an isolated vascular lesion. This
segment was placed inline with a 21 cm length of 1/8" ill 3350 Tygon tubing, retaining
the overall total fluid loop circumference (Fig. 5.3). The .....0 1: 1 aspect ratio of vessel
radius to reactive site length fit within our scheme of lesion geometry (Fig. 5.2) and was
selected to provide a standardized reactive site geometry. Although the dimensions could
be easily tailored to satisfy other conditions as desired, such standardization was
important to create a nominal situation that could be functionally characterized and
perturbed for investigating the role of altered hemodynamic situations. Using our same
total loop circumference as in our homogenous fluid loop model (imposed by rotor
design; Fig 2.15), we obtained a reactive site length to loop circumference ratio of 1:8
which reasonably modeled the discrete vascular lesion setting.
3. b.
Figure 5.3 Reactive sites and fluid loops. a. Silicone; b. Glass
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Figure 5.4. Potential reactive site
geometries. a. 50% stenosis; b. constant
diameter; c. 25% aneurysm; d. 50%
aneurysm
In these modified fluid loops, co-axial layers serve as either injection or withdrawal ports
(section 2.2.2). Two additional sleeves are required to secure the reactive site in place.
By eliminating the need for inline valves and connectors and by maintaining square
segment ends for flush juxtapositioning, luminal flow and surface disruptions can be
minimized.
While the reactive site can be made of any material, two options we considered were
glass and silicone as their material properties allowed us to develop an array of
geometrically relevant situations. Upon heating, glass is easily and permanently
shapeable into a variety of pathological geometries (stenotic constrictions, aneurismal
expansions; Fig. 5.4a-d). As the geometry is altered, blood contact surface area can be
maintained by properly adjusting the reactive site length. Though the properties of glass
allow tight control of the wall boundary, the glass surface is non-yielding and thus not
able to support proper endovascular stent
expansion. Typicall y, these devices require
some wall elasticity for proper wall 3.
apposition (Fig. 5.5 a, b). Silicone on the
other hand is complaint and thus suitable for b.
modeling endovascular interventions by
enabling proper device expansion and wall
contact. While the altered physical c.
properties on glass and silicone were
selected for their ability to model certain
vascular conditions, compliance changes d
•
have been shown to play a role in affecting
pulsatile pressure driven flows by enabling
time-dependent wall expansions [75, 103,
144]. However, in our system, which is
driven by wall shear as opposed to pressure
forces, we did not notice a significant effect
on flow as a result of these changes in wall properties (Fig. 5.6).
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a.
b.
Figure 5.5. Stented reactive sites. a. Silicone (good stent-wall apposition is visualized through
diplaced dye); b. Glass (poor wall apposition).
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Figure 5.6. A typical triangular now pulse (200 mllmin peak now) generated in reactive sites of
silicone and glass material using identical wall motion profiles.
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5.1.2 Surfaces
We selected glass and silicone tubing as their varied structural qualities allow easy
manipulation through molding (when heated) and elastic deformation respectively.
However, it is widely recognized that the blood contacting surface itself interacts with
blood components, playing an important role in dictating vascular responses (as we
further explore in chapters 3 and 4). To move our model away from an investigation of
foreign surface response (be they glass, silicone, or otherwise) and towards an
investigation hemodynamic vascular situations, we coated the reactive segments and fluid
loops with passive, biologically reactive, protein layers. An immense variety of potential
biological substrates exist, and in the current model development, we immediately
restricted ourselves to those of known physiological relevance with regards to platelet /
substrate interactions (Fig 5.7).
Platelets exhibit a wide array of surface moieties which interact with their
environment (section 1.2). In addition to mediating intercellular function, a portion of
these mediate surface adhesion responses by interacting with specific vascular wall
subsubstrates upon endothelial presentation (P-selectin, fibrinogen, vWF, etc.) or
subendothelial exposure (collagen, fibronectin, laminin, vWF, etc.). By coating the glass
and silicone reactive sites with individual components or subsets of these, specific
interactions can be explored. As the primary focus of this work was to develop and study
hemodynamic effects of endovascular thrombosis, we currently focused on the well
characterized substrates collagen and albumin, which provided simple models of a
reactive and unreactive vessel wall.
Collagen
Collagen is an important component of the subendothelial layer that initiates platelet
adhesion when exposed to blood. Adhesion is supported by specific binding sites that
enable direct interactions with vWF and platelet collagen receptors [24, 26, 29, 115, 145].
Accordingly, collagen has been a commonly used substrate for in vitro studies of platelet
adhesion in flow. There are several types of collagen that exist within the body, with
types I. III, and
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Figure 5.7. Potential reactive site surfaces to create a spatially distinct region within an otherwise,
albumenized, inert fluid loop.
IV being the most prevalent in the vascular wall [21]. The various collagens each
promote subtle differences in response and it is important to consider these differences
when selecting surface coatings. For example, while the primary collagen integrin a.2~1
supports general, non-specific firm adhesion to collagen types I-VITI, type-specific
receptors have recently been cloned for collagens I and III [36, 146]. A variety of
biological processes also affect the state of collagen. It has recently been established that
collagen turnover by matrix metallo-proteases (MMPs) in the fibrous cap region of
atherosclerotic lesions contributes to cap and plaque weakness by degrading collagen
fibrils [68, 147]. As these rupture-prone sites play an important role in the progression to
acute coronary syndromes, the effects of a degraded collagen surface on vascular cell
recruitment is also of great interest.
In our present work, we focus on the type I collagen surface whose platelet
interactions have been well characterized through prior in vitro studies [26, 97, 115].
Using an established protocol, we prepared a 2.1 mglml collagen solution in 0.5 M acetic
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acid by mixing 1 g type I acid-insoluble collagen (bovine Achilles' tendon) into 12 ml of
glacial acetic acid and 198 ml water. The mixture was homogenized for two hours, 200
ml of water was added, and an additional hour of homogenization applied. The final
suspension was centrifuged for 10 min at 1000 RPM, and the supernatant solution was
collected and stored at 4 C [115].
To make collagenized reactive sites, the 3 cm tube segments were filled with this
solution, capped at both ends, and held at 25 C for 90 minutes to allow surface
adsorption. The segments were then uncapped, thoroughly flushed with phosphate
buffered saline (PBS) to remove any loosely adherent collagen and stored at 4 C in PBS
until use. Similar amounts of collagen adsorption to either the glass or silicone surfaces
(1.2 btg/cm2 vs. 0.9 [tg/cm 2 ) were observed using a BCA protein assay (Pierce).
Albumin
When a bare foreign surface comes into contact with blood, one of the first events to
transpire is passive protein absorption. Such a protein layer can support enzymatic
reactions (i.e. intrinsic coagulation, compliment activation) or cellular adhesion (i.e.
fibrinogen-dependent platelet adhesion). Albumin is a large, unreactive plasma protein
which can be used to saturate the surface, thus blocking unwanted surface reactions [23,
26].
Blood homeostasis is typically maintained through an active, endothelial layer
which is sophisticated, dynamic, and complex. We approximate this bio-compatible
surface with a passive, albumenized coating as it allows us to spatially focus the
thrombotic nidus to the reactive site, though also acknowledging the simplicity of this
step (Fig. 5.7) The 21 cm tubing lengths were filled with a 1% human or bovine serum
albumin solution (HSA, BSA); in PBS for 60 minutes at room temperature. BSA, which
is functionally indistinguishable from HSA, is preferred both from on infectious risk
standpoint as well as the greatly reduced cost for the relatively large batch sizes and
tubing volumes used. The tubes were flushed and stored in PBS prior to use. Following
a similar protocol, albumin can also be used to saturate the reactive site surface itself,
thus limiting surface reactions to those dictated by controlled, pre-coated protein layers
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(i.e. collagen) or completely eliminating such interactions if used in isolation (see Section
5.2).
Other coatings
Along with the collagens and albumin, there are a slew of other potential surface coatings
which can be used to capture particular platelet reactions. Individual proteins, such as
fibrinogen, vWF, fibronectin, laminin, etc., interact with specialized platelet surface
receptors and it is important to consider each in kind for a detailed, understanding of
adhesive mechanisms. Yet, we must remember that it is a combination of interactions
that orchestrates adhesion in vivo. Indeed, various studies have shown functional
differences between single and multiple protein layers [23, 26]. As more is understood
about the basic pathways of adhesion, it is important to consider these increasingly
complex surfaces, moving towards a goal of considering a functional, reactive,
endothelial layer. With the added layers, it is important to sufficiently characterize the
surfaces to retain stable understanding and control of the in vitro environment. For
instance, while subendothelium can be readily generated by stripping off a confluent
layer of endothelial cells, the composition of the isolated material can change widely
depending upon the endothelial origin, the conditions under which they are grown and the
stripping technique employed. The use of complex model surfaces in conjunction with
simple, pared down substrates, provides a balance between reductionist and predictive
goals in understanding vascular platelet responses.
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5.2 Reactive Site Characterization
In the current section, we begin to functionally characterize the platelet adhesion
response to our reactive sites considering a nominal, non-stented hemodynamic setting of
constant diameter (Fig. 5.3). Although many prior studies have extensively probed the
interactions of platelets with collagenized and albumenized surfaces (which led us to their
selection in the first place), it is important to establish the functional nature of these
substrates in our specific system.
Various differences exist between our model and prior systems. By and large,
other studies have considered constant flow conditions. Our flow model creates highly
pulsatile conditions pertinent to the coronary flow setting, potentially resulting in
observable changes. Furthermore, many of these prior studies have been performed on
coated, planar, glass slides in the context of microscopic flow chambers. In our reactive
site model, we consider both tubular glass and silicone surfaces which enable different
vascular situations to be modeled. Although we have shown that glass and silicone both
support similar amounts of protein adsorption (collagen; section 5.1.2), the functional
nature of these layers may be different. Varied protein conformations may be exposed
upon interaction with specific surface, either potentiating or diminishing platelet
interactions. Alternatively, sensible qualities of the base material itself (charge,
roughness, porosity, etc.) that are incompletely masked by the coating layer may
differentially interact with blood. In the current section, we study platelet adhesion to
both glass and silicone reactive sites of constant diameter (1/8") over a range of pulsatile
flow conditions and compare our findings to previous platelet/substrate investigations.
Through these studies, we provide an essential foundation that must be develop before we
can explore how altered hemodynamic settings may affect the thrombotic platelet
response.
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5.2.1 Methods
Hemodynamic Environment
We applied our reactive site model to characterize the anti-coagulated platelet response
over a range of [58] potential coronary-like flow rates (50-200 ml/min peak flow; Fig.
5.8) [51, 148].
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Figure 5.8. Generated flow profiles to simulate coronary conditions on a beat to beat basis. ** It
should be explicitly noted that these figures only represent one cycle of the bidirectional generated
flows as previously described.
The fluid loops were made from a 21 cm length of 1/8" inner diameter (ID), 3/16" outer
diameter (OD) 3350 Silicone Tygon tubing into which a 3 cm reactive tubing segment
(glass or silicone) was inserted (see Fig. 5.3). The reactive segments (glass or silicone)
were coated with either Type I, acid insoluble bovine collagen or 1% bovine serum
albumin (BSA) as models of reactive and unreactive vascular segments. The 21 cm
lengths were uniformly coated with a 1% BSA blocking solution.
Platelet Source
In these studies, we used anticoagulated, leukocyte-depleted blood as a platelet source.
The use of anticoagulated blood components is a required reductive step in functionally
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characterizing our reactive site models. As we explore in section 4.2, coagulative
synergy dramatically complicates the picture of flow dependent platelet surface
interactions. Before we can begin to understand added complexities (be they with added
coagulative function, altered hemodynamic environments, or otherwise) we must develop
a stable understanding of the basic but highly important platelet reactions as they occur
within our reactive site model. Given the recognized, clinical importance of the platelet
as a key, initiating player in the vascular response to injury, the anticoagulated blood
model is a well-justified point at which to develop a solid basis for further exploration.
Whole blood obtained from healthy volunteers was drawn via a 20-gauge needle into a
1/10 dilution of ACD and 80 ,IM (final concentration) PPACK anticoagulant. To remove
the leukocyte component, the whole blood was lightly centrifuged at 200g for 15 minutes
and the top platelet-rich plasma (PRP) was separated from the packed red blood cell
layer. These layers were passed through appropriate, low volume leukocyte-reduction
filters (PurecellTM/PL, and PurecellTM/Neo, Pall Biomedical) and then recombined to
achieve a hematocrit of -40%. This procedure was found to reduce the total platelet
count from -2.5% to 2.0%, while having a minimal effect on platelet activation (<2%) as
assessed through P-selectin expression via flow cytometry (FACScan, Benton
Dickinson). The blood was used within 30 min of withdrawal and was recalcified (2
mmol Ca2 +) immediately before injection into the fluid loops.
Observing the Platelet Subsystem
To assess surface platelet adhesion, we adopted a rapid LDH (lactase dehydrogenase; see
section 4.1) assay as opposed to the relatively labor intensive surface extraction
procedure used in section 4.2. Once a given run was complete, the fluid loops were open
and the blood was emptied. When necessary, 100ul of blood was fixed in 1%
paraformaldehyde for subsequent analysis of bulk platelet activation and microaggregate
formation. The reactive segments were removed, and thoroughly flushed with 50ml
Hanks Balanced Salt Solution (HBSS), supplemented with 2mM Ca2+. The segments
were then filled with a lysis buffer to lyse any residual RBC. The segments were
emptied, flushed, and again filled with a 0.09% Triton-X, 250mmol glucose solution (in
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PBS,) and left for 1 hour at room temperature. 200ul of this solution was then taken and
analyzed for LDH amount as an indirect marker of surface adherent platelet number
(CytoTox 96® Non-Radioactive Assay, Promega) [115]. Adherent leukocytes were
assumed to be minimal in comparison to the platelet number due to the leukocyte
reduction process and verified by the absence of nuclear staining (as described below) on
collagenized glass samples. While providing an indirect marker of surface platelet
number, the speed and cost-effectiveness of theses LDH protocol greatly promoted
parametric studies, justifying its use over the more platelet specific surface extraction /
flow cytometric strategy used previously.
When required, other tests of surface analysis and platelet function were performed. To
visually assess the adherent layer, flushed reactive sites were filled with a 3.7%
paraformaldehyde solution and fixed for 20 minutes at room temperature. The reactive
sites were then washed twice with PBS and filled with a 0.1% of Triton-X in PBS. After
3.5 minutes, the segments were again emptied, washed twice with PBS, and filled with a
blocking 1% BSA solution for 20 min. Subsequently, the sites were drained and
incubated with a staining solution of 5 U/ml BODIPY FL phallacidin (for actin staining;
Molecular Probes, Eugene, OR) and bis-benzimide (for nuclear staining; Sigma), and 1%
BSA in PBS at room temperature for 20 minutes in the dark. The stained samples were
then washed twice with PBS, filled with a 1:1 solution of PBS and glycerol, capped, and
visualized with a fluorescence microscope equipped with fluorescein and ultraviolet
filters (Leica Microsystems Inc., Bannockbum, IL).
To assess bulk activation.PE (Beckton Dickinson). The reaction was stopped
with 1 ml 1% paraformaldehyde after 20 minutes and the samples were assessed in a flow
cytometer (FACscanTM, Becton Dickinson). The platelet population was determined
from CD61 binding in conjunction with forward and side scatter measurements (FSC,
SSC). Bulk platelet activation, was assessed from percentage of CD62p+ platelets.
Chapter 5:: The Coronary Lesion Environment 120
5.2.2 Functional Validation
Glass vs. Silicone Base Substrates
Collagen
We first compared the functionality of collagen coated glass versus silicone substrates in
the absence of stenting. To functionally compare the two base substrates, 4 collagenized
glass and 4 collagenized silicone reactive sites were run for 3.5 min at each of the 4 flow
conditions. After each run, the total adherent platelet number was determined via LDH
quantification, revealing similar levels of platelet adhesion to both substrates after 3.5
min of flow (Fig. 5.9).
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Figure 5.9. Comparison of LDH quantified platelet/thrombus adhesion to glass and silicone reactive
site materials at varying flows following a 3.5min run. (Mean ± SD)
Additionally, we witness a significant increase in surface adherent thrombus/platelets
with flow for both the collagenized glass and silicone sites. Although we could not
visualize through the porous, translucent silicone surface, these studies were qualitatively
confirmed through actin staining and visualization of glass reactive sites at both the 50
and 200 ml/min peak flow condition where we again see a significant increase in surface
bound thrombus with flow (Fig 5.10 a, b). Furthermore, the lack of significant nuclear
staining indicates the lack of a leukoctytic component (Fig 5.10 c, d).
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Figure 5.10. Glass reactive site surface visualization post exposure to whole blood at either 50 or 200
ml/min peak flow conditions (left/right) depicting actin staining (top) and nuclear staining (bottom).
Note the lack of nuclear staining, which indicates a lack of a leukocytic component.
Albumin
To investigate the effectiveness of albumin in blocking reactive site adhesion, we ran 3
albumenized and 3 non-albumenized (non-coated) reactive sites for both the glass and
silicone base surfaces at the median 100 ml/ntin peak flow condition for 3.5 min. Again,
the LDH analysis was carried out (Fig. 5.11). COlnparing these results with those of the
collagenized surface (Fig. 5.9), we see a significant decrease in bound thrombus for both
the non-coated and albumenized surface. Although there is a small degree of adhesion
present in the non-coated cases, this signal is totally abolished with albumin coating on
both the glass and silicone substrates. Again, we visually confirmed this by the lack of
actin staining to albumenized glass reactive sites (results not shown).
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Figure 5.11. Comparison of LDH quantified platelet adhesion to non-coated and albumin coated
reactive sites composed of glass or silicone material following a 3.5 min run at the 100 ml/min
condtion, showing the effectiveness of albumin in creating an unreactive surface. While the non-
coated cases were low as well (compare LDH scale to Fig. 5.9), they exhibited detectable signals.
(Mean + SD)
Adhesion Time Course
To determine the time dependent nature of platelet adhesion to our reactive sites, we
performed a time course study (3.5, 10, 30, 60, 90 min) using collagenized silicone
reactive segments (a signal was not detectable on the albumenized surfaces for +90min;
results not shown). At each of the three flow rates, 2 runs of 10 segments were
performed. For each run, 2 segments were stopped and analyzed for total number of
adherent platelets at each of the five prescribed time points (yielding a total of four
samples per time point for each of the three flow rates). We see that the level of surface
adherent platelets climbs from the initial, 3.5 min time point, reaching a plateau for the 50
and 100 ml/min peak flow conditions by -30 and 60 min respectively (Fig. 5.12). The
200 ml/min flow condition peaks more quickly (10 min), but then decreases significantly
at the longer time points. In all cases, the anticoagulated platelet (thrombus) signal does
not grow indefinitely, but is composed of an initial transient phase followed by a steady
state response.
I-I-
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Figure 5.12. Time course of platelet response (quantified by LDH measurement) at 50, 100, and 200
ml/min peak flow rates.
5.2.3 Discussion
It is important to establish how platelets adhere in a nominal reactive site model of
constant diameter coated with simple, reductive surfaces (collagen, albumen) before
expanding to more complex issues of pathological and interventional geometries or
surfaces. Here we have validated our techniques of reactive site preparation along with
the LDH assay protocols that enable fast, efficient platelet quantification.
While non-coated glass sites exhibited negligible platelet adhesion, plain silicone
sites yielded a small but noticeable signal. Such discrepancies could be the result of
differential plasma protein adsorption to the bare surfaces upon blood contact or other
qualities of the materials themselves such as altered roughness, porosity, etc. that may be
sensible through the rapidly adsorbed protein layer. These material dependent
differences were largely masked upon individual collagen or albumin coating. Basic
functional similarities to both the collagenized glass and silicone segments were observed
as transient platelet adhesion increased over a range of potential coronary-like flow rates.
Similar flow-dependence of platelet / collagen adhesion has been widely shown using
constant shear parallel plate chambers and is a result of increased surface transport and
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flow-dependent platelet activation . When coated with albumin, the platelet response is
completely eliminated on both surfaces.
Time is an important parameter to recognize in dynamic responses such as
thrombosis. While the 3.5 min results represent a fairly early time point, we were also
interested in characterizing the time dependent nature of platelet accumulation to
collagen surfaces given the possibility of various outcomes. For instance, platelet /
thrombus accumulation may grow unrestrained, eventually blocking off the lumen as
with acute occlusive thrombotic events or in our loop occlusion time trials (sections 3.2.3,
3.2.3). Alternatively, a sub-occlusive state may be reached. In our collagenized reactive
site model, we observe significant restraint on surface thrombus accumulation as the
platelet/thrombus signal does not grow indefinitely, but rather is composed of an initial
transient phase followed by a steady state response. The discrepancies between these
findings and our previous occlusive trials are likely a result of the potent inhibition of
coagulation via PPACK used in the present study (indeed collagenized reactive site loop
occlusion was observed to occur <20 min with coagulation present; results not shown).
In the presence of anticoagulation, growing thrombus cannot be stabilized with a fibrin
mesh or potentiated by other coagulative functions (section 1.2, 4.2).
The time course response represents a balance between platelet surface capacity,
accumulation (adhesion and aggregation) and removal (micro/macro embolization) and
can be characterized by various features. From our studies, we see that accumulation
rates, steady state signals, peak signals, time to steady state and time to peak response are
required to sufficiently describe our time dependence. Appreciating these features of the
dynamic response is important as different situations may affect only a portion of them,
leaving others unaltered. For instance, while the accumulation rate of platelet adhesion
under the 50 ml/min peak flow condition was less than that of the 100 ml/min conditions
(which resulted in lower 3.5 min observations at the low flow condition), a similar steady
state level was eventually reached. Dynamic changes may go unappreciated (or
conversely be over-appreciated) if a more detailed picture is not recognized.
Using real time observations, various investigations have shown similar results,
where a constant surface platelet level is attained under moderate shear levels. With high
shear conditions (similar to levels attained during the peak of our high flow condition),
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platelet adhesion initially rises, with a subsequent decay as a result of surface
microembolization [72, 73, 97, 115]. Although the current embodiment of our system
did not allow us to perform real time analysis to further document this occurrence, both
the increased standard deviation indicative of a more complex, stochastic process and the
decrease in surface bound platelets are suggestive that such embolizations are taking
place within our system at high flow. Still, these are only loose relationships. Given the
importance of embolization as a thrombotic outcome, strategies of further observing this
phenomenon in our hemodynamic model would be of significant use.
When developing and applying in vitro models, it is important to consider their
placement with respect to real-world scenarios given the goal of potentiating studies of
predictive relevance. In previous chapters, we studied interactions of blood components
with specific: endovascular devices in a simple, homogenous fluid loop. While novel
findings are undoubtedly possible using such a scheme, we hoped to increase the
applicability of our system in studying vascular situations, recognizing the model's
unique nature of setting up a highly controllable, pulsatile flow environment within
relevant arterial geometries.
In the current chapter, we have considered model placement by introducing
reactive segments into our fluid loops as a model of discrete vessel wall injury. Using
glass and silicone materials, we developed models to support various applications
requiring a moldable (pathological vessel architecture) or compliant (endovascular device
implantation) vessel wall and coated them with individual protein layers to reductively
model vascular situations. Specifically, we show how collagen and albumin can be used
as simple models of reactive and unreactive vascular segments. In these models of
vascular injury, we have begun to characterize and explore the important platelet
adhesion reaction occurring within our in vitro setting as a key mediator of the biological
response. Given this background, we now turn to more pointed investigations concerning
issues of the local hemodynamic environment and how real-world factors such as spatial
and temporal flow disturbances may play an important role in directing local biological
responses.
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CHAPTER 6 Real-World Hemodynamic Environments
The local hemodynamic environment plays a critical role in directing the local thrombotic
response. While many of the fundamental, flow mediated interactions have been
delineated through prior in vitro and in vivo work (section 1.3), much remains to be
learned with regards as to how these factors play out in real-world scenarios. Deeper,
situational studies require highly controllable, highly observable systems which
recapitulate both the flow and geometric conditions present within specific vascular
environments. Such systems could help to bridge the gap between overly reductive and
overly complex models, optimizing the path from bench top discovery to bedside
application. In preceding chapters, we have established methods to parameterize
important biological and physical properties of the platelet response within our in vitro,
reactive site model. In doing so, we have begun to characterize the platelet response
within a coronary-like, pulsatile, hemodynamic setting, thus establishing a foundation
from which we can further explore aspects of the hemodynamic environment.
Real-world hemodynamic scenarios exhibit a high degree of spatial and temporal
variability. As blood flows through the vasculature, it experiences a multitude of
environments that change over time and length scales of varying magnitudes. Given that
platelets are responsive to their shear environments, we must delineate the levels at which
they can sense local changes in environment. In some cases, spatio-temporal fluctuations
may go by unperceived, while in other situations, they may play a crucial role in
mediating the local biological reaction. In this chapter, we investigate the platelet
response to variations in the hemodynamic environment induced by highly idealized
situations which we develop in our reactive site model. Specifically, we more closely
look at the effects of coronary-like flow pulsatility and those induced by endovascular
stent presence as examples of temporal and spatial variability respectively. Given that
these highly relevant hemodynamic factors create observable differences in the local
platelet response, we also begin to explore the efficacy of antithrombotic agents whose
mechanisms of action target specific platelet/wall interactions. As the mechanisms
governing thrombotic processes change, the effectiveness of inhibitory strategies which
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work to block such occurrences must be confirmed, and if needed, new strategies
implemented.
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6.1 Temporal Variations in Hemodynamic Environments
Mechanistic platelet wall adhesion to collagen has been widely studied in other steady
flow in vitro models (section 1.2). At steady shear rates greater than 1500 s-', GPIb-vWF
interactions are essential in mediating initial platelet recruitment to vascular surfaces.
Antibodies, specific agents or component removal (depletion, genetic defects, knockouts,
etc.) directed against this axis can totally abolish high flow adhesion [24, 26].
Alternatively, agents directed against the aIIb3 integrin significantly reduce wall
adhesion across all flows by blocking firm vWF mediated collagen adhesion, as well as
subsequent fibrinogen cross linking and aggregation [35, 149]. Considering the diversity
of vascular environments encountered within the body, mechanistic investigations into
flow dependent platelet adhesion have proven essential to our understanding of vascular
thrombosis, as well as in the development of anti-thrombotic strategies that are effective
throughout the vascular compartment (i.e. in settings of both arterial high flow or venous
low flow thrombosis).
Along with region-specific shear variations, temporal variations in flow exist with
flow pulsatility being recognized as an important modulator of vascular states [58, 66,
112, 150, 151]. Understanding the mechanisms of platelet adhesion in pulsatile flow is
an important goal, particularly considering the vital coronary environment where periodic
low and high flow conditions exist on a beat to beat basis. In section 5.2, we have begun
to consider the pulsatile environment, observing qualitatively similar, flow dependent
platelet adhesion in our flow model as compared to findings made in other constant shear
systems. However, these studies only begin to explore the platelet surface reaction. Just
as total loop occlusion (section 3.2) results from the integration of many thrombotic
responses, platelet adhesion is the integration of many platelet responses. Even when
isolated, the richness of the platelet response cannot be fully appreciated without further
reductive, mechanistic studies.
No study to our knowledge has investigated the specific, mechanistic role of
platelet receptors under physiologically relevant, pulsatile flow conditions. Given that
important flow-dependent responses such as wall tethering and adhesion are enabled and
controlled at the receptor level, we sought to focus our investigations deeper, specifically
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considering the role of the GPIb tethering axis in pulsatile flow. We hypothesized that
the mechanisms of platelet adhesion under coronary-like, highly pulsatile conditions
would be different than those under constant shear conditions. In contrast to the later the
former would allow specimens to be exposed in an alternating fashion to both high and
low shear phenomenon, potentially bypassing the need for GPIb tethering.
6.1.1 Methods
Hemodynamic environment
Previously (section 5.2), we related our observational platelet adhesion studies to prior
findings obtained in other model systems. To more rigorously establish the effects of
pulsatility on platelet wall interactions, we must have more suitable internal controls. As
rotor accelerations are required to maintain relative fluid/wall motion, we could not
recreate steady flow conditions for comparison (see section 2.12). Instead, we hoped to
use square wave profiles to approximate constant wall shearing conditions on a beat to
beat basis. While we have previously discussed the use of square wave wall
accelerations to induce flow (section 2.1), we must more fully develop and characterize
this important control pulse to understand the use and potential limitations of such a
strategy for approximating the constant flow condition.
Approximating the Steady Shear Condition: The Boosted Square Wave
Relatively gradual time responses (with respect to our system time constant of -0.1 sec)
are simple to generate with our methodology. Al though we sought to create square type
waves of a low (1 Hz) fundamental frequency, high frequency components are required
to accommodate the discontinuous boundaries of each pulse. To approximate the effects
of these discontinuities, we can reconsider the results obtained from our analytical
straight tube model given a square wave wall acceleration profile (Fig 2.6; section 2.2),
where a 95%/ rise time of -0.3 sec was determined (30% of pulse duration). This type of
pattern only provides a rough approximation of a constant shear condition.
To generate these profiles, a square wall acceleration was applied. As we hope to
maintain square fluid motion characteristics which inertially lag behind the driving wall
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velocities (recall the square
profile example in Fig.3.2), we
can modify the wall profiles in
an effort to counterbalance the
sluggish effects of fluid inertia.
The simplest method is to
provide an impulsive spike
near the beginning of the
square acceleration profile.
Given the additive nature of the
Fourier series, these impulsive
spikes can simply be added to
the square profiles (Eq. 12),
yielding a summed wall
acceleration of:
0
C.
-c
e1-1c0Q)
W
W
5 T 5 5Time (sec)
Figure 6.1. Impulsively boosted square wave
wall acceleration profile (black) overlain on a
plain square profile (red).
d2Z(t)l ein ei
dt 2 n=1,3,5... n=l
(18)
Figures 6.1 and 6.2 show the driving wall motion profile (overlain on a simple square
profile) and the resultant relative fluid velocity profile respectively.
To more clearly witness the effects of these impulsive spikes, we can integrate the axial
velocity over the tube cross section for both the simple and boosted square wave
conditions, obtaining the bulk flow rate (Fig. 6.3). Comparing the two profiles, it is clear
how the impulsive function indeed works at the point of discontinuity to create a much
better approximation of a square wave pattern.
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Figure 6.2. Relative axial fluid velocity over a radial distribution as a function of time given a boosted
square wall motion using Eq. 17 to drive Eq. 7; R=O.16 em, v=O.04 dynes em/sec. This solution may
be compared to the simple square driving motions on Fig. 2.6.
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Figure 6.3. Integrated bulk flow profiles for the boosted (black solid line) and plain (red dashed line)
square wave wall driving conditions. The boosted condition provides a much better approximation
of a square flow pattern.
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Appreciating the nature of bulk flow is important as this is the output of our Transonic
flow transducers and thus, the principle handle through which we develop and observe
fluid motion within our loops. However, the flow paran1eter that interacts most
apparently at the level of platelet receptors is the shear rate. Indeed, parallel plate flow
chambers which have largely been used to characterize shear dependent platelet functions
enable high shear rates at low flows. Although the square and modified square wall
acceleration pulses can be used to approximate near-steady flow conditions (in an
absolute sense), we must consider their effects on wall shear as well. In figure 6.2, we
can see that brief portions of flow reversal and increased wall velocity result at the points
of flow discontinuity. To more directly assess the effects of these disturbances on shear,
we graphed wall shear rate (absolute value) as a function of time for both the square and
boosted square profiles (Fig. 6.4).
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Figure 6.4. Wall shear rates for boosted (black solid line) and plain (red dashed line) square wall
driving profiles. While providing a greatly reduces 95% rise time (-0.1 sec vs. -0.3 sec), the boosted
signal shows a large overshoot error (75%)
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From this analytically derived figure, we can get a sense of the magnitude and duration of
the flow disturbance on directional change. In the non-boosted case (red dotted line), we
see an expected 95% steady state (SS) shear rise time of 0.3 sec (note the use of SS in this
case is defined over an individual pulse). With the superimposed impulses (black solid
line), this 95% rise time is reduced to 0.1 sec though at the expense of a brief but
considerable overshoot (-75% for the depicted conditions).
While a single, well placed
impulse, allows wall shear
rates and flow to be a
maintained above a certain
level for the vast majority of '
the flow cycle, the resultant *
overshoot error in wall shear
creates an unwanted departure ,
from our goal of modeling
constant shear conditions. To
rnirsiivo this: mnrrtitll oal.lIIIULClt LlIldlilllLUUC;21 UlI,
Time (sec)
we can further modify our wall
motion profile, decreasing the Figure 6.5. Boosted square wave with a train of discrete
impulsive functions.
amplitude of the impulse
function and temporally
spreading it out over a train of impulses (Fig. 6.5). These increasingly complex functions
allow wall shear rates (black solid line; Fig. 6.6) to be quickly changed and maintained
throughout the flow cycle, at the same time minimizing overshoot error to within 5% of
SS value for 90% of pulse cycle (for the conditions presented).
II1 our bench top model, such complex boosting functions are readily produced as
practical limitations on rotor response automatically smear impulsive functions over a
finite interval (-0.1 sec; section 3.1). Moreover, this spreading occurs in a continuous
fashion as opposed to a chain of discrete impulse functions. Though we could not
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directly observe wall shear in our system to provide the ideal feedback for creating our
near constant shearing conditions, we satisfied ourselves with matching the integrated
bulk flow profile pattern found through the (black dashed line; Fig 6.6), noting
principally the need for a fairly rapid rise time to peak flow as compared to the relatively
sluggish flows generated using an ordinary square-driving profile (red dashed line).
O.
5
1.
5
Time (see)
2.
5
Figure 6.6. Calculated wall shear rate (top set of curves; solid lines) and fluid flow profiles (bottom
set of curves; dashed lines) for a square wave wall motion boosted with an impulsive train, showing
the rapid rise time and minimal overshoot error in wall shear.
("Generated Flow Waveforms
To analyze the effects of coronary-like pulsatility on platelet adhesion, we used 1 Hz
triangular pulses to roughly approximate the coronary wave form (section 3.1)
characterized by gradual flow onset and depletion rather than abrupt flow disruptions (red
line; Fig. 6.7). These gradual temporal changes were readily accommodated for
considering the relatively fast response time of our system. Square waves of half the
amplitude (equivalent mean flow) were developed using a strategy of boosted, square-
tYPe wall accelerations. In an effort to model absolute constant shear conditions, our
acceleration strategy allowed us to quickly (minimizing duration error), though steadily
(minimizing overshoot error) reach the peak flow condition (black line; Fig 5.19).
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Figure 6.7. One cycle of generated triangular and square-like pulsatile profiles of equivalent mean
flow rates, providing a representation of coronary-like pulsatility and an absolute constant shear
condition respectively.
With these prototypical shapes,
we spanned a range of shearing
physiological to pathological
settings (section 1.3). Every
triangular pulse was matched
with a control square pulse of
identical mean flow (Fig 6.8; 50-
400 mllmin mean flow, -250-
2000 s-1 mean shear rate; peak
shear rates of 4000 S-I).
conditions relevant to
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Figure 6.8. Generated triangular square flow patterns
spanning a physiological to pathological range of pulsatle
flow conditions; ** Note one cycle of the bidirectional
profiles is shown.
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Reactive Sites
Reactive segments were used as a reductive model of vessel injury. Briefly, fluid loops
were made from a 21 cm length of 1/8" inner diameter (ID), 3/16" outer diameter (OD)
3350 Silicone Tygon tubing into which a glass reactive tubing segment was inserted
(glass was used to enable surface visualization). The reactive segments were coated with
Type I, acid insoluble bovine collagen and the 21 cm lengths were uniformly coated with
a 1% BSA blocking solution (section 5.1).
Platelet Isolation, Manipulation, and Observation
Whole blood was drawn from healthy volunteers using D-Phe-Pro-Arg chloromethyl
ketone (PPACK, 80 lM final concentration; Calbiochem-Novabiochem Corp. La Jolla,
CA) as an anticoagulant and used within 30 min of withdrawal as source of platelets.
Given that we were investigating initial (5 min) adhesion processes during which time
little leukocyte incorporation could take place, whole blood (as opposed to the leukocyte
depleted blood; section 5.2) was chosen to minimize handling. To study the effect of
GPIb mediated wall tethering, the blood was incubated with 20 pg/ml AK2 or 20 [tg/ml
IgG1 isotype control (both from Serotec, Oxford, UK) for 15 minutes prior to a run. The
murine monoclonal anti-GPIb antibody AK2, has been previously characterized and
shown to functionally block GPIb-vWF interactions at these concentrations [152].
Platelets were quantitatively assessed through LDH staining and qualitatively
through surface visualization (BODIPY FL phalloidin staining) as previously detailed
(section 5.2. 1).
6.1.2 Platelet Adhesion in Pulsatile Environments
Dependence of platelet adhesion on flow profile shape
To determine the effects of pulsatility on platelet tethering, we incubated PPACK anti-
coagulated whole blood with either the function blocking anti-human GPIb antibody
(AK2) [152] or IgG1 isotype control and circulated the blood over the reactive sites for 5
minutes to allow thrombus growth. We characterized the importance of the GPIb axis on
platelet adhesion under pulsatile flow conditions over the range of physiological and
pathological flow rates by quantitatively assessing the surface adherent layer using the
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LDH assay as a marker of thrombus size and indirect platelet adhesion (these surface
adherent layers were found to be predominantly composed of platelets given the lack of
significant nuclear staining; data not shown).
In the absence of inhibition, both square and triangular profiles supported similar degrees
of flow dependent platelet adhesion and thrombus growth (Fig. 6.9; grey lines). These
results are agreement with our previous findings where we show an increase in adherent
platelets with flow (transient case; section 5.2). That the increase occurs with both
triangular and square flow patterns of identical mean flow rates indicates that this
observation is relatively profile independent, supporting similar observations which have
been made in a variety of other settings as well [26, 97].
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Figure 6.9. Triangular and square pulsatile flow dependent platelet adhesion (as quantified by LDH
measure) with and without GPIb axis blockade using the monoclonal antibody AK2. (Mean + SEM)
In the presence of AK2, thrombus formation was uniformly eliminated with increasing
flow rates under square flow conditions (our model for constant shear), while the
coronary-like triangular profiles allowed significant platelet accumulation (Fig. 6.9; black
lines). These findings were visually confirmed through actin staining of reactive sites run
under the extreme flow conditions (50 and 400 ml/min mean flow; Fig. 6.10).
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Figure 6.10. Actin visualization of surface thrombus formation at extreme (50 mllmin; 400
mllmin mean flow) pulsatile flow conditions with and without AK2 treatment. S indicates square
profiles; T indicates triangular profiles.
Comparing surface platelet accumulation between the triangular and square wave flow
patterns at either mean or peak shear rates, we witness a dramatic divergence that occurs
between 1000 and 2000 S-1 for the GPIb inhibited pulses (normalized to the respective-
AK2 condition; Fig. 6.11). That the jump occurs at a similar limit considering either
peak or mean values is indication that profile shape (triangular vs. square) is the robust
difference in mediating the GPIb-bypass effect. The divergence is a result of the
complete blockade of platelet adhesion with the GPIb inhibition under high, square
conditions (2: 300ml/min, 1500 S-I, black dashed line; Fig. 6.9), This correlates well with
the limiting 1500 S-1 shear rate above which GPIb tethering has been shown to be
essential under steady shear conditions.
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Figure 6.11. Ratio of relative platelet burden under triangular flow conditions to those under square
flow conditions of either equivalent mean (black) or peak (white) pulse flow rates.
Importance of Low Flow Phase in Bypassing GPIb axis
A major difference between triangular and square wave patterns that we hypothesized
rnay account for our observations is the significant fraction of triangular flow profiles that
can be spent in low flow regimes, during which time platelets may adhere independently
of GPIb tethering. We can characterize the portion of the cycle spent in the low flow
phase, TLow, by determining the duration of the cycle that is less than some threshold flow
rate QLow, below which GPIb/vWF independent adhesions are supported (Fig 6.12).
Considering our square profile dynamics (black dashed line; Fig. 6.9), we can
approximate this level to be -200 mllmin, above which GPIb inhibition dramatically
reduces platelet adhesion.
If the peak flow rate, Qpeak never exceeds the prescribed threshold, QLow , then the
entire cycle is within the low flow bounds. If on the other hand, Qpeak exceeds QLow, then
the time spent in the low flow regime is simple given by the simple ratio:
QPeak
(19) TTotal xQ
T = Low
Low
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where TTotal is the full pulse period (1 sec). Thus, for the 100, 200, 400, and 800 peak
triangular flow rates, TLow was 1.0, 1.0, 0.5, and 0.25 sec respectively.
Qoeak TLow
C
E
0
-
I UU -
750
500
250
1 OOml/min
Q Peak
Q Low - 200ml/min
0
0 0.5
TLow
1
200ml/min
400ml/min
800ml/min
1.5
1.0 sec
1.0 sec
0.5 sec
0.25 sec
Time (sec)
Figure 6.12. Definition of TLow.. Note that while QPeak is a function of the considered flow profile,
QLow is purely of function of platelet physiology, and is given by the flow rate that is capable of
supporting GPIb independent adhesion (Fig 6.9).
To isolate the importance of such alternating high and low flow conditions in a given
pulsatile flow waveform and see if these could account for a profile mediated
circumvention of the GPIb-vWF axis, we sought to find a minimal low flow period
required for platelet adhesion to occur (TAdhesion).
Modified Flow Profiles for Determining Platelet Adhesion Time (TAdhesion)
To isolate and explore these temporal parameters, we developed a series of truncated
square flow patterns with a variable duty cycle (low flow period/total flow period)
retaining an overall 1 Hz frequency (Fig. 6.13). In each of these profiles, high (above
which platelets could not bind given GPIb inhibition; > 300 ml/min) and low (nominal;
<< 300 ml/min) flow magnitudes of 350 and 50 ml/min were used for the high and low
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flow periods (TH, TL; as defined in Fig. 6.13) respectively. Non-zero flows were used
for the duration of the low flow phase to eliminate flow stagnation.
Duty Cycle = TL/ (T L+TH)
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Figure 6.13. High I Low phasic flow profiles with changing duty cycle, TI/(TL+ TH) where TL is
the portion of the cycle spent in the low flow regime and TH is the remander spent at the high
flow condition
Characterizing TAdhesion given GPIb blockade
GPIb inhibited, anti-coagulated whole blood was run for 5 and 10 minutes under the
varied duty cycle conditions and platelet/thrombus accumulation was quantified through
LDH measurement. Each condition was compared to a control, high flow square pulse
case (0 duty cycle; 350 mVmin) for 8 individuals. Platelets uniformly failed to
accumulate when the low flow period, TL, was ~ 0.125 s. This indicated that under the
shortest duty cycle condition, platelets did not have sufficient time to firmly adhere and
accumulate before the onset of high flow at which point platelet adhesion would no
longer be supported in the absence of GPIb function. As TL was further increased,
individuals began to variably respond by 0.25 s, with all sh<;>wingsignificant thrombus
formation by 0.75 s (Fig. 6.14). These results yield an estimate of intrinsic platelet
adhesion time, TAdhesion, (between 0.125 and 0.25 sec).
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Figure 6.14. Platelet adhesion (quantified via LDH) as a function of TL and normalized to a full
square pulse condtion (0 TL). These results depict the minimum adhesion time, TAdhesion,
required for platelet accumulation given GPIb inhibition (0.125-0.25 sec);** 1.01 value at
TL=0.125.
6.1.3 Discussion
By parametrically considering hemodynamic environments relevant to the coronary
circulation and through inhibition of the GPIb platelet tethering receptor, we have
mechanistically investigated the effects of pulsatility on surface platelet adhesion. To do
this, we developed square flow profiles as a comparative control. However, these square
profiles do not exactly produce steady absolute shear levels as the flow briefly jumps
from one level to the next. While these rapid discontinuities upon directional change
may be postulated to mediate the profile dependent differences observed between our
square wave and our more slowly changing triangular profiles, the ability of altered duty
cycle square waves (which also create such abrupt discontinuities; Fig. 6.13) to support
platelet adhesion indicates that this is not the case. Furthermore, we observed that the
limiting shear rate above which platelets could not adhere with GPIb blockade occurred
similarly at 1500 s-1 for both our square flow profiles as well as the constant shear pattern
which they sought to approximate, providing additional support for validity of these
controls.
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We compared triangular and square flow pulses over a range of magnitudes. In
the absence of GPIb inhibition, platelet accumulation was found to increase with flow
rate, but in a manner that was independent of profile shape. Also, under low flow
conditions, pulsatile profile shape does not significantly affect platelet adhesion
irrespective of GPIb blockade. This corroborates numerous other studies which show
that under conditions of low flow, GPIb mediated tethering is not essential. However,
under higher flow, pulsatility can bypass the GPIb-vWF tethering axis (Fig. 6.9, 6.10).
The effect seems to be dependent largely on the presence of low flow periods of
sufficient duration, during which time GPIb-independent adhesion can occur. So long as
the cycle's low flow phase is greater than the time required for platelet attachment,
T Adhesion, platelet accumulation and thrombus growth are supported.
From our studies using modified square profiles of varying duty cycle (Fig. 6.13),
TAdhesion with GPIb blockade was determined to be between 0.125 and 0.25 sec (Fig.
6.14). These results give important insight into understanding the varied responses
observed between our triangular and square pulse profiles at high flow. Using our
boosted square wave wall motion strategy, we were able to maintain near constant flow
conditions (in an absolute sense), theoretically keeping wall shears to within 5% of the
steady state values throughout all but 0.1 sec of the pulse. That this time is less than the
observed TA(dhesion time (0.125-0.25 sec) is a likely rational for the effectiveness of our
square profiles in modeling the constant shear condition. Given triangular pulse patterns
which exhibit gradual rise and fall characteristics, considerably longer portions of the
cycle can be spent in low flow regimes (Fig. 6.12). For the maximum, 800 ml/min peak
triangular flow wave considered, this low flow time would be around 0.25 sec, greater
than the TAdhesion time required to support GPIb inhibited adhesion. Indeed, GPIb axis
inhibition yielded significant platelet adhesion under these conditions. To test triangular
waves with a low flow period less than the 0.125 sec, we would need to generate pulses
with a maximum flow rate of 1600 ml/min. Though this extreme condition would further
confirm the importance of low flow duration on bypassing the GPIb axis, these profiles
were not possible given the current motor specifications and system embodiment. Still,
considering the reducing trend of platelet adhesion by the higher flow rates under GPIb
inhibited triangular pulse conditions (black solid line; Fig. 6.9), it is reasonable to
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postulate that these lines would project to the eventual elimination of platelet adhesion by
1600 ml/min.
Many studies considering platelet adhesion have taken place in constant shear settings,
showing the critical nature of shear on platelet receptor function. In the body, blood flow
is far from constant, exhibiting widely varying temporal fluctuations. Using our pulsatile
flow system, we have shown that temporal variations in flow profile shape, similar to
those in a coronary arterial setting, may mediate mechanistic differences in platelet
adhesion pathways as compared to a constant flow setting (modeled with our square flow
patterns). Accordingly, when investigating complex, situational thrombotic events flow
profile is an important parameter to consider. Given this understanding, we revisit the
scenario of endovascular stenting. Using our reactive site model, we can now consider
not only device/blood interactions, but the induced hemodynamic situation, as the
structure of the stent creates spatial variation in the local shears experienced by the
reactive vessel wall.
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6.2 Spatial Variations in Hemodynamic Environments
In section 6.1, we show how pulsatility can lead to altered mechanisms of platelet
adhesion, specifically through a bypass effect of the GPIb tethering axis which is
typically required for high ~hear platelet adhesion. Along with temporal changes, abrupt
disturbances in vessel geometry can also affect the local hemodynamic situation, having
further implications on localized mechanisms of platelet adhesion and thrombosis. While
the previous example (section 6.1) considered a reactive site and fluid loop model of
constant internal diameter, the unique nature of our in vitro system allows us to not only
establish carefully controlled flow environments, but geometrical ones of relevance to the
arterial setting. We now consider the case of intervention ally induced spatial changes as
modeled in our idealized in vitro environment and how these may affect the dynamics of
local platelet/wall interactions.
Coronary Interventions: Angioplasty and Stenting
Percutaneous interventions (PCn have become the mainstay of treatment for acute
coronary syndromes (ACS). Over the past two decades, the beneficial effects of
percutaneous transluminal coronary angioplasty (PTCA; Fig. 6.15a) versus thrombolytic
strategies have been shown [153, 154]. More recently, numerous clinical trials
3. b.
Figure 6.15. Coronary interventions. a. Percutaneous Transluminal Coronary Angioplasty (PTCA)
; b. Endovascular Stenting
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have shown coronary stenting (Fig. 6.15b) to be an effective technique in achieving even
greater post-procedural luminal gains while offering a lower incidence of recurrent
ischemia and a resultant reduction in the need for target vessel revascularization [155-
157]. While the marked success of these catheter-based approaches has led to their
widespread use in both urgent and elective cases, these procedures are not without
consequence.
Upon intervention, the local coronary environment can be dramatically altered.
With coronary disease, the luminal surface may already be badly damaged as a result of
endothelial erosion or rupture of the atherosclerotic plaque region, exposing
subendothelial matrix components and atheromatous debris. Following angioplasty, what
was left of the once-protective endothelial layer can be further removed leading to
reactions such as those covered in chapter 5. While the local expansion of a stent can
help to mechanically stabilize the lumen and prevent occlusive wall dissections, the
device may also have adverse environmental effects. The mere presence of a foreign
surface can interact strongly with various biological components (section 4.2).
Moreover, that these devices function in a flowing environment provides a mechanism
whereby the geometry can influence the local situation by inducing changes in the
hemodynamic environment. Whether induced by foreign devices or injured vascular
surfaces or both, the biological response to intervention is heralded by site platelet
accumulation which serves as an important component in both the acute and long term
response.
Recognition of the critical, targeted role of platelets in affecting high flow, arterial
thrombosis has lead to the effective use of anti-thrombotic strategies that limit clinical
cases of acute/subacute outcomes in the setting of coronary intervention. Still, there
remains a significant risk of mortality associated with thrombotic vascular occlusion,
along with a risk of hemorrhagic complications accompanying the use of powerful anti-
thrombotic agents. Moreover, clinically silent mural thrombosis is an apparently
ubiquitous process that serves as the inciting and promoting event for subsequent repair
and remodeling that leads to pathological inflammation and restenosis. Accordingly,
elucidation and control of the local thrombotic process induced by iatrogenic states is of
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great importance for the continued use and optimized development of coronary
therapeutic modalities such as angioplasty and stenting.
We have previously considered the effects of endovascular stent surfaces on thrombotic
reactions, showing assorted interactions between biological and physical factors (chapters
3, 4). While these studies provided much needed insight required to parameterize and
place our model, they raised more questions than they answered. What factors mediate
the observed differences between non-polished, polished, gold, and treated gold stents?
Why is does stainless steel more strongly activate the intrinsic pathways of coagulation
while gold more strongly interacts with the platelet component? Why does platelet
responsiveness increase with flow for both stent surfaces under conditions of low
coagulation, but not under high coagulation levels? Though we can provide
rationalizations for these findings, to more fully understand these issues reqUIres
considerable effort. Before spending excessive energy to mechanistically delineate such
observations we must consider that they were made in the absence of a reactive wall
component. Expanding our study from one of endovascular devices to one of
endovascular situations, we can consider the effects of stent placement in our reactive site
model, where wall interactions could specifically be enabled or eliminated. In doing so,
we hoped to gain an appreciation for the functional influence of stent presence in the
regional platelet response.
6.2.1 Methods
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Figure 6.16. Generated triangular flow waveforms modeling
coronary-like profiles.
Hemodynamic Environment
We applied our reactive
coronary site model to
investigate the anti-coagulated
phitelet response to stented and
non-stented situations over a
range of flows typifying the
physiologic, coronary- like
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environment (50-200ml/min; Fig. 6.16). In doing so, we provide a greatly simplified,
idealized, in vitro model of the interventional stent and PTCA conditions. By creating an
environment where the physical geometries would closely match the in vivo condition,
we were not only able to accommodate physically relevant stents and proper mechanical
expansions (section 5.1), but ensure that the developed shear profiles would closely
match those found in the respective coronary interventional situations.
Qualitative effects of stenting on hemodynamic environment
In the setting of non-stented geometries, the tubular fluid flow is relatively
straightforward, and while curvature effects create secondary flows that may be
considered, the principle flows are those given by the analytical model which we consider
in section 2.1. Although a great deal of variability may exist in time, the wall flows are
axially symmetric. With the placement of a stent, the situation becomes far more
complex, and simple analytical models are not suitable. Given the importance of
understanding the hemodynamic environment induced with stenting, computational fluid
models have been widely applied towards understanding the nature of the established
conditions. From these studies, even in light of the widely varying input conditions,
many qualitative similarities exist in the spatially varying flow conditions.
Although high shear rates may occur on the stent struts themselves, recirculation
zones are formed in the immediate, upstream and downstream vicinity of each strut. In
these regions, flow can be considered near stagnant. The sizes of these regions are
largely dependent on strut dimensions and flow speed, making the conditions in the
center portions of the inter strut regions far more complex. When strut spacing is close
enough together (in relation to strut height) or when flow velocity is sufficiently high, the
recirculation zones between two adjacent struts may connect to form a single large, near-
stagnant region (Fig. 6.17a). Alternitively, with larger spacing or lesser flow speeds,
flow reattachment may occur, thus maintaining appreciable flow between struts (Fig.
6.17b). Still, various numerical studies have shown the magnitudes of such flows are
greatly reduced as compare to non-stented regions of similar bulk flow.
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Figure 6.17. Qualitative stent induced changes in flow. a. Close strut spacing and high flow promote
a single flow recirculation zone; b. Distant strut spacing and low flow promote distinct flow
recirculation zones, with inter-strut regions of flow reattachment. Flow in the recirculation zones is
near-stagnant, while reattachment allows reasonable shears, though still only a fraction of what
would be achieved in the absence of stent placement.
As we have explored in section 6.1, pockets of low flow may create a situation where the
mechanisms of platelet adhesion are different. Although the global flow condition may
be indicative of the need for platelet GPIb axis tethering to enable platelet wall
interaction, regions of low flow may circumvent this need. Previously, we explored the
significance of temporal pockets of shear. Now we consider stent induced spatial
variations. To make the effects of stent presence on GPIb tethering more clear, we
generated high flow square wave forms (our model of a constant shear condition; section
6.1) of 300 ml/min flow rate (Fig 6.8). By creating conditions when GPIb function
would normally be required (Fig. 6.9), this flow pattern allows us to isolate the spatial
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effects of stenting from the temporal effects of flow pulsatility, which in itself, could
bypass the tethering axis.
Reactive sites
Following coronary interventions, localized regions of endothelium are disrupted through
the mechanical expansion of intravascular devices (balloons, stents). This provides a
situation of subendothelial exposure which matches well with the idealized conditions
established within our reactive site model. To make these localized sites, the fluid loops
were constructed from a 21 cm length of 1/8" inner diameter (10), 3/16" outer diameter
(OD) 3350 Silicone Tygon tubing into which a 3 cm reactive tubing segment of identical
diameter (ill, OD). As an initial model of the reactive coronary wall, the 3 cm silicone
reactive segments were coated with Type I, acid insoluble bovine collagen while the 21
cm lengths and 3 cm unreactive segments were coated with a 1% human albumin solution
to block non-specific platelet-surface interactions (section 5.1).
To make the stented segments, 9-mm, 7-cell, stainless steel NIR@ stent (closed-cell
design, Fig 6.18a; Medinol, Jerusalem ISRAEL) or Tristar@ (open-cell design, Fig 6.18b;
Guidant,) were expanded to a 3.0 mm post-inflation diameter under 10 atm of pressure
via a Maxxum™ 3.0 Scimed@ balloon catheter (Boston Scientific Corporation). To
ensure similar handling conditions, a balloon was similarly expanded within the non-
stented segments (which we found to have no observable effect on platelet response).
a. b.
Figure 6.18. 8. Closed-Cell (NIR); b. Open-Cell (TriStar) stent geometries.
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Platelet Isolation, Manipulation, and Observation
To assess the effect of stent presence on the regional accumulation of platelets, we chose
to consider anti-coagulated, leukocyte-depleted blood as a platelet source as we hoped to
consider not only early time points (indicative of transient events) but longer time studies
when platelet accumulation would saturate to surface capacity (Fig. 5.12; section 5.2).
Again, this decision was made to minimize a leukocytic component in our integrative
L,DH measure, which could become a factor in long time studies (section 5.2). Whole
blood obtained from healthy volunteers was drawn via a 20-gauge needle into a 1/10
dilution of acid citrate dextrose (ACD) and 80 uM (final concentration) PPACK
anticoagulant. The leukocyte component was removed as previously described (section
5.2) and reconstituted blood components were recalcified (13mM Ca2 +) immediately
prior to use.
For the functional studies, given the short 5 min run times, anti-coagulated whole
blood was directly incubated with AK2 or IgG isotype control (20'ug/ml) and run
without leukocyte removal to minimize extraneous handling as described previously
(section 6.1).
To assess platelet function, LDH quantification was performed on the flushed reactive
sites (section 5.2). Bulk platelet activation was also determined using platelet P-selectin,
CD62p surface expression as determined by flow cytometry (section 4.2).
6.2.2 Platelet Accumulation in Stented Environments
Collagenized Reactive Sites
To assess the flow dependence of platelet accumulation to silicone segments with and
without stent presence, we compared 6 closed-cell stented and 6 non-stented collagenized
segments at each of the three flow conditions both after 3.5 min and 45 min runs.
At 3.5 min (Fig. 6.19), we again witness a significant, flow dependent increase in surface
bound platelet number (as assessed by LDH quantification) on the non-stented segments
(recall section 5.2, 6.1). In the presence of a stent, the 50 ml/min peak flow condition
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promoted slightly increased surface bound platelet adhesion. However, at the 100 and
200 ml/min peak flow conditions, the stent caused a dramatic reduction in the number of
3.5 min adherent platelets as compared to the non-stented trials.
At the 45 min time point, we observed similar numbers of surface adherent
platelets to our non-stented segments at the 50 and 100 ml/min peak flow conditions with
a lower number at the 200 ml/min rate (perhaps indicative of increased surface
embolizations as discussed previously; section 5.2). At this longer time point, the effect
of stent presence in reducing local platelet adhesion was no longer apparent and in fact,
there was a trend towards stent promotion of platelet accumulation.
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Figure 6.19. Effects of stent presence at early (3.5 min) and late (45 min) time points on platelet
adhesion to a collagenized reactive site. Note a flow dependent protective effect that is eliminated
with time. (Mean ± SD)
In all cases, no significant differences were noticed in the bulk fluid CD62p expression
between the stented and non-stented cases (results not shown).
Albumenized Reactive Site
To study the effects of stenting without a reactive wall substrate, 4 albumenized stented
and 4 non-stented reactive sites were studied at each of the 3.5 min and 45 min conditions
described above.
In these trials (Fig. 6.20), we observed a dramatic, generalized reduction in surface bound
platelets as compared to the reactive, collagen-coated sites. Also, we see a significant
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increase in the number of bound platelets in the stented trials as compared to the non-
stented cases. Given that very few platelets were adherent to the albumenized, non-
stented segments, we rationalized that the majority of platelets in the stented, albumin
coated cases were bound to the stent surface onto which reactive plasma proteins such as
fibrinogen may adsorb to mediate stable platelet adhesions. We note that the stent-
dependent rise significantly diminishes with increasing flow (as has been reported on
fibrinogen treated surfaces [23]. Furthermore, noting similarity across the 3.5 min and 45
min groups, we can surmise that a steady state, low level of stent bound platelets is
quickly reached, perhaps as a result of an overall diminished surface capacity.
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Figure 6.20 Effects of stent presence at early (3.5 min) and late (45) time points on platelet adhesion
to an albumenized unreactive site. (Mean SD)
Robustness of findings
Testing the robustness of model findings increases confidence in their predictive value
(section 4.2). Although we have witnessed significant, flow dependent effects of stent
presence on platelet adhesion, these findings may be limited to particular aspects of the
model system (stent type, anti-coagulated blood source, reductive protein coatings, etc).
Here we consider varying stent geometry to assess the robustness of our stent dependent,
reactive site platelet adhesion findings. In the preceding trials, we evaluated a stent of
closed cell geometry (NIR®; Fig. 6.18a). We now present a case of significantly
different geometry.
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An open-cell stent design (Tristar®; Fig. 6.18b) was used to probe the robustness
of platelet accumulations to collagenize and albumenized reactive sites at the more
extreme 50 and 200 ml/min peak flow conditions both at 3.5 and 45 minutes. Six stented
sites (4 in the albumin case) were compared with respective non-stented control sites for
each flow condition and the results are given in Table 6.1.
Table 6.1. Robustness of findings to stent geometry (Mean ± SEM).
COLLAGEN ALBUMIN
Stent vs. Non-Stented Case Stent vs. Non-Stented
LDH Measure Case
Time point Peak Flow LDH Measure
50 ml/min 540 45 vs. 417 63 84 + 8 vs. 22 3
3.5 min
(Transient)
200 ml/min 709 ± 45 vs. 1362 ± 115 33 ± 7 vs. 18 ± 3
50 mi/min 2470 + 351 vs. 1789 + 151 89 + 9 vs. 17 1
45 min
(Steady state)
200 ml/min 1017 + 191 vs. 533 + 150 29 + 4 vs. 15 ± 2
These results show that the open cell geometries share similar key dynamic features with
our previous closed cell results. Platelet accumulation is greatly enhanced to stented
collagenized reactive wall segments as compared to the stented albuminized segments.
Furthermore, at 3.5 minutes, we note a significant reduction in accumulation with stent
presence, selectively at high flow. By long times (45 min) this protective effect was
again eliminated. That we have observed similarities in our response for stents of
significantly dissimilar geometry is indication these results are robust within the confines
and considerations of our in vitro model.
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Altered Adhesion Mechanisms in Stented Environments
These reactive site accumulation findings offer evidence that general stent presence
affects the local environment in a flow dependent fashion. As in the case of flow
pulsatility, where temporal variations exposed blood to functionally important pockets of
both high and low shear under high, time-averaged flows, the stented environment
exposes blood to positionally spaced low flow pockets (Fig 6.17). Paralleling the
pulsatile case, we hypothesized that the mechanisms of platelet adhesion under such
fluctuating conditions would be different than those under non-stented conditions,
allowing GPlb-independent adhesion to occur in otherwise GPIb-dependent conditions.
Stented loops were filled with either blood incubated with AK2 or vehicle
controls and run for 5 min under square high flow conditions (300 ml/min; 1500 s-I
mean values; Fig 6.8). Two runs of 4 stented loops (2 w/AK2, 2 w/ vehicle) were
performed and the reactive sites were assessed for platelet adhesion via LDH
measurement.
Normalizing to the vehicle control, we found that the AK2 inhibited stented site
conditions were able to support significant platelet wall accumulation (0.34+0.05). This
is in stark contrast to the complete levels of inhibition witnessed under non stented
conditions (recall 300 ml/min square conditions, Fig. 6.9; section 6.1), showing that a
localized spatial disturbance can indeed alter the mechanisms of platelet wall interaction,
circumventing the requirement for platelet wall tethering in a global, high flow
environment.
6.2.3 Discussion
By evaluating platelet accumulation to stented and non-stented sites, we considered
greatly simplified, idealized models of the post-stenting and post-angioplasty situations
where discrete, reactive vascular settings are iatrogenically induced through the
mechanical disruption of the local endothelial layer, with or without the added presence
of a stent.
We found that stenting profoundly affected local platelet surface adhesion as
quantified by LDH levels. The 3.5 min time point represents a transient effect at which
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point platelets are still accumulating on the surface (see time course response; Fig. 5.12).
At this time, the flow dependent increase of thrombus growth was largely blunted with
the presence of a stent. A simple masking of a portion of the reactive wall by the stent
cannot fully explain these protective findings given that this reduction with stent
placement occurred in a flow dependent fashion as well as that the reduction exceeded
50% in the high flow conditions (the stent had an expanded footprint of -0.15cm 2 while
the total reactive site surface area was 3.0 cm2). By verifying these results on stents of
significantly dissimilar closed and open cell geometry (Table 6.1), we show these
findings are robust, albeit in our pared down reactive site model.
These protective effects are in opposition to the widely accepted notion that
stenting creates a greater thrombotic risk than angioplasty through the added presence of
a foreign surface [157]. To put these findings in context, we must stress our use of an
anti-coagulated, pre-occlusive model and that a decrease in transient accumulation (or
growth rate) does not imply a decrease in final accumulation. Indeed, the stented trials
supported similar or greater amounts of platelet accumulation as compared to the non-
stented cases by 50 minutes (perhaps by altering surface embolization properties as
discussed above). Moreover, these studies were performed under stringently
anticoagulated conditions. As we have witnessed (section 4.2), synergistic coagulative
presence could significantly affect the local thrombotic situation (of note, we have
observed similar reduced 5 min thrombotic growth rates with stenting in the presence of
coagulation, which by 10 min had reversed to a situation where there is increased
thrombus accumulation with stenting).
These measurements of platelet accumulation are interesting, but give an integrative view
of the local situation where stent and vessel wall interact in some fashion to affect these
responses. To more closely consider the situation and compare the relative importance of
the stent with that of the reactive vessel wall in mediating these altered platelet
accumulations, we can consider the closed cell, stented results for both the albumenized
and collagenized surfaces where wall reactions were either disabled or enabled
respectively. Taking the albumenized case to be reflective of stent surface accumulation
(as rationalized in section 6.2.2), we show the relatively minor importance of the stent
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surface as compared to the reactive wall regions in supporting local platelet adhesion
(Fig. 6.21). It also is clear that the importance of stent surface decreases with increasing
flow and with time (albumenized/collagenized stented site peak ratio of 0.15 at the
3.5min, 50 rml/min flow condition).
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Figure 6.21. Ratio of platelet site accumulation (LDH quantified) of the albumenized/collagenized
stented conditions. Right half of graph shows results at 3.5 min; Left side shows 45 min results. The
low fractions indicate the relative importance of the reactive vessel wall as compared to the strut
surface itself in adding to regional platelet surface capacity
The small contribution of stent surface adhesion to total site accumulation implies that
the major impact of stent presence (consider the greater than 50% reduction under early,
high-flow conditions) is brought about through altered wall interactions. That the stent
can have such an impact on the local platelet response while only supporting low platelet
adhesion onto itself is remarkable and likely results from stent-induced flow variations
over the vessel wall (reduced shear zones, recirculant flow patterns) and altered transport
phenomena [59, 85, 144]. In these regions, convective mass transport, intimately tied to
flow, is greatly reduced. Given that the platelet wall reaction has been shown to be
governed by diffusion limited kinetics [50], reduced transport could well play a role in
the reduced accumulation rates we observe with stenting (as represented in our 3.5 min
transient findings; Fig.6.19). The involvement of rate limiting transport phenomena is
further supported by the increased dependence of altered accumulation rates with flow
(greatest at 200 ml/min, not observed at 50 ml/min peak flow), as well as the fact that
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given sufficient time, the stented trials eventually achieve similar (or larger) surface
accumulation.
To more directly observe the potential functional impact of induced low flow regions,
we again considered the flow dependent GPIb axis, noting a significant accumulation of
platelets in the presence of AK2 under conditions which were found to be prohibitive in
the absence of a stent. While we have not created a numerical model of our exact
stenting situation, we can consider the computational results obtained from prior work
[82, 85, 144. 158]. Considering cases which used similar geometric and flow conditions
as our model parameters (3 cases; Table 6.2), we see that significantly reduced wall
shears are maintained within the inter-strut regions as compared to peak shears in the
absence of stenting in all cases well with in the limits that can support GPIb-independent
adhesion. Moreover, while these peak shear values occur in zones of reattachment
(found to occur in all three cases; Fig. 6.17b), a significant fraction of the inter strut
region is covered by recirculant zones where near stagnant conditions and drastically
reduced wall shear rates occur.
Table 6.2. Computational Results for flow over stents using geometric and flow parameters similar to
our experimental conditions. Note, that these were 2-D simulations, and precise geometries are not
definable (i.e. strut spacing) for our model.
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OUR MODEL CASE 1 CASE 2 CASE 3
Artery Diameter 3.175 mm 2 mm 4 mm 4 mm
GEOMETRIC Strut Thickness 0.1 mm 0.070 mm 0.079 mm 0.079 mm
PARAMETERS Strut Spacing -1 mm
0.64 mm 0.83 mm 0.83 mm(Fig. 6.18a)
Pulse rate 60 Hz 70 Hz 70 Hz 130 Hz
FLOW Peak Wall
PARAMETERS Shear 1500 s- ' 1550 s' 815 s- ' 2504 s-'
w/o Stent
Peak Wall Shear
??? 205 210 310
w/ Stent
% Recirculation
Zone ??? 37-49 % 34 41% 35 59 %
Wall Coverage
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Considering these computational findings, it is clear that spatially induced pockets of low
flow with a structural disturbance such as a stent (as we previously have shown with
temporal variations) can readily lead to situations which can bypass the GPIb axis in
otherwise prohibitive flow conditions.
In this section, we have considered the flow dependent impact of stenting on the local
environment. While flow variations over stents have been widely shown through
computational studies, we now show that such variations yield functionally relevant
biological responses. We found a major functional impact of stenting to be in the
induction of low flow regions over the reactive vessel wall. Specifically we observed
reduced, flow dependent wall accumulation rates with stenting, implicating reduced
transport phenomena. Furthermore, we tested and found the reduced flows were capable
of supporting GPIb independent platelet adhesions under conditions that would otherwise
preclude such events. Given these flow dependencies, it would be interesting to more
precisely delineate the actual induced flow regimes over stents of our particular
geometries, rather than rely on the qualitative findings of other computation studies.
However, for the purposes of these examinations, where our observations were based on
integrated site accumulations and designed to test for the overall impact of stent presence
in reactive wall setting, such detailed scrutiny was not warranted. To develop accurate
3-D models of the stent and flow conditions (which would be required in order to
improve upon the qualitatively based understanding gleaned from other models) was
prohibitive at this stage. Still, given the importance of stent induced flow-changes on our
experimentally observed biological function, computational models that fit closely to
experimental parameters would be of considerable value if used in sync with more
discretized biological observational techniques which allow us to not only measure total
accumulation, but patterns and distributions of platelet interaction, activation status, etc.
Currently, we are beginning to address these issues in studies where we parameterize
strut thickness. These should allow to investigate the not only the functional impact of
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stent presence of the local acute platelet response, but the functional impact of stent
design.
In section 6.1, we have seen how temporal variations in flow are an important factor in
determining the local hemodynamic environment, resulting in mechanistic differences in
platelet adhesion. Currently, we show how the presence of a stent structure can also
spatially affect the local hemodynamic setting, altering platelet / wall interactions. Both
of these examples (flow pulsatility and stenting) offer situations that are highly pertinent
to real-world scenarios and show that global hemodynamics may not be indicative of
local, instantaneous conditions. When considering the effects of hemodynamic
environment in real-world thrombosis, this level of detail is important to recognize. We
now consider an example where these issues come to bare.
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6.3 Optimizing Platelet Inhibition to Hemodynamic Settings
Anti-thrombotic agents have proven invaluable in the treatment and management of
prothrombotic conditions. In cases of acute coronary thrombosis, such as those following
plaque rupture or induced by interventional procedures, some of the most effective
strategies work by inhibiting platelet function (section 1.2). However, the benefits of
these and other anti-thrombotic drugs are tempered by an increased risk of hemorrhagic
complications [148, 159]. To limit this risk, continued effort has been placed on
identifying targeted anti-thrombotic strategies whose functions are limited to a particular
vascular setting. That platelets exhibit receptor-based mechanistic differences under
varying shear conditions is indication that the flow environment can be used as a handle
by which specific environments can be separately considered and targeted. It is for these
reasons that much attention has been given to the GPIb-vWF axis [12, 160-162]. Given
that this axis is selectively critical in high flow regimes, its inhibition has been proposed
as a method to deliver powerful anti-thrombotic effects to high flow settings as found in
the arterial circulation, while still allowing lower flow thrombosis to occur. Such a
strategy offers the potential to minimize bleeding complications while maintaining anti-
thrombotic efficacy.
Care must be taken when considering therapies which are isolated to specific
hemodynamic settings. In the case of flow sensitive GPIb/vWF axis inhibition in arterial
environments, efficacy studies have been inconclusive [51, 87, 162-165]. Many possible
explanations for these varied responses exist (severity of disease, inhibitor
concentrations, species variability, etc.) [87]. In sections 6.1 and 6.2, we have further
explored the possibility that real-world fluctuations in the hemodynamic environment
likely serve as additional confounding factors. Both flow pulsatility and the mere
placement of a stent were shown to affect platelet / wall interactions. That these
'disturbances' can be perceived by platelets has important implications on the potential
for the GPIb/vWF axis to be used as a therapeutic target in pulsatile conditions or other
situations where the global, time-averaged fluid flow conditions are not indicative of
local, instantaneous shears. Indeed, our studies reveal that both temporal and spatial
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pockets of low flow can bypass the need for the GPIb axis under otherwise high flow,
GPIb-dependent conditions.
To inhibit platelet adhesion to these surfaces in the presence of periodic low flow, one
potential strategy is to target the integrin family of surface receptors. These molecules,
when activated, mediate firm adhesion to specific ligands (lIIb~3/fibrinogen;
(l2~1/collagen; (lV~3/ fibronectin, etc.) and it is a combination of these interactions which
orchestrate the development of stable aggregates (section 1.2) [26, 35]. We sought to
examine the role of specific integrin inhibition on platelet thrombus formation in pulsatile
flow environments. Given our collagenized reactive site model, we focused on the
collagen integrin receptor, (l2~1, given our collagenized reactive site model, as well as
the clinically relevant fibrinogen receptor, (lIIb~3, essential for platelet cross-linking and
thrombus growth [166, 167]. In doing so, we consider therapeutic strategies that may be
of use in localizing anti-thrombotic effects to pulsatile, high flow environments by taking
advantage of the redundancy of adhesion pathways and kinetics of platelet response.
Specifically, we develop and test the potential of dual receptor blockade (l2~1 in
conjunction with GPIb) in enabling selective, high flow inhibition in the presence of
temporal fluctuations relevant to real world hemodynamic settings. Finally., we consider
the utility of such a strategy in the added presence of a stent.
6.3.1 Methods
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We applied our reactive coronary
site model to investigate the
effectiveness of platelet inhibitory
strategies in blocking platelet wall
int~ractions under temporally and
spatially fluctuating flow
conditions. As we wanted to test
Figure 6.22. Generated triangular flow wave forms
spanning a range of physiological to pathological
coronary like flow conditions (100-800 mllmin peak; 50-
______________ 400 mllmin mean flow rates). **One pulse shown.
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the ability of these strategies to selectively target specific flow environments regardless
of pulsatility, we developed triangular flow patterns that spanned a range from low to
high flow conditions (100-800 ml/min peak, 50-400 ml/min mean flow rate Fig. 6.22).
Reactive segments were used as a reductive model of vessel injury. Briefly, fluid loops
were made from a 21 cm length of 1/8" inner diameter (ID), 3/16" outer diameter (OD)
3350 Silicone Tygon tubing into which a glass reactive tubing segment was inserted
(glass was used to enable surface visualization). The reactive segments were coated with
Type I, acid insoluble bovine collagen and the 21 cm lengths were uniformly coated with
a 1% BSA blocking solution (see section 5.1).
For the stented trials, 3 cm silicone (rather than glass; Fig. 5.5) reactive segment
were prepared in a similar fashion, into which 9-mm, 7-cell, stainless steel NIR® stents
(Fig 6.18a; Medinol, Jerusalem ISRAEL) were expanded to a 3.0 mm post-inflation
diameter as previously described (section 6.1).
Platelet Isolation, Manipulation, and Observation
Whole blood was drawn from healthy volunteers using D-Phe-Pro-Arg chloromethyl
ketone (PPACK, 80 M final concentration) as an anticoagulant and used within 30 min
of withdrawal was used as a platelet source. The blood was incubated with the specified
antibodies (20 [tg/ml AK2, 10 ptg/ml Gi9, 20 ptg/ml abciximab, PBS vehicle; Table 6.3)
for 15 minutes prior to run to block specific platelet receptors. The murine monoclonal
anti-GPIb antibody, AK2 as previously described has been shown to functionally block
GPIb-vWF interactions [152]. The anti-integrin a2[1 monoclonal antibody Gi9
(Immunotech International, Marseilles, France) functionally blocks collagen adhesion to
this receptor [168, 169]. The anti-chimeric Fab fragment of the monoclonal antibody
7E3 (c7E3 Fab-abciximab; Eli-Lilly Centocor, Leiden, The Netherlands) inhibits
a I b,3 11/fibrinogen interaction.
Platelet surface adhesion was quantitatively assessed through LDH staining as
described previously (section 5.2).
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Table 6.3. Platelet receptors and specific functional blocking strategies.
RECEPTOR LIGAND FUNCTION BLOCKING
ANTIBODY
GPIb vWF Platelet Tethering, AK2 (20 jig/ml)
Activation
AIIb33 Fibrinogen, Platelet Adhesion, Abciximab (20 jig/ml)
vWF Aggregation
a231 Collagen Platelet Adhesion Gi9 (10 jtg/ml)
6.3.2 Platelet inhibition in complex hemodynamic environments
Inhibition in temporally varying conditions (Flow Pulsatility)
To study the effects of blocking specific platelet/wall interactions through targeted
receptor inhibition, we incubated anti-coagulated whole blood with the function blocking
anti-human a2131 antibody (Gi9) [168, 169], either alone or in combination with AK2, or
with the inhibiting anti-human alIbP3 Fab fragment, abciximab alone. We ran 4-6 loops
per inhibitor condition for 5 minutes under the triangular profiles over the entire range of
flow rates along with PBS vehicle controls. We then analyzed the reactive sites for
surface adherent platelets/thrombi via LDH quantification (Fig. 6.23).
Abciximab dramatically reduced platelet accumulation at all flow rates as compared to
vehicle control, with ever increasing effectiveness at higher flow rates. Incorporating the
previous AK2 findings (Fig. 6.9; section 6.1) blocking the GPIb axis alone partially
reduced platelet accumulation at increasing flow rates. Remarkably, while a23 1
blockade (Gi9) had little effect by itself, co-inhibition of GPIb and a2p31 allowed full
platelet accumulation at the lower pulsatile flow conditions (50, 100 ml/min mean flow),
while uniformly eliminating it under the high triangular flow conditions (200, 400
ml/min).
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Figure 6.23. Effect of specific receptor blockade on pulsatile, triangular flow dependent platelet
adhesion to collagenized reactive sites. Reopro (abxicimab) blocked platelet adhesion across all flow
rates with ever-increasing effectiveness at the higher rates. While AK2 showed a reducing trend,
neither it nor Gi9 (showing no inhibitory effect at any flow rate) were able to block surface site
adhesions completely at any flow level tested. The combination of AK2+Gi9 powerfully inhibited
high flow platelet binding, while allowing low flow accumulation to occur.
Kinetic Mechanism of GPIb/a2bl coinhibition
Modified Flow Profiles for Determining Platelet Adhesion Time (TAdhesion)
To determine whether the dramatic anti-platelet effect with GPIb/a2b 1 coinhibition was a
result of an incapacitated ability to resist high shear forces or a more subtle kinetic effect
of prolonging the time required for firm wall adhesion to occur (TAdhesion; recall section
6.1), we again generated a set of pulses of varying duty cycle. To test the hypothesis of
prolonged TAdhesion, duty cycle patterns with extended periods of low flow were needed.
Such pulses require sustained periods of constant acceleration which would lead to
rapidly compounding rotor velocities (Fig 2.4). To accommodate these prolonged low
flow situations while maintaining rotor velocities to reasonable limits, we generated 1 Hz,
bidirectional, square pulses of low magnitude (50 ml/min) through out the prescribed low
flow portion (Fig. 6.24). With this strategy, we generated flow waveforms with a fixed
0.5 TH phase (350 ml/min) and a variable duration TL phase (50 ml/min), ranging from
0.5-00 s (TH and TL are the periods spent at high and low flow states respectively).
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Figure 6.24. Modified High/Low phasic flow profiles of varying duty cycle. Lengthened TL periods
through the use of bidirectional low flows have been employed to test prolonged TAdhesion times.
We ran collagenized reactive sites for 5 minutes with anti-coagulated whole blood
incubated with AK2+Gi9, and subsequently assessed them for platelet adhesion. As a
result of variability in individual responses, we adopted a screening strategy to determine
the minimal time required for platelet adhesion to occur. For each individual (n=8),
platelet accumulation was determined via LDH quantification under the 0.5 s and 4 s TL
conditions. If significant platelet adhesion occurred under the 4 s condition, we
performed another trial with the 1 and 2 s conditions (there was uniformly no detectable
response at 0.5 s). Otherwise, a final trial was performed under the 8 s and TL
conditions. Given the clear, high (> 0.50 LDH absorbance) or low (< 0.05 LDH
absorbance) nature of these responses, we represented our findings with the % of people
who supported platelet adhesion (> 0.50 LDH) by a given TL. Individuals began to
respond by 2 s, with all individuals responding by 8 s (Fig. 6.25). These results implicate
a finite TAdhesion (2-8 sec) and hence, the kinetic nature of the GPIb, a2p1 co-inhibitory
strategy as opposed to a total elimination of firm adhesion.
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Figure 6.25. Platelet TAdhesion given dual GPIb / a2pl axis blockade
Inhibition in spatio-temporally varying conditions (Coronary stenting)
In section 6.2, we found that similar to flow pulsatility, stent presence was able to
circumvent the effectiveness of GPIb blockade in inhibiting high-flow platelet wall
accumulation. Interestingly, we currently have the shown that GPIb, a2pl1 coinhibition
can maintain anti-adhesive effects in selective, high flow environments under pulsatile
flow conditions. To see if this dual inhibitory strategy was also capable of maintaining
blockade in the added presence of a stent, where both spatial and temporal pockets of low
flow exist, stented, collagenized segments were considered under low and high flow
conditions (50, 200 ml/min mean flow rate) using the triangular pulse profiles (Fig. 6.22)
under conditions of either dual GPIb/a231 or aIIbp3 inhibition. For each condition, two
5 min runs of 3 stented segments (2 inhibited, 1 non-inhibited control) were performed
(total of 4 stents/ condition). Again, platelet / thrombus adhesion was assessed by LDH
quantification.
Considering our results (Fig. 6.26), we see dramatically reduced platelet adhesion with
aIIbP3 blockade at both high and low flows regardless of stent presence as compared to
uninhibited controls (non-stented conditions carried over from Fig. 6.23). Given GPIb/
a23lcoinhibition, we observe a significant amount of platelet adhesion under low flow
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conditions as compared to aIIbB3 blockade, again irrespective of stenting condition.
However, considering the high flow case, we observe reduced, but significant platelet
accumulation in the presence of a stent, which was eliminated in the absence of the
device. While the dual inhibitory strategy was effective in eliminating pulsatile flow
adhesion selectively at high flow in a non-stented environment, it was no longer
sufficient given the added presence of a stent (in marked contrast to blocking levels
achieved by alIbP3 inhibition)
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Figure 6.26 Effectiveness of GPIb/a2P1 vs. aIIbP3 blockade in stented and non stented pulsatile
environments. Mean ± SEM
6.3.3 Discussion
Blocking clot formation at the same time minimizing hemorrhagic risk is an important
goal in the optimized prevention of thrombotic events. Although the GPb-vWF axis has
been harnessed as a potential high flow anti-thrombotic target, finding stable, high flow
settings possess a concern. Real world hemodynamic settings are complex, exhibiting
wide fluctuations in both space and time. Even within settings that can globally be
defined as high flow, pockets of low flow may exist which can bypass GPIb pathways
(section 6.1, 6.2). While it is important to optimize thrombotic inhibitors to a specific
prothrombotic setting, it is even more critical to insure sufficient levels of inhibition.
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One way to achieve robust anti-thrombotic effects is to forego the goals of
targeting specific environments altogether through the use of unselective, systemic
strategies. Agents that block the platelet aIIbf3/fibrinogen receptor accomplish such a
goal. The effectiveness of aIIbp3 blockade on platelet inhibition across a wide range of
shear rates has been shown through numerous in vitro and in vivo studies [170].
Moreover it has proven valuable in a variety of thrombotic clinical settings where the
hemodynamic situation is far from certain, including the complex coronary stent
environment [12, 167, 171]. In our current reactive site study, we also show strong
inhibition at both high and low flow conditions both in the presence of pulsatile
disturbances as well as to the compounded spatial disturbance of a stent. While the
inhibitory strength seems to increase with flow, the significant blocking effects even
under low flow, can be attributed to the role of the aiib3 receptor in mediating platelet-
platelet fibrinogen cross-linking, without which the crucial aggregation step cannot take
place. While a slew of antibody-derived and small molecule agents directed against the
alIbof3/fibrinogen axis are in use, their potent effect on platelet inhibition brings with it
the increased risk of bleeding complications [12, 159]. Balancing the potential benefits
with these adverse outcomes tempers the circumstances where the use of such agents is
warranted.
Another technique to achieve robustness is to find strategies that are specifically
insensitive to the fluctuations (rather than insensitive to the hemodynamic setting
altogether). In this section, we assessed the possible efficacy of GPIb/a2 1 dual
inhibition and remarkably found high flow adhesion was completely and selectively
eliminated given highly pulsatile, triangular flow patterns (our model of coronary-like
flow conditions). This inhibition was observed even under conditions when the low flow
duration would be approximately half the pulse cycle (-0.5 sec for the 200 ml/min mean
flow rate triangular pulse; Fig 6.12, section 6.1). By considering specialized flow
profiles of varying low flow duration, we propose that a likely mechanism which can
explain the effectiveness of this dual inhibitory technique is through an increased time
required for firm platelet adhesion to take place (TAdhesions). On a background of GPIb
inhibition, we found TAdhesions to be -0.125-0.25 sec in the absence of a2p1 coinhibition
(Fig. 6.14; section 6.1) while in the presence of a2pl coinhibition we obtained a
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considerably prolonged adhesion time between 2-8 seconds (Fig. 6.25). These prolonged
TAdhesions may offer a mechanism of 'skipping' through temporary pockets of low flow.
Interestingly., the minimum TAdhesions of 2 seconds given GPIb/ a2p 1 coinhibition suggests
that this is a potentially effective strategy for naturally pulsatile, high flow conditions
where the pulse rate is greater than 30 bpm (time spent in low flow is necessarily less
than 2 sec). Still, larger studies are needed to both to verify this lower bound (we
observed large variations over a limited sample size), as well as to delineate the
firequency independence/dependence of these methods.
The effect of a2p1 in playing a participatory, non-essential role in platelet adhesion to
collagen has been recognized [172-175]. In our reactive site model, sole a2p1 blockade
with Gi9 did not have a noticeable effect at any flow rate. With additional blockade of
GPIb, we found that adhesive events still took place, given sufficient time spent in a low
flow regime (2-8 sec). These findings are in agreement with a recently proposed matrix
model of platelet collagen adhesion/activation [176, 177]. In a dynamic, parallel process,
weak GPVI (an essential collagen activation receptor) and a2p11 / collagen associations
allow GPVI to interact increasingly efficiently with collagen by promoting receptor
clustering, enhanced signal transduction, and platelet activation. Activating signals cause
a2p1 and a slew of other integrins to adopt their high affinity conformation, supporting
firm substrate adhesions while further potentiating GPVI/collagen associations. In such a
scheme, a2p31, while enhancing the efficiency of surface collagen interactions, serves a
non-essential role in mediating firm adhesive events, so long as sufficient time is allowed
for GPVI activation and parallel pathways of integrin mediated firm adhesion to occur.
Under conditions when only a2P31 is inhibited, GPIb tethering interactions could slow
platelet translocation, thus enabling the necessary surface interactions to take place (while
promoting integrin and general platelet activation in its own right). When GPIb is
concurrently inhibited and tethering is disabled, platelet translocation must be slowed
physically through reduced flow to allow sufficient time for reactions to take place.
The effect of a231 in altering the kinetics of firm platelet adhesion raises the
question as to the possible efficacy of other dual GPIb/vWF + X inhibitory strategies
which may alter platelet wall interactions such that the time required for firm adhesion to
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take place is greater than the times spent in regions of low flow (TAdhesion > TLow).
Recently, co-inhibition of GPIb and aIIbp3 has been shown to synergistically inhibit
platelet adhesion in both in vitro and in vivo settings, allowing relatively low doses of
each to be used, while retaining maximal effects [27, 162]. Other methods, such as
aspirin or clopidigrel administration, which alter platelet activatability, would also be
interesting, potential strategies [12]
While increasing TAdhesion seems to be an effective strategy for inhibiting high flow
platelet adhesion regardless of pulsatility, we found that with the added disturbance of a
stent, significant surface platelet accumulation was permitted (0.32+0.03, normalized to
uninhibited stented case; Fig. 6.26 ). Though it is hard to predict what sufficient or
insufficient levels of inhibition would be from an in vitro model, these findings are
clearly increased from levels achieved with either dual inhibition in the absence of
stenting, or with aIIbP3 blockade.
To understand why GPIb/a23 1 coinhibition, whose mechanism of action seems to
lie in prolonging the time needed for firm adhesion to take place, works in pulsatile
settings but not in the stented case, we can consider the nature of the induced regions of
low flow. With purely pulsatile conditions, the time platelets spend in low flow/low shear
is uniform and easily definable. With each pulsation, all platelets in contact with the wall
experience the same pattern of high and low shear. In the case of stenting, the platelet
residence time in low flow zones is far more complex secondary to altered transport
phenomena. Some platelets may spend seconds in recirculant zones, while others (as we
see here) may never leave. In such complex, spatial diverse flow where platelet wall
residence times are hard to predict on an individual basis, finding unique, targetable
hemodynamic parameters may not be feasible. In the face of these issues, strategies such
as aIIbB3 blockade that are relatively flow independent and have already shown their
utility may be required.
Using our in vitro model, we have studied the effectiveness of potential anti-
thrombotic strategies in the context of specific real-world situations (pulsatility, stenting).
In doing so, we have found the coinhibitory strategies such as GPIb/a2P1 may prove
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useful in more selectively defining targeted areas. That this particular combination seems
to work well in settings of high flow, regardless of pulsatility is intriguing, particularly
given the nature of coronary flow. However, we must recognize the limitations of our
study. The same reductive strategies, which we used to simplify and test specific
hypothesis also make our findings for less predictive. The pulsatile conditions under
which we observed an effect were in an idealized, geometric setting. As we have seen,
even the simple insertion of a stent can reduce the observed levels of inhibition likely
through the induction of stationary pockets of low flow and prolonged platelet residence
times. The actual coronary environment is far more complex and spatial and temporal
effects can not be separated as they can in our in vitro system. Furthermore, we have
currently only considered a simplified, collagen coated reactive layer. Realistic
subendothelial layers (not to mention endothelial layers) are far more complex, with
components that interact with several other platelet receptors (section 5.1). Accordingly,
on more complete substrates, TAdhesion may no longer be as prolonged as more parallel
pathways of adhesion enabling GPIb-independent stable adhesions to take place during
periods of low flow. Before we can be more confident in making real-world predictions,
we must test the robustness of this strategy by parametrically studying other surfaces, as
well as delineate geometric conditions when the strategy breaks down. Furthermore
given the importance of TAdhesion in mediating this strategy, we must also recognize the
highly variable results that we found and the limited population size considered.
Accordingly, larger populations must be observed, both to test model robustness, but also
to more fully characterize the nature of the variance. Given its importance in promoting
or preventing adhesion in our idealized pulsatile settings, we must consider more
generally, its diagnostic potential.
The local hemodynamic environment plays a critical role in directing the local thrombotic
response. While many of the fundamental, flow mediated interactions have been
delineated through prior in vitro and in vivo work (section 1.3), much remains to be
Chapter 6:: Real World Hemodynamic Environments 173
learned with regards as to how these factors play out in real-world scenarios. Deeper,
situational studies require highly controllable, highly observable systems which
recapitulate both the flow and geometric conditions present within specific vascular
environments. Such systems could help to bridge the gap between overly reductive and
overly complex models, optimizing the path from bench top discovery to bedside
application. In preceding chapters, we have established methods to parameterize
important biological and physical properties of the platelet response within our in vitro,
reactive site model. In doing so, we have begun to characterize the platelet response
within a coronary-like, pulsatile, hemodynamic setting, thus establishing a foundation
from which we can further explore aspects of the hemodynamic environment.
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CHAPTER 7 Limitations, Conclusions, and Future
Directions
Thrombosis is a crucial physiological response that helps to maintain vascular integrity.
However, when harnessed inopportunely or pathologically, it can result in devastating
outcomes. One setting which it is especially important to consider is that of acute
coronary thrombosis. Formation of clot within the coronary arteries occurs in states of
both pathology (atherosclerotic plaque rupture; acute coronary syndromes) and
intervention (angioplasty, stenting). The involved thrombotic reactions are complex and
involve an intimate partnership of both biological and physical components.
Accordingly., understanding and control of thrombosis requires the establishment and
control of models that recapitulate relevant aspects of these biophysical environments.
While many of the fundamental, flow mediated interactions have been delineated
through prior in vitro and in vivo work (section 1.3), much remains to be uncovered with
regards as to how these factors play out in real-world scenarios. Deeper, situational
studies require highly controllable, highly observable systems that can recapitulate and
parameterize both the flow and geometric conditions present within specific, local
vascular environments. Such systems could help to bridge the gap between overly
reductive and overly complex models, optimizing the path from bench top discovery to
bedside application.
In the current thesis, we have established a novel method of creating oscillating flow
patterns that can match coronary-like flows on a beat-to-beat basis. The method of
producing flow is atraumatic to the blood, even at the considerable shear and flow rates
found in the arterial setting. The technique allows the flow environment to be easily
varied and parameterized through modulating wall acceleration. Importantly, the system
offer the uniquely ability to maintained these atraumatic flows in highly relevant,
physiological arterial geometries. Not only is wall shear rate considered (as in standard
parallel plate systems), but the overall hemodynamic setting.
One limiting aspect of the current system that must be kept in mind as a departure
from true flows generated in the coronary setting is the oscillatory, recirculant nature of
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the generated flows. While flow in the coronary artery is highly pulsatile, there is net
directionality to the flow. However, as the current system's inertial tube flows are
generated through wall accelerations, net directional flows would necessarily mean net
accelerations and hence, unbounded motor velocities. The bidirectional strategy
employed allows coronary flow's to be matched on a single beat, after which flow is
driven in an opposite, but symmetric fashion as discussed in chapters 2 and 3. Such
oscillations could alter flow sensitive processes such as thrombosis through a variety of
mechanisms, from altered wall transport as in a 'breathing' reactor, to phenomenon such
as cell wall rolling. One method of creating uni-directionality would be through the
introduction of a one-way valve (discussed in chapter 3). However, the inclusion of such
a mechanism in the flow path would have create additional disturbance in measurement
and alternate: divergence from an in vivo setting. Thus, while flow oscillation represents
an undeniable limitation in the embodied system, it was felt that the ability to generate
temporal and spatial flow fluctuations offers a sufficiently novel handle to explore
interesting, relevant hemodynamic phenomena. However, in light of such departures, as
in the case of any in vitro system, the significance of derived results must eventually be
substantiated in the in vivo setting.
In chapters 3, 4, and 5, we established methods to parameterize important biological
and physical properties of the platelet response within our oscillating in vitro, reactive
site model. In particular, we characterized the platelet response within our coronary-like,
oscillating, hemodynamic setting, thus establishing a foundation from which we can
further explore aspects of the hemodynamic environment. Subsequently, we considered
aspects of real-world hemodynamic scenarios, which exhibit a high degree of spatial and
temporal variability. Given that platelets are responsive to their shear environments, it is
important to delineate the levels at which they can sense local changes in environment.
In some cases, spatio-temporal fluctuations may go by unperceived, while in others
situations, they may play a crucial role in mediating the local biological reaction.
In chapter 6, we investigated the platelet response to variations in the hemodynamic
environment induced by highly idealized situations which we develop in our reactive site
model. Specifically, we focused on the effects of coronary-like flow pulsatility and
endovascular stent presence as examples of temporal and spatial variability respectively
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and found both to significantly affect the manner in which platelets accumulate at a local
site on injury. One limitation in the spatial variation stent study was that we were limited
to using stents provided by industrial manufacturers and thus, did not truly parameterized
the geometric setting. Indeed, while we noted significant variation given the presence of
a stent, no significant variations were noted in between stent geometry. To further
explore this important issue, we are currently generating methods to create highly
controllable geometries of stent dimension directly onto our reactive site surfaces.
Given our findings that highly relevant hemodynamic factors create robust,
observable differences in the local platelet response, we further explored the efficacy of
anti-thrombotic agents in these temporally and spatially varying settings. This allowed us
to consider both the mechanisms by which platelet/wall interactions occur in given
settings, as well as explore the potential efficacy of important clinical agents in real world
scenarios. Notably, we found that the clinically relevant aIIbf33 inhibitor was highly
effective in a wide variety of settings, regardless of flow rate or spatially and temporally
inhomogeneous flows. GPIb axis inhibition selectively blocked high flow adhesions but
not in slowly changing pulsatile conditions. Interestingly, GPIb/a211 co-inhibition was
selectively effective under high flow conditions regardless of pulsatility offering a
potential strategy for creating selective blockade in specific hemodynamic settings.
Perhaps most interesting was the manner in which various platelet receptors worked
together in a given hemodynamic setting to create stable platelet adhesions, especially in
light of the many subtle platelet receptor polymorphic variations known to exist in the
normal population Still, much work remains to be done to further delineate these
phenomena and to establish their relevance in the in vivo setting.
The developed in vitro model has allowed us to consider both flow and geometry as
critical aspects of the hemodynamic environment and in doing so, has allowed us to gain
insight into the importance of real-world temporal and spatial flow fluctuations on
aspects of local thrombosis. We will continue to use the system to gain further insight
and hypothesis that can subsequently be substantiated through in vivo consideration. It is
our hope that such an in vitro model will be of use in accelerating the pace of bench-top
discovery to bed-side understanding and therapy.
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Appendix A: IQ Master Programs
Basic IQ Master program files for generating rotor motion profiles/flow waveforms.
Initial programs were created using general knowledge of how loop accelerations lead to
fluid velocities as determined through straight tube approximations. These examples
were then fine-tuned through real-time flow observations until the desired flow profiles
were generated. The final programs for generating flows are given. The functions:
"Impulse", "Square", "Triangle", "Sine" were applied to tubes using PRP as a test fluid,
while the "50" , "100", "200", "400" ml/min peak flow functions were applied to whole
blood.
IMPULSE FUNCTION
title "impulse"
;assign variables
assign vcity vl
assign accl v2
assign decl v3
assign tc v4
;SET CONSTANTS
reset;
fdr=100; 100% federate
scale=4000; 1 rev=4000 encoder counts
fel=3; following error limit
;start motor at init velocity
accl=500
tc=.3
vcity=50
main:
jaccel=accl
jdecel=accl
forward:
delay=tc
movv=(vcity)
if vell<vcityjump forward
reverse:
delay=tc
movv=(-vcity)
if vell>(-vcity)jump reverse
jump main
end
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SQUARE FUNCTION
title "square"
;assign variables
assign vcity v I
assign accl v2
assign decl v3
assign vcity2 v4
assign vcity3 v5
assign vcity0 v6
assign sclvel v7
assign scltme v8
;SET CONSTANTS
reset;
fdr=100; 100% federate
scale=4000; I rev=4000 encoder counts
fel=.2; following error limit
;start motor at init velocity
accl=5
scltme=.5
sclvel=l
main:
d=-.08/scltme, v=280/sclvel
d=-.055/scltme, v=257/sclvel
d=-.18/scltme, v=165/sclvel
d=-.13/scltme, v=55/sclvel
d=-.02/scltme, v=0/sclvel
d=-.15/scltme, v=155/sclvel
d=-.15/scltme, v=220/sclvel
d=-.2/scltme, v=270/sclvel
d.=-. 17/scltme, v=300/sclvel
d=.06/scltme, v=280/sclvel
d:=.055/scltme, v=257/sclvel
d:=. 18/scltme, v= 165/sclvel
d:=. 13/scltme, v=55/sclvel
d=.02/scltme, v=0/sclvel
d:=. 15/scltme, v=155/sclvel
d=.2/scltme, v=22C/sclvel
d:=.2/scltme, v=270/sclvel
d:=. 17/scltme, v=3C0/sclvel
jump main
end
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TRIANGULAR FUNCTION
title "triangle"
;assign variables
assign vcity vl
assign accl v2
assign decl v3
assign vcity2 v4
assign vcity3 v5
assign vcityO v6
assign sclvel v7
assign scltme v8
;SET CONSTANTS
reset;
fdr= 100; 100,
scale=4000;
fel=.2;
;start motor at init velocity
accl=5
% federate
1 rev=4000 encoder counts
following error limit
scltme=l
sclvel=1.2
main:
d=-.16/scltme, v=294/sclvel
d:=-. 11/scltme, v=285/sclvel
d=-.36/scltme, v=225/sclvel
d:=-.26/scltme, v= 143/sclvel
d:=-.15/scltme, v=O/sclvel
d:=-.25/scltme, v=200/sclvel
d=-.25/scltme, v=250/sclvel
d-=-.5/scltme, v=270/sclvel
d.=-l/scltme, v=300/sclvel
d:=.16/scltme, v=294/sclvel
d-=. 1/scltme, v=285/sclvel
d=.36/scltme, v=225/sclvel
d-=.26/scltme, v=143/sclvel
d=. 15/scltme, v=O/sclvel
d=.25/scltme, v=200/sclvel
d=.25/scltme, v=250/sclvel
d-=.5/scltme, v=270/sclvel
d::=/scltme, v=300/sclvel
jump main
end
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SINUSOIDAL FUNCTION
title "sine"
;assign variables
assign vcity vl
assign accl v2
assign decl v3
assign vcity2 v4
assign vcity3 v5
assign vcityO v6
assign sclvel v7
assign scltme v8
;SET CONSTANT'S
reset;
fdr= 100; 100'
scale=4000;
fel=.2;
;start motor at init velocity
accl=5
% federate
I rev=4000 encoder counts
following error limit
scltme= 1
sclvel=1.2
main:
d=-.l/scltme, v=287/sclvel
d:=-.075/scltme, v=270/sclvel
d=-.25/scltme, v=190/sclvel
d=-. 18/scltme, v= 1 0/sclvel
d:=-.1/scltme, v=O/sclvel
d:=-.2/scltme, v=155/sclvel
d-=-.2/scltme, v=220/sclvel
d =-.25/scltme, v=2'70/sclvel
d-=-.2/scltme, v=300/sclvel
d-=-l/scltme, v=300/sclvel
d:=-.1/scltme, v=28'7/sclvel
d=-.075/scltme, v=:270/sclvel
dz=-.25/scltme, v=190/sclvel
d=-. 18/scltme, v=l 10/sclvel
d=-.l/scltme, v=--O/sclvel
d=-.2/scltme, v=155/sclvel
d=-.2/scltme, v=220/sclvel
d=-.25/scltme, v=2'70/sclvel
d=-.2/scltme, v=30(0/sclvel
d=-l/scltme, v=300/sclvel
jump main
end
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TRIANGULAR FUNCTION (50ml/min peak)
title "50tri" ; 50 ml/min peak triangular wave
;assign variables
assign vcity vl
assign accl v2
assign decl v3
assign vcity2 v4
assign vcity3 v5
assign vcityO v6
assign sclvel v7
assign scltme v8
;SET CONSTANTS
reset;
fclr= 100; 100% federate
scale=4000; 1 rev=4000 encoder counts
fel=.2; following error limit
;start motor at init velocity
accl=5
scltme=3.4
sclvel=4.5
main:
ol=off
o2=on
o3=off
d:=-.2/scltme, v=320/sclvel
d:=-.3/scltme, v=290/sclvel
d-=-.3/scltme, v=l 110/sclvel
d=-.05/scltme, v=0/sclvel
dac 1=5
dz=.3/scltme, v=190/sclvel
dac 1 =0
d=.3/scltme, v=250/sclvel
d=.3/scltme, v=290/sclvel
d=.3/scltme, v=310/sclvel
d=.2/scltme, v=320tsclvel
d=.3/scltme, v=330/sclvel
d=.4/scltme, v=330/sclvel
ol=off
o2=on
o3=off
d=.2/scltme, v=320/sclvel
d=.3/scltme, v=290/sclvel
d=.3/scltme, v= 110/sclvel
d=:.05/scltme, v=O/sclvel
dacl=5
d=-.3/scltme, v=190/sclvel
dacl=0
d=-.3/scltme, v=250/sclvel
d=-.3/scltme, v=290/sclvel
d=-.3/scltme, v=310/sclvel
d=-.2/scltme, v=32C0/sclvel
d=-.3/scltme, v=330/sclvel
d=-.4/scltme, v=330/sclvel
jump main
end
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TRIANGULAR FUNCTION (100ml/min peak)
title "100tri" ; 100 ml/min peak triangular wave
;assign variables
assign vcity vl
assign accl v2
assign decl v3
assign vcity2 v4
assign vcity3 v5
assign vcityO v6
assign sclvel v7
assign scltme v8
;SET CONSTANTS
reset;
fdr=100; 100% federate
scale=4000; I rev=4000 encoder counts
fel=.2; following error limit
;start motor at init velocity
accl=5
scltme= 1.5
sclvel=2
main:
ol=off
o:2=on
o3=off
d=-.2/scltme, v=320/sclvel
d:=-.3/scltme, v=290/sclvel
d:=-.3/scltme, v=l 1 O/sclvel
d=-.05/scltme, v=O/sclvel
dac 1 =5
d:=.3/scltme, v=19CV0/sclvel
dac 1 =0
d-=.3/scltme, v=25C0/sclvel
d-=.3/scltme, v=290/sclvel
d:=.3/scltme, v=310/sclvel
d-=.2/scltme, v=320/sclvel
d-=.3/scltme, v=330/sclvel
d=.4/scltme, v=330/sclvel
o l =on
o2!=off
o3=on
d==.2/scltme, v=320/sclvel
d=:.3/scltme, v=290/sclvel
d=.3/scltme, v=l 10/sclvel
d=-.05/scltme, v=O/sclvel
dacl=5
d=-.3/scltme, v=190/sclvel
dacl=0
d=-.3/scltme, v=250/sclvel
d=-.3/scltme, v=290/sclvel
d=--.3/scltme, v=3 0/sclvel
d=:-.2/scltme, v=320/sclvel
d=-.3/scltme, v=330/sclvel
d=-.4/scltme, v=330/sclvel
jump main
end
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TRIANGULAR FUNCTION (200ml/min peak)
title "200tri"; 200 ml/min peak triangular wave
;assign variables
assign vcity vl
assign accl v2
assign decl v3
assign vcity2 v4
assign vcity3 v5
assign vcityO v6
assign sclvel v7
assign scltme v8
;SET CONSTANTS
reset;
fdr=100; 100% federate
scale=4000; 1 rev=4000 encoder counts
fel=.2; following error limit
;start motor at init velocity
accl=5
scltme=0.8
sclvel=l
main:
ol=off
o2=on
o3=off
d=-.2/scltme, v=320/sclvel
d:=-.3/scltme, v=290/sclvel
d:=-.3/scltme, v=l 10/sclvel
d=-.05/scltme, v=0/sclvel
dacl=5
d:=.3/scltme, v=190/sclvel
dac 1=0
d:=.3/scltme, v=250/sclvel
d:=.3/scltme, v=290/sclvel
d-=.3/scltme, v=310C/sclvel
d:=.2/scltme, v=320/sclvel
d=.3/scltme, v=33C0/sclvel
d:=.4/scltme, v=330/sclvel
o I =on
o2=off
o3=on
d=.2/scltme, v=320/sclvel
d=.3/scltme, v=290/sclvel
d=.3/scltme, v=l 10/sclvel
d=.05/scltme, v=0/sclvel
dac 1=5
d=-.3/scltme, v=190/sclvel
dac I =0
d=-.3/scltme, v=250/sclvel
d=-.3/scltme, v=290/sclvel
d=-.3/scltme, v=310/sclvel
d=:-.2/scltme, v=320/sclvel
d=:-.3/scltme, v=330/sclvel
d=-- 4/scltme, v=330/sclvel
jump main
end
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TRIANGULAR FUNCTION (400ml/min peak)
title "400tri"; 400 ml/min peak triangular wave
;assign variables
assign vcity vl
assign accl v2
assign decl v3
assign vcity2 v4
assign vcity3 v5
assign vcityO v6
assign sclvel v7
assign scltme v8
;SET CONSTANTS
reset;
fdr=100; 100% federate
scale=4000; 1 rev=4000 encoder counts
fel=.2; following error limit
;start motor at init velocity
accl=5
scltme=.35
sclvel=.45
main:
ol=off
o:2=on
o3=off
d=-.2/scltme, v=320/sclvel
d:=-.3/scltme, v=290/sclvel
d=-.3/scltme, v= 110/sclvel
d:=-.05/scltme, v=0/sclvel
dacl=5
d:=.3/scltme, v=19CI/sclvel
dac 1=0
d:=.3/scltme, v=250/sclvel
d:=.3/scltme, v=290/sclvel
d=.3/scltme, v=310/sclvel
d:=.2/scltme, v=320/sclvel
d:=.3/scltme, v=330/sclvel
d=.4/scltme, v=330/sclvel
ol=on
o2=off
o3=on
d=.2/scltme, v=320/sclvel
d=.3/scltme, v=290/sclvel
d=.3/scltme, v= 110/sclvel
d--.05/scltme, v=O/sclvel
dacl=5
d---.3/scltme, v=190/sclvel
dacl=0
d=-.3/scltme, v=250/sclvel
d=-.3/scltme, v=290/sclvel
d=-.3/scltme, v=310/sclvel
d=-.2/scltme, v=320/sclvel
d=-.3/scltme, v=330/sclvel
d=-.4/scltme, v=330/sclvel
jump main
end
Apedx 
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Appendix B: Experimental Data
Stented Loop Occlusion Time Data
Stented loop occlusion time data expressed in minutes:
Polished
Trial 1 3'3.90365
34.60707
51.48928
Trial 2 32.06226
35.77335
46.16439
'Trial 3 45
44.41558
45.58442
Table B. 1: Comparison
endovascular stents.
Trial 1
Trial 2
Trial 3
Polished
58.75
70.27
Unpolished
36.8
32.8
24.8
30.4
25.84
27.36
26.1
29.25
35.55
of polished
Gold
33.79
36.67
40.51
46.27 39.55
47.23 43.39
70.27
38 30
39 31
Trial 1
Trial 2
Trial 3
and unpolished stainless steel 7-9 NIR®
Polished
41.47
46.27
59.71
Gold +
Heat
33.79
41.47
52.99
62.59 49.15
62.59 62.59
79.87
38 40
39 53
Trial 4 66 36 Trial 4 66 66
68 37 68 72
Table B.2: Comparison of gold-coated and gold-coated+heat treated stainless steel 7-9
NIR® endovascular stents with polished stents of identical geometry
n B
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Parameterized Stent Data (Gold vs. Steel comparisons)
Trial 1
Control
0.444
0.46
Gold
Trial 2
Steel
0.562
0.586
0.663
0.766
1.899
1.847
1.312
1.268
0.491 1.128 1.807
0.608 1.053 1.55
Table B.3: Pre-normalized omparison coagulation activation (assessed through
production of PT1+2) of non-stented control, gold-coated and stainless steel 7-9 NIR®
endovascular stents.
Control Gold
Trial 1 267
Trial 2 386
Trial 3 311
Trial 4 286
Steel
950
750
833
975
750
642
1100
1140
850
1072
924
1140
565
469
710
692
414
448
529
774
786
681
734
933
Table B.4 Pre-normalized omparison surface bound platelets of non-stented control, gold-
coated and stainless steel 7-9 NIR® endovascular stents.
Control Gold
Trial 1 0.0103 0.009904
0.011444
0.010383
Trial 2 0.01012 0.010066
0.01384
0.011035
Trial 3 0.01015 0.011507
0.009258
0.008222
Trial 4 0.01103 0.010383
0.00956
0.01274
Steel
0.009909
0.010089
0.008482
0.00976
0.012784
0.013518
0.008644
0.009417
0.008296
0.009875
0.008783
0.001016
Table B.5: Pre-normalized comparison of bulk platelet activation of non-stented control,
gold-coated and stainless steel 7-9 NIR® endovascular stents.
STENT OCTI .1CTI .5CTI 1CTI
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1 5790 3449 1685 1444
2 5589 3249 1615 1391
3 6715 3180 2642 1480
4 6974 3107 1355 1350
Table B.6: Pre-normalized platelet surface adhesion data for stainless steel 7-9 NIR®
endovascular stents with increasing amounts of CTI anticoagulant.
STENT OCTI
1 0.043478
2 0.043478
3 0.039007
I.CTI
0.033003
0.031034
0.029221
.5CTI 1CTI
1 0.034483 0.(
0.028571 0.(
0.031746 0.(
)33582
)35971
)32374
4 0.041667 0.035714 0.029032 0.032143
Table B.7: P're-normalized platelet bulk activation data for stainless steel 7-9 NIR®
endovascular stents with increasing amounts of CTI anticoagulant (mg/ml).
STEEL GOLD
Stent High Flow Low Flow High Flow Low Flow
1 4256 3918 6926 3616
2 3006 2236 2456--
3 4701 1796 5020 3234
4 3605 1882 5532 4384
5 3672 1716 4422 4038
6 3186 1686 4044 1842
7 3654 2221 5035 2853
8 3892 2185 4986 3456
Table B.8: Pre-normalized platelet surface accumulation data for stainless steel and gold-
coated 7-9 NIR® endovascular stents at high CTI anticoagulant concentration (0.5mg/ml)
for high (200ml/min peak flow) and low (40ml/min peak flow) flow conditions.
STEEL GOLD
High Flow Low Flow High Flow Low Flow
1 6715 1876
2 4974 4094
3 2915 2930
4 3500 3260
5 3449 3040
6 3249 4235
7 3180 3305
8 3107 3100
Table B.9: Pre-normalized platelet
2982 2500
2876 5000
2565 5425
2560 3905
2746 4208
2650 4975
2845 3500
2579 5235
surface accumulation data for stainless steel and gold-
coated 7-9 NIIR® endovascular stents at low CTI anticoagulant concentration (0. lmg/ml)
for high (200ml/min peak flow) and low (40ml/min peak flow) flow conditions.
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Effect of Coronary-Like Flow Pulsatility Data
Run 800T
1
2
3
4
5
6
7
8
800T+AK2 400S
3.545
3.405
3.538
3.52
2.886
2.939
4.467
4.4
Table B. 10: Triangular
values (as quantified by
flow of 400ml/min.
0.154
0.758
0.649
0.07
0.645
2.287
2.134
0.08
400S+AK2
2.805
3.005
3.82
3.55
2.915
2.795
3.967
4.095
0.07
0.074
0.065
0.064
0.068
0.062
0.07
0.061
(T) and Square (S) pulsatile flow dependent platelet adhesion
LDH absorbance) with and without AK2 treatment at a mean
600T 600T+AK2 300S
1 2.143 0.277
2 2.367 0.975
3 2.956 2.43
4 2.827 0.896
5 3.543 2.765
6 3.563 0.365
7 4.354 2.327
8 3.546 0.131
Table B.11: Triangular (T) and Square (S) pulsatile
values (as quantified by LDH absorbance) with and
flow of 300ml/min.
400T
1
2
3
4
5
6
7
8
400T+AK2 200S
2.938 1.975
2.891 2.934
2.548 2.76
2.694 1.875
2.288 0.305
2.392 0.295
2.867 0.945
2.345 0.865
300S+AK2
2.61 0.144
2.332 0.168
2.29 0.181
2.347 0.19
3.105 0.088
3.375 0.095
3.547 0.14
2.592 0.156
flow dependent platelet adhesion
without AK2 treatment at a mean
2.911
2.909
2.513
2.515
2.225
2.225
2.243
2.805
200S+AK2
0.54
0.428
1.405
1.368
0.061
0.06
0.353
0.388
Table B.12: Triangular (T) and Square (S) pulsatile flow dependent platelet adhesion
values (as quantified by LDH absorbance) with and without AK2 treatment at a mean
flow of 200ml/min.
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Run 200T
1
2 1
3 1
4 1
5 1
6 1
7 1
8
Table B. 13: Triangular
values (as quantified by
flow of 100ml/min.
200T+AK2 100S
2.092 1.787
..982 1.543
..299 1.124
..317 1.154
..696 1.386
..877 1.418
..695 1.599
1.75 1.593
(T) and Square (S) pulsatile
LDH absorbance) with and
100S+AK2
1.649 1.34
1.688 1.402
1.493 1.197
1.473 1.234
1.333 1
1.367 1.12
1.313 1.077
1.354 1.085
flow dependent platelet adhesion
without AK2 treatment at a mean
100T+AK2 50S
0.971
1.047
0.998
1.152
1.178
1.27
1.015
1.205
50S+AK2
0.905 0.876
0.961 0.903
1.095 0.984
1.11 0.821
0.814 0.756
0.865 0.79
0.875 0.956
1.051 0.766
Table B. 14: Triangular (T) and Square (S) pulsatile flow dependent platelet adhesion
values (as quantified by LDH absorbance) with and without AK2 treatment at a mean
flow of 50ml/min.
TL
Run 0 sec 0.125 sec0.25 sec0.375 sec0.5 sec 0.75 sec
1 0.038
2 0.043
3 0.04
4 0.014
5 0.085
6 0.075
7 0.03
8 0.067
0.04
0.044
0.022
0.019
0.076
0.092
0.023
0.074
0.091
0.078
0.065
0.064
0.125
0.149
0.285
0.224
0.059
1.766
0.147
1.77
0.135
0.132
1.458
0.132
0.041
0.045
1.132
1.507
2.405
2.23
0.183
0.285
0.94
1.015
1.315
1.215
0.874
0.753
0.536
1.586
Table B.15: Pre-normalized platelet adhesion values (as quantified by LDH absorbance)
as a function of TL (0-0.75 sec) for 8 individuals.
Appendices
1OOTRun
1
2
3
4
5
6
7
8
1.004
1.05
1.122
0.956
1.35
1.204
1.051
1.362
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Platelet Inhibitor Data
50ml/min 100ml/min 200ml/min 400ml/min
RUN -- +G19 -- +G19 -- +G19 -- +G19
1 1.123 1.005 1.756 1.819 2.544 2.749 3.654
2 0.876 0.765 1.865 1.765 2.355 2.57 2.987
3 0.995 0.998 1.535 1.498 2.055 2.477 3.867
4 0.985 1.064 1.256 1.105 2.767 2.713 3.97
5 1.155 1.12 1.423 1.527 2.624 2.845 3.132
Table B.15: Effect of G19 (a2B2 inhibitor) on platelet adhesion to collagen reactive site
(quantified by LDH measurement) as a function of pulsatile, triangular flow rate.
50ml/min 100ml/min 200ml/min 400ml/min
RUN -- +G19,AK2 -- +G19,AK2 -- +G19,AK2 -- +I
1 1.086 1.021 1.982 2.114 2.929 0.161 3.399
2 1.097 1.085 2.092 2.125 2.912 0.162 3.128
3 0.814 0.895 1.299 1.138 2.545 0.12 3.356
4 0.872 0.818 1.317 1.212 2.467 0.135 3.587
5 1.234 1.175 1.511 1.227 1.897 0.155 2.985
Table B.16: Effect of co-administration of G19 (a2B2 inhibitor) and AK2 (GPIb
inhibitor) on platelet adhesion to collagen reactive site (quantified by LDH measurement)
as a function of pulsatile, triangular flow rate,
319,
3.595
3.323
4.185
4.075
3.324
AK2
0.065
0.14
0.154
0.098
0.076
50ml/min 100ml/min 200ml/min 400ml/min
RUN -- +Reopro -- +Reopro -- +Reopro -- +Reopro
1 0.678 0.133 1.345 0.111 1.877 0.077 3.145 0.068
2 1.12 0.145 1.435 0.121 2.254 0.089 3.455 0.077
3 0.956 0.165 1.123 0.098 2.545 0.105 3.56 0.067
4 0.675 0.12 0.928 0.088 2.765 0.076 3.987 0.058
5 0.765 0.205 1.423 0.108 1.928 0.077 3.745 0.058
Table B. 17: Effect of Reopro (IIbIIIa inhibitor) on platelet adhesion to collagen reactive
site (quantified by LDH measurement) as a function of pulsatile, triangular flow rate.
50ml/min 200ml/min
G19/AK2 Reopro Control G19/AK2 Reopro Control
Trial 1 0.489 0.122 0.638 0.315 0.077 0.855
0.525 0.134 0.274 0.067
Trial 2 0.398 0.118 0.575 0.333 0.095 0.939
0.41 0.105 0.267 0.088
Table B.18: Effect of co-administration of G19 (a2B2 inhibitor) and AK2 (GPIb
inhibitor) or Reopro (IIbIIIa inhibitor) on platelet adhesion to stented, collagenized
reactive sites (quantified by LDH measurement) at 50 and 200 ml/min peak pulsatile,
triangular flow.
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